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Background: Each year in England and Wales, 150,000 people die from cancer, of whom 110,000 will
suffer from cancer pain. Research highlights that cancer pain remains common, severe and undertreated,
and may lead to hospital admissions.
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Objective: To develop and evaluate pain self-management interventions for community-based patients
with advanced cancer.
Design: A programme of mixed-methods intervention development work leading to a pragmatic
multicentre randomised controlled trial of a multicomponent intervention for pain management
compared with usual care, including an assessment of cost-effectiveness.
Participants: Patients, including those with metastatic solid cancer (histological, cytological or
radiological evidence) and/or those receiving anti-cancer therapy with palliative intent, and health
professionals involved in the delivery of community-based palliative care.
Setting: For the randomised controlled trial, patients were recruited from oncology outpatient clinics
and were randomly allocated to intervention or control and followed up at home.
Interventions: The Supported Self-Management intervention comprised an educational component
called Tackling Cancer Pain, and an eHealth component for routine pain assessment and monitoring
called PainCheck.
Main outcome measures: The primary outcome was pain severity (measured using the Brief Pain
Inventory). The secondary outcomes included pain interference (measured using the Brief Pain Inventory),
participants’ pain knowledge and experience, and cost-effectiveness. We estimated costs and health-
related quality-of-life outcomes using decision modelling and a separate within-trial economic analysis.
We calculated incremental cost-effectiveness ratios per quality-adjusted life-year for the trial period.
Results: Work package 1 – We found barriers to and variation in the co-ordination of advanced
cancer care by oncology and primary care professionals. We identified that the median time between
referral to palliative care services and death for 42,758 patients in the UKwas 48 days.We identified key
components for self-management and developed and tested our Tackling Cancer Pain resource for
acceptability.Work package 2 – Patients with advanced cancer and their health professionals recognised the
benefits of an electronic system to monitor pain, but had reservations about how such a systemmight work
in practice.We developed and tested a prototype PainCheck system.Work package 3 –We found that
strong opioids were prescribed for 48% of patients in the last year of life at a median of 9 weeks before
death. We delivered Medicines Use Reviews to patients, in which many medicines-related problems
were identified. Work package 4 – A total of 161 oncology outpatients were randomised in our clinical
trial, receiving either supported self-management (n = 80) or usual care (n = 81); their median survival
from randomisation was 53 weeks. Primary and sensitivity analyses found no significant treatment
differences for the primary outcome or for other secondary outcomes of pain severity or health-related
quality of life. The literature-based decision modelling indicated that information and feedback
interventions similar to the supported self-management intervention could be cost-effective. This model
was not used to extrapolate the outcomes of the trial over a longer time horizon because the statistical
analysis of the trial data found no difference between the trial arms in terms of the primary outcome
measure (pain severity). The within-trial economic evaluation base-case analysis found that supported
self-management reduced costs by £587 and yielded marginally higher quality-adjusted life-years
(0.0018) than usual care. However, the difference in quality-adjusted life-years between the two trial
arms was negligible and this was not in line with the decision model that had been developed. Our
process evaluation found low fidelity of the interventions delivered by clinical professionals.
Limitations: In the randomised controlled trial, the low fidelity of the interventions and the challenge
of the study design, which forced the usual-care arm to have earlier access to palliative care services,
might explain the lack of observed benefit. Overall, 71% of participants returned outcome data at 6 or
12 weeks and so we used administrative data to estimate costs. Our decision model did not include
the negative trial results from our randomised controlled trial and, therefore, may overestimate the
likelihood of cost-effectiveness.
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Conclusions: Our programme of research has revealed new insights into how patients with advanced
cancer manage their pain and the challenges faced by health professionals in identifying those who need
more help. Our clinical trial failed to show an added benefit of our interventions to enhance existing
community palliative care support, although both the decision model and the economic evaluation of
the trial indicated that supported self-management could result in lower health-care costs.
Future work: There is a need for further research to (1) understand and facilitate triggers that prompt
earlier integration of palliative care and pain management within oncology services; (2) determine the
optimal timing of technologies for self-management; and (3) examine prescriber and patient behaviour
to achieve the earlier initiation and use of strong opioid treatment.
Trial registration: Current Controlled Trials ISRCTN18281271.
Funding: This project was funded by the National Institute for Health Research Programme Grants for
Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 9, No. 15. See the NIHR Journals Library website for further project information.
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Each year in England and Wales, 150,000 people die from cancer, of whom 110,000 will suffer fromcancer pain. Research shows that, for the 65–80% of cancer patients who spend the last 6 months
of life at home, pain remains common, severe and undertreated, and may lead to hospital admissions.
We interviewed patients, carers and health professionals and found that pain in advanced cancer is
difficult for patients to manage, and that referral for palliative care support is often late (within weeks
of death). We found that patients could benefit from better access to strong opioids and from better
support in managing pain medicines.
We identified aspects of care that would most support patients in managing themselves and we
developed and tested our Tackling Cancer Pain resource and an electronic pain monitoring system
called PainCheck.
We recruited 161 oncology outpatients with cancer pain to our clinical trial and randomly allocated
them to an intervention arm or a control arm. The intervention arm patients received supported
self-management alongside standard community palliative care (Tackling Cancer Pain and PainCheck).
The control arm patients received standard palliative care support alone. We found no differences
in pain severity or in quality of life between the two trial arms. The economic evaluation of the trial
indicated that supported self-management could result in lower health-care costs than usual care.
In conclusion, the trial demonstrated that patients were experiencing high levels of pain at trial
entry (around 1 year before they die), that earlier involvement of palliative care resulted in significant
improvements in pain for participants in both trial arms and that it is feasible to engage this population
in large-scale research. The lack of difference could be because patients and professionals did not use
the interventions as much as we had hoped, and because control arm patients had earlier access to
palliative care than with routine practice.
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Each year in England and Wales, 150,000 people die from cancer, of whom 110,000 will suffer from
cancer pain. Patients spend 65–80% of their last 6 months of life living at home (community-based
patients). Research shows that, for these patients, pain remains common, severe and undertreated,
and may lead to hospital admission.
Objectives
1. To model and test a cancer pain pathway for patients with advanced cancer that optimises
support and advice, delivers brief educational interventions and can be delivered to promote
self-management.
2. To develop systems for capturing and communicating clinical and patient-reported outcomes
on pain assessment that can be integrated into the routine practice of community-based
health professionals.
3. To determine whether or not key aspects of medicines management, such as prescribing practice
and access to analgesia, can be modified to ensure that patients with cancer pain benefit from
timely intervention.
4. To implement and evaluate the clinical effectiveness and cost-effectiveness of a cancer pain
pathway (based on objectives 1–3) in reducing pain and related distress, and in reducing
pain-related hospital admissions.
Methods
Our work comprised four workstreams: three intervention development workstreams and one
evaluation workstream.
1. People: an integrated system of support
We conducted longitudinal qualitative interviews with patients and caregivers from oncology and
palliative care, exploring their experiences of pain and pain management. We analysed local data and
obtained data from 64 hospices nationally. We calculated the interval between time from referral
to palliative care services and death for each patient, and then calculated the median value of this
variable for the whole sample. We identified which factors influenced this interval.
We explored oncology health professionals’ perceptions of the advanced cancer trajectory, their work
relating to it and their engagement with palliative care over its course, and examined variations in
primary care practice. We then reviewed existing literature on patient support materials and surveyed
regional oncology units to assess information provision for patients with advanced cancer regarding
palliative care support.
We took the results from four existing systematic reviews of educational interventions and integrated
these with the findings of three systematic reviews of qualitative research exploring patient and carer
experiences of specific cancer pain management advice to inform the development of an educational
intervention for patients and carers. We undertook focus groups to ascertain specialist palliative care
health professionals’ views on patient self-management of cancer pain. This work informed the
development and feasibility testing of our educational intervention, Tackling Cancer Pain.
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2. Data: routine assessment and monitoring of pain
We conducted face-to-face interviews with both patients with advanced cancer receiving palliative care
and health professionals providing community palliative care to understand user needs and concerns.
We began by identifying existing approaches to information and communication technology use in pain
management in palliative care services through a systematic review. Requirements identified from user
engagement activities informed the architecture and content of an information and communication
technology system.We tested the underlying infrastructure of the system to ensure its integrity for
data collection. We conducted this work with participants with chronic pain before carrying out usability
testing of a prototype system with patients with advanced cancer and health professionals, which led to
the inclusion of the information and communication technology system in the main feasibility study.
3. Medicines: good management of analgesic drugs
Using an innovative cross-organisation data linkage process, we linked data from patients who died
from cancer and analysed prescribing data in the year before death to determine access to opioids
and factors that influenced this access. We conducted a systematic review of studies that examined
the association between regular systemic opioid analgesia and survival in adult patients with cancer to
determine whether or not opioid analgesia was associated with a shorter survival period. We examined
the extent and impact of non-medical prescribing within palliative care through regional and national
surveys of nurse and pharmacist prescribers. We developed a novel methodology to establish the level
of non-medical prescribers’ activity in palliative care across England between April 2011 and April 2015
using specific palliative care drugs prescribed by these health professionals. We used data extracted by
NHS Digital from the electronic Prescribing Analysis Cost Tool (ePACT) system.
Using a structured online survey, we explored the knowledge, experience and opinions of health
professionals about the role that community pharmacists could play in the management of patients
with cancer pain.We conducted a qualitative study to explore how patients with pain from advanced
cancer used community pharmacies and their attitudes towards medicine consultations with pharmacists.
We triangulated these findings to establish pathways to identify and refer patients to a community
pharmacy for a Medicines Use Review intervention.
We modelled a Medicines Use Review for patients with cancer pain and their carers. We first
conducted a systematic review and meta-analysis of pharmacist educational interventions for cancer
pain management. Following this, we held a multistakeholder workshop and used these, together
with our patient interview findings, to inform our Medicines Use Review intervention prior to
evaluating its feasibility and acceptability.
We invited patients with advanced cancer living in the community to a consultation with a pharmacist
in the pharmacy or remotely by telephone outreach. We provided an interactive learning event for the
pharmacists to address consultation and palliative care team networking skills. After the consultations,
we assessed medicines-related problems and actions by the pharmacists, including referral of patients
to other team members, and conducted a survey of patients’ experiences.
4. Evaluation: cost-effectiveness and feasibility
We developed two approaches to estimate the cost-effectiveness of a supported self-management
intervention: a model-based economic evaluation and a trial-based economic evaluation. For the
model-based economic evaluation, we conducted a discrete choice experiment with patients with
cancer pain to understand their preferences for pain management services and to inform service
development. Focus groups were used to develop the attributes and levels of the discrete choice
experiment. We explored how a questionnaire survey could capture quality of life (utility) and
resource use to inform the model-based economic evaluation.
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In the trial-based economic evaluation, we estimated costs and health-related quality-of-life outcomes
using seemingly unrelated regression. We calculated incremental cost-effectiveness ratios per quality-
adjusted life-year for the trial period.
We conducted a pragmatic, multicentre, randomised controlled trial to assess the feasibility, acceptability,
clinical effectiveness and cost-effectiveness of a multicomponent intervention for pain management in
patients with advanced cancer (the trial was registered as ISRCTN18281271). The intervention comprised
our Tackling Cancer Pain patient support book (developed in work package 1) and the PainCheck online
symptom monitoring system (developed in work package 2).We recruited 160 patients with solid tumours
(locally progressive or metastatic), rather than those with haematological cancers, and randomised
them to receive either enhanced supportive care alongside standard community palliative care support
(intervention) or standard palliative care support alone. Evaluation measures were conducted at baseline,
week 6 and week 12 (end of study).
Results
1. People: an integrated system of support
We found that pain in advanced cancer is complex, multidimensional and dynamic. This presented
a major challenge for patients in managing it and in securing ‘good enough’ relief, consistent with
balancing medication side effects and sustaining what they valued in their lives. For patients and
caregivers, neither pain relief nor the expertise in managing it was secured once and for all.
Nationally, the median time between referral to palliative care services and death for 42,758 patients
is 48 days. Significant differences in referral to death days are found between those with cancer
(53 days) and those without cancer (27 days). As age increases, the median number of days from
referral to death decreases.
Oncology health professionals said that although the term ‘advanced cancer’ is commonly understood
as ‘active’, non-curable cancer, it conceals considerable variability in the advanced cancer trajectory.
The varied pattern of survival across cancer types reinforces the need for supportive care alongside
treatment in advanced cancer.
Within primary care, we identified distinct differences in the drivers of and barriers to community
advanced cancer care co-ordination. These included proactive identification processes, time and
resource pressures, unclear roles and responsibilities, poor multidisciplinary working, and inflexible
models of referral and prescribing.
Our literature review identified patient-related barriers to earlier integration of palliative care, including
misconceptions about what palliative care is and a limited understanding of the role and breadth of services
available. Our regional survey found that patient information relating to palliative care was rarely available.
Four systematic reviews of effectiveness were identified and integrated with three qualitative evidence
syntheses. Key components for self-management included individualised approaches to care; the
importance of addressing patients’ knowledge, skills and attitudes towards pain management; and the
significance of interdisciplinary working in the management of pain. We developed and tested our
Tackling Cancer Pain resource for acceptability.
2. Data: routine assessment and monitoring of pain
Patients with advanced cancer told us that an electronic system needs to take account of the complexity
of pain experiences and existing relationships with health professionals. Health professionals could
envisage the potential benefits of an electronic patient-reported pain monitoring system but had
reservations about how PainCheck would be implemented.
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The majority of the literature identified for our systematic review of the information and communication
technology system development in palliative care employed non-experimental research designs, and
no systems had been successfully implemented in routine care. Most information and communication
technology systems measured pain as part of quality-of-life measurements, although approaches to
assessing pain varied widely.
We developed and tested a prototype PainCheck system, which users were generally positive about and
found easy to understand, although they had some concerns about how it might work in clinical practice.
3. Medicines: good management of analgesic drugs
Strong opioids were prescribed for 48% of patients in the last year of life at a median of 9 weeks before
death. Prescribing was not influenced by cancer type, duration of illness or sex, but it was strongly
associated with patient age; older patients were much less likely to be prescribed a strong opioid
than younger patients. Our systematic review suggested that opioids were associated with a shorter
survival period, but no definitive conclusions could be made because of methodological weaknesses.
Non-medical prescribers prescribed a wide range of drugs for cancer pain, but we identified scope to
maximise economic and clinical benefit by improving the transition from qualified to active non-medical
prescriber. Nationally, the number of prescriptions issued by non-medical prescribers rose by 28%
every year between 2012 and 2015; this growth was almost entirely attributable to an increase in
opioid prescriptions. However, the contribution of non-medical prescribing to overall palliative care
prescribing was very small.
Patients largely agreed that community pharmacists should become part of the palliative care team
but said that additional training about cancer pain management and consultation skills were needed.
Patients had low expectations of what community pharmacists and their teams might provide, but
most accepted the idea of a community pharmacy medicines consultation. We found a need for pain
medicines support among patients with advanced cancer, particularly among those who were not
receiving specialist palliative care.
Our systematic review and meta-analysis found improvements in pain intensity following a pharmacist-
based medicines review. In our Medicines Use Review feasibility study, we delivered consultations to
patients in which many medicines-related problems were identified. Most patients would recommend
the consultations to others, and a small number of patients reported that their knowledge about their
pain medicines had improved.
4. Evaluation: cost-effectiveness and feasibility
We found both interventions to be cost saving. The model-based economic evaluation demonstrated
that the most important driver of cost-effectiveness was the level of pain reduction, and, using a
cost-effectiveness threshold of £20,000 per quality-adjusted life-year, there was a 67% chance that our
interventions were optimal. The model-based evaluation was not used to extrapolate the outcomes of
the trial over a longer time horizon because the statistical analysis of the trial data found no difference
between the trial arms in terms of the primary outcome measure (pain severity). The trial-based economic
evaluation indicated that our interventions reduced health-care costs by £587 per patient. The difference
in quality-adjusted life-years between the trial arms was negligible and this was not in line with the decision
model that had been developed.
Between October 2015 and January 2018, 161 patients were randomised [80 in intervention (supported
self-management), 81 in control (usual care)]. Three-quarters of randomised participants had Brief Pain
Inventory score of 4–6, representing mild to moderate levels of pain, whereas one-quarter had a score of
7–10, representing severe levels of pain.
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In the intervention arm, 72 patients (90%) received Tacking Cancer Pain and 47 (58.8%) were introduced
to the PainCheck online monitoring system. A total of 115 (71.4%) patients completed at least one
successful follow-up, with questionnaires completed at 6 or 12 weeks post randomisation. Median
survival from randomisation was 53 weeks. Primary and sensitivity analyses found no significant
treatment differences for the primary outcome or for other secondary outcomes of pain severity items
on the Brief Pain Inventory. The trial did not demonstrate that the intervention significantly affected
health-related quality of life or cancer-specific quality of life. The supported self-management arm
appeared to incur higher hospice use costs than usual care, but the latter arm incurred higher hospital
use cost.
Our process evaluation revealed that half of patients and one-third of oncology professionals described
the association of palliative care with closeness to death as a barrier to accessing supportive care
for pain. Patients felt that taking part in the trial had enhanced their care and provided them with a
support system. Patients and health professionals asserted that both Tackling Cancer Pain and PainCheck
improved patients’ self-management of pain. However, many health professionals reported a lack of
knowledge about, understanding of and familiarity with PainCheck, which, in turn, undermined their
support and enthusiasm when introducing it to patients.
Limitations
In the randomised controlled trial, the low fidelity of the interventions (in particular the low
engagement of patients and professionals with PainCheck) and the challenge of the study design
that forced the usual care arm to have earlier access to palliative care services might explain the
lack of observed benefit. Overall, 71% of participants returned outcome data at 6 or 12 weeks and
so we used administrative data to estimate costs. Our decision model did not include the negative
trial results from our randomised controlled trial and, therefore, may overestimate the likelihood of
cost-effectiveness.
Conclusions
Our programme of research has revealed new insights into how patients with advanced cancer manage
their pain and the challenges faced by health professionals in identifying those patients who need more
help. This was also evidenced by late referrals to palliative care nationally and the lack of information
available to patients regarding this type of care. We found that access to opioid analgesia occurs
relatively shortly before death. Initiatives such as non-medical prescribing have the potential to improve
this situation, but their current impact is limited. There is a clear opportunity to provide better support
for medicines management by engaging pharmacists more closely in cancer pain management, and we
have demonstrated a means of delivering this, which still requires further evaluation.
Patients and health professionals recognised the value in providing materials to support self-management
and in using electronic symptom monitoring systems. Patients and health professionals had reservations
about how these might be implemented in practice. Nevertheless, we co-designed these interventions
with patients and health professionals using a theoretical basis and user testing to optimise acceptability.
We do regard the low engagement not as a failure of the research study but as a finding; engagement
with digital technology in routine palliative care was low.
We identified aspects of pain management of greatest value to patients and used these to develop a
health economic model. Our clinical trial showed that enhancing existing community palliative care
support with patient educational materials and electronic symptom monitoring did not result in
additional benefit. Both the decision model and the economic evaluation of the trial indicated that
supported self-management could be cost-effective. The trial clearly demonstrated that patients
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experience high levels of pain around 1 year before they die, and that earlier integration of palliative
care (involvement in the trial a median of 53 weeks before death compared with undergoing routine
care a median of 7 weeks before death) resulted in significant reductions in pain among participants in
both trial arms.
Trial registration
This trial is registered as ISRCTN18281271.
Funding
This project was funded by the National Institute for Health Research (NIHR) Programme Grants for
Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 9, No. 15. See the NIHR Journals Library website for further project information.
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During the research programme, we made one significant modification to the original protocol. Specifically,
we amended the recruitment strategy in our randomised controlled trial (RCT) (work package 4) after the
trial commenced to increase accrual. Our trial opened in October 2015 at six sites in which we aimed to
screen for oncology outpatients and for those with pain. We wanted to randomise participants to usual
care (UC) or to an intervention that consisted of early referral to palliative care, educational support and
electronic pain monitoring. We realised that the design had inadvertently inhibited recruitment and caused
trial recruitment to fall behind the target. Our screening process for the trial identified patients with pain
who would not have been identified as such in routine care. This screening process alerted the oncology
teams, who were then reluctant to enter patients into a trial in which the control arm was to continue
with UC (i.e. no specific support). We recognised this issue early and in February 2016 began to discuss
amending the design so that all patients identified with pain could be randomised to standard palliative
care support or enhanced palliative care support, which included several of our interventions. We moved
to secure all sponsor and Health Research Authority approvals as quickly as possible, and the new protocol
was in place by 12 April 2016, supported by a new round of site visits for additional training.There was a
clear increase in recruitment following the protocol change and sites were much more comfortable entering
patients to the new design.The inevitable delays in our project plan necessitated an application for a trial
extension, which we discussed with our National Institute for Health Research (NIHR) Programme Grants for
Applied Research (PGfAR) manager and which was supported by our independent Trial Steering Committee.
Background
Pain is the most common presenting feature at the diagnosis of cancer and is the symptom that patients
with this disease fear most.1,2 This fear is supported by studies of pain prevalence and intensity. A
systematic review by van den Beuken-van Everdingen3 showed that pain prevalence rises with disease
progression and that pain affects approximately 64% of patients with advanced cancer; a large
European survey1 showed that 45% of all patients with advanced cancer experienced pain of moderate
to severe intensity (at least 5 on a pain rating scale of 0–10).3 More recently, in an update to these data
that was published almost 10 years later,4 these estimates were 66% and 55%, respectively, suggesting
that little progress had been made in cancer pain management during this period. Each year in England
and Wales, 150,000 people die from cancer; these data suggest that 110,000 of these patients will
suffer from cancer pain.
Greco et al.5 estimated the adequacy of treatment for cancer pain and identified that approximately 32%
of patients did not received analgesia proportionate to their pain severity. This potentially represents an
improvement on an earlier estimate,6 which suggested that 43% of cancer patients were undertreated.
Nevertheless, a significant number of patients with cancer pain are not well managed.
Aims and objectives
We aimed to develop and evaluate pain self-management interventions for community-based patients
with advanced cancer. We conducted a programme of mixed-methods intervention development work
leading to a pragmatic multicentre RCT of a multicomponent intervention for pain management
compared with UC, including an assessment of cost-effectiveness (Figure 1).
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Our specific objectives were to:
1. model and test a cancer pain pathway for patients with advanced cancer that optimises support and
advice, delivers brief educational interventions and can be delivered to promote self-management
2. develop systems for capturing and communicating clinical and patient-reported outcomes on pain
assessment that can be integrated into the routine practice of community-based health professionals
3. determine whether or not key aspects of medicines management, such as prescribing practice and
access to analgesia, can be modified to ensure that patients with cancer pain benefit from
timely intervention
4. implement and evaluate the clinical effectiveness and cost-effectiveness of a cancer pain pathway
(based on objectives 1–3) in reducing pain and related distress, and on reducing pain-related
hospital admissions.
Work package 1: can we model and test a cancer pain pathway for patients with
advanced cancer in which support and advice are optimised, and in which brief
educational interventions can be delivered to promote self-management?
Work package (WP) 1 (Figure 2) explored patient, caregiver and health professional perspectives on
existing care pathways for pain management in advanced cancer. Previous research7 highlighted the
complexity of advanced cancer pain, with pain control often understood by patients as whether or not
activities or tasks can be completed and if relationships with family or friends are maintained. Gaining
a greater understanding of patient interaction with health services and barriers to pain management
at the level of health professional or health system is crucial when refining cancer pain pathways.
Furthermore, an understanding of existing pathways can inform the timing and format of interventions
seeking to support and improve pain management in patients with advanced cancer.
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Work package 1: people – an integrated
system of support
Three key areas of activity were undertaken in this WP, underpinned by the following researchquestions:
1. Which mechanisms exist within current systems of cancer care for identifying and co-ordinating
support and treatment for cancer-related pain and what barriers exist at the health professional
and system levels?
2. What is the optimal timing for palliative care interventions for patients with advanced cancer and
their carers?
3. What is the evidence for educational approaches in the self-management of cancer pain and how
can this be used to develop resources for patients with advanced cancer?
The first two questions were addressed through research activities to determine factors that influence
access to and interaction with services to support cancer pain management. The third question involved
the design and development of a self-management education tool for pain management in patients
with advanced cancer. By ‘palliative care services’, we mean those services that provide specialist
multidisciplinary palliative care (hospice inpatient units, day-care centres and outpatient and community
nursing services, as well as hospital-based palliative care teams). These services are characterised by
multidisciplinary teams whose members have undergone recognised training in palliative care. This is
different from a generalist palliative care approach used by non-specialist professionals, such as general
practitioners (GPs), oncologists and district nurses.
Work package 1.1: modelling a care pathway
Understanding the perception of services to support pain management by patients with
advanced cancer and their carers
Hackett et al.8
We interviewed patients and carers at two time points to explore their experiences of pain in advanced
cancer and the processes in which they engaged to manage pain. Patients were drawn from oncology
outpatient clinics in a tertiary cancer centre and a hospice palliative care service. In total, 35 patients
(29 patient–caregiver dyads and six patients on their own), of whom 21 were first interview participants
and 14 were second interview participants, were interviewed. Four open-ended audio diaries were
completed. A grounded theory analytic approach was employed. We used the method of constant
comparison within cases over time and across cases to explore patterns of variation in the experience
of pain and the strategies employed to manage it, as these were shaped by the course of illness, disease
process, treatment regimen and access to supportive care, including for pain.
We found that pain in advanced cancer is complex, multidimensional and dynamic: patients and
caregivers reported varying types and sources of pain, experienced both singly and together, that
altered over the advanced illness course. For patients, pain management is an active, dynamic process,
involving considerable ongoing work, so that developing expertise in pain management is not a one-off
achievement. The amelioration of pain is uncertain and involves much trial and error (including by
professionals) in the combinations of pharmacological and other therapeutic options, particularly
because bone pain and neuropathic pain, common here, are more difficult to treat. Thus, a medication
regimen often involves different types and combinations of drugs alongside prophylaxis medication to
manage side effects. For most patients, managing pain is about securing ‘good enough’ relief that is
consistent with balancing the side effects of medication and sustaining what they value in their lives.
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Three distinct patterns of pain were identified, varying in their degree of complexity, severity,
transience/persistence and perceived control over pain, which are of practical and theoretical
significance. This research has been published.8
Determining factors that influence the timing of palliative care
interventions for patients with advanced cancer and their caregivers
With a focus on access to services to support patients with advanced cancer, we sought to determine
at which point before death patients are referred to palliative care services. Through a retrospective
data analysis, we determined the timing of referrals to palliative care services prior to death in a large
UK city, before extending our work to determine the timing of referrals across the UK.
Emerging evidence indicates the benefits that can arise from contact with palliative care, including
improvements in symptom control and quality of life, better outcomes for families, and increased
satisfaction with care.9 Early referral to palliative care has also been shown to lead to multiple
benefits for patients and their families.10 The drive to increase referrals at an earlier stage in the
disease trajectory has been notable for patients with cancer through, for example, the integration
of oncology and palliative care services.11 This was highlighted recently by the American Society
of Clinical Oncology and the European Society for Medical Oncology, which suggested that, for those
with advanced cancer, palliative care should form part of care alongside active treatment.12,13 The
literature on the benefits of early referral for patients with conditions other than cancer also highlights
multiple benefits and supportive needs across the illness trajectory.14 A current research priority is
to understand approaches to early referral and the barriers to the integration of palliative care.15
A key starting point is to understand current practice.
A marker of the quality of palliative care, reflecting how services are operating, can be the timing of
referrals to services.16 There are, however, very few data on the length of time that patients have
access to palliative care at a population level, limiting efforts to understand how this access can vary
based on the patient’s diagnosis or other characteristics.17 Data are also limited beyond the UK, with
wide variation across the literature when reporting the time between referral to a service and death.
Reports that are available show a varied picture both across and within countries. For example, when
looking across the Republic of Korea, the USA and the UK, figures vary from 12 to 21 days,18–20 which
can then be compared with figures in Canada of 60–70 days.21 Through a series of studies, we sought
to determine and report, with greater accuracy, the duration of palliative care received by patients in
the UK both regionally and nationally.
Timing and duration of palliative care in a large UK city
Bennett et al.20
We sought to determine when referrals to palliative care occur by exploring the length of time between
an initial referral and death. A retrospective cohort study was undertaken that sought to determine the
timing of referrals to three specialist palliative care services: two hospice-based community palliative
care services and one hospital-based inpatient palliative care service. For each patient who had been
referred to any of the three services, we identified the date on which they were first referred to the
service and then calculated the median number of days between the first referral and the patient’s
death. We also examined variation in the timing of referral before death across a range of characteristics
of the patient (age, sex and diagnosis) and the service to which they were referred. Data were included
for 4650 patients referred to specialist palliative care services in Leeds between April 2012 and March
2014. The median age of the sample was 75 years, and 3903 (84.0%) of the patients had a diagnosis of
cancer. Overall, the median duration from referral to death for all patients was 34 days. This varied by
hospital-based (20 days) and community-based palliative care (46 days). Age, diagnosis and place of
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referral were significant predictors of the duration of palliative care before death.We found that age was
independently associated with the duration of palliative care, regardless of diagnosis. For patients aged
> 75 years, 29 fewer days of palliative care were received than for patients aged < 50 years. Furthermore,
patients with conditions other than cancer were found to receive 13 fewer days of palliative care than
patients with cancer. When looking at services, we found that patients referred to hospital palliative care
were receiving 24.5 fewer days of palliative care than patients being referred to community palliative care
services. The study suggests that the current timing of referral to palliative care may limit the benefits
to patients in terms of improvements in end-of-life care, particularly for older patients and patients with
conditions other than cancer. Given that retrospective routinely collected clinical data were used, we do
not have data on date of diagnosis, which prevents us from relating the duration of palliative care services
to the duration of clinical awareness of disease. Late diagnosis may be a key factor in late referral,
although the almost universally short duration of palliative care in our cohort suggests that this factor is
unlikely to account for the observed referral pattern. This research has been published.20
Timing and duration of palliative care across the UK
Allsop et al.22
Having identified that patients in Leeds were receiving a median of 34 days of palliative care prior to
death [when community (46 days) and hospital (20 days) service data were combined], we sought to
understand the national picture. Working in partnership with Hospice UK (London, UK), the research
team conducted a national retrospective cohort study of the timing of referral to hospice-based
specialist palliative care. The aim of the study was to identify patient and organisational factors that
influence the duration of hospice-based palliative care in the UK prior to death. Overall, 64 UK hospices
(i.e. one-third of all UK hospices) providing specialist palliative care inpatient beds and community services
extracted data for all adult decedents (aged > 17 years) with progressive advanced disease who had
received a prior referral (e.g. inpatient, community teams and outpatient), who died between 1 January 2015
and 31 December 2015. Data were requested for factors relating to both the patient and the hospice
site. In total, data for 42,758 decedents were included in the analysis. The overall median time from
referral to death was 48 days. Significant differences in referral to death days were found for those with
cancer (53 days) and for conditions other than cancer (27 days). As age increases, the median number of
days from referral to death decreases (those aged > 50 years, 78 days; those aged 50–74 years, 59 days;
and those aged ≥ 75 years, 39 days). An adjusted multivariable negative binomial model demonstrated
that increasing age was a significant predictor of fewer days of hospice care, as was being male, having
a missing ethnicity classification and having a non-cancer diagnosis. This work provided a broader
context for earlier findings on the timing of referral, with more than half of all patients being referred
to palliative care < 7 weeks before death. This provided the national context in which to understand the
Leeds data. The median of 46 days between referral and death for community-based patient in Leeds
aligns with the 48 days found in national data relating to referrals to hospices before death.
The national survey highlights that, despite increasing rhetoric around the need for early referral to
palliative care, patients with advanced disease across the UK receive referrals to hospice specialist
palliative care very late in their illness trajectory. Age and diagnosis persist as determinants of duration
of hospice specialist palliative care before death. Recent projections of the demand for palliative care
by 2040 suggest that health-care systems need to adapt to the age-related growth in deaths from
chronic illness, with dementia and cancer likely to be the main drivers of increased need.23 Findings
from this study suggest that there may be a need for reorientation of services to both older age
groups and non-cancer conditions; both groups are associated with limited duration of hospice-based
palliative care prior to death. The remit of palliative care has expanded to have relevance for any
patient at an early stage in the disease process whose death can be medically anticipated.24 Such
a broad remit, when people are living longer with an increased illness burden, suggests that many
patients will need primary, secondary and specialist palliative care. With increasing calls to reduce
DOI: 10.3310/pgfar09150 Programme Grants for Applied Research 2021 Vol. 9 No. 15
Copyright © 2021 Bennett et al. This work was produced by Bennett et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
7
hospital bed-days in the last months of life and to support patient preferences for home death, it is
particularly important that community-based specialist palliative care can consider how provision
might match demand. This research has been published.22
Work package 1.2: early identification of patients by health professionals
Exploration of oncology health professionals’ perceptions of the advanced cancer trajectory
We explored oncology health professionals’ perceptions of the advanced cancer trajectory, and identified
transition points requiring mobilisation of supportive and palliative care and the mechanisms in place to
effect transition. Interviews were conducted with 16 health professionals in a tertiary cancer centre: nine
medical and clinical oncologists and seven clinical nurse specialists (CNSs) providing treatment and support
to patients in respect of eight cancer types (multiple myeloma, colorectal, breast, prostate, gynaecological,
head and neck, lung, and renal). Data were analysed using a grounded theory approach.
We found that, although the term ‘advanced cancer’ was commonly understood as ‘active’, non-curable
cancer among oncology health professionals, it concealed considerable variability in the advanced
cancer trajectory. The varied pattern of survival across cancer types, including new treatment
modalities that extend life, means that the trajectory projected for advanced cancer may extend
for years at one end of the spectrum (typical of breast and prostate) to months at the other (lung),
with varying patterns of oncology involvement from intermittent to continuous with advance cancer
patients. Drawing on professionals’ accounts and prior interviews with patients and carers, and time
to death, we delineated three broad advanced cancer trajectories that varied in duration and shape,
and that informed the pattern of engagement of cancer specialists with patients and the overall work
organisation. Within each trajectory, critical transitions were identified, requiring mobilisation of support
and resources including support with symptom management from palliative care services alongside
treatment. The length of time that patients may be involved with oncology services and the regularity of
their engagement mean that these services provide a level of continuity of support, perceived expertise
and accessibility for patients in crises, such that they are regarded as the ‘key’ services.
Alongside oncologists, CNSs provided emotional support and comfort, provided clinical expertise in
illness and symptom management, and navigated patients to services and support. We did not find that
oncology professionals were reluctant to involve palliative care alongside treatment or to facilitate
transition to end-of-life care. CNSs in particular assumed a proactive role in encouraging patients to
accept such assistance, although patients themselves were often reluctant, viewing this acceptance as
‘giving up’. Apparently at odds with the ‘big data’ picture, this applied only to those patients in receipt
of treatment to control their advanced cancer, which tends to exclude those with frailty and who are
unable to tolerate treatment toxicities and those who refuse further treatment.
Exploration of primary palliative care teams on co-ordinating and managing people
with advanced cancer
Hackett et al.25
Alongside patients’, caregivers’ and oncologists’ perspectives, we engaged with primary health-care
teams, which are a key component of care delivery to patients with advanced cancer during the last year
of life. The Gold Standards Framework is proposed as a mechanism for co-ordinating and guiding
identification, assessment and support. There are still considerable variations in practice despite its
introduction. The aim of this qualitative study was to improve understanding of variations in practice
by exploring the perspectives and experiences of members of primary health-care teams involved in
the care of patients with advanced cancer. Qualitative, semistructured interviews, focus groups and
non-participatory observations involving 67 members of primary health-care teams providing palliative
care were undertaken. Data were analysed using a grounded theory approach. We identified distinct
differences in the drivers of and barriers to community advanced cancer care co-ordination, which
WORK PACKAGE 1: PEOPLE – AN INTEGRATED SYSTEM OF SUPPORT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
relate to identification and management, and access to effective pain management, and go some way to
explaining variations in practice. These include proactive identification processes, time and resource
pressures, unclear roles and responsibilities, poor multidisciplinary working, and inflexible models for
referral and prescribing. These provide valuable insights into how health professionals work together
and independently within an infrastructure that can both support and hinder the provision of effective
community palliative care. Although the Gold Standards Framework is a guide for good practice, alone
it is not a mechanism for change. Rather, it provides a framework for describing quality of practice that
was already occurring. Consequently, there will continue to be variations in practice. This research has
been published.25
Information provision for patients with cancer
Taylor et al.26
Increasing evidence suggests that, for patients with a range of advanced cancers, earlier integration
of palliative care should be an essential component of their care.27–31 Communication is an important
element of the provision of advanced cancer care32 and may play a role in facilitating awareness of
and access to palliative care services. However, a high level of unmet information needs exists among
patients whose care has become palliative in focus.33 We conducted a study to understand the current
evidence on the information provision for patients with advanced cancer while exploring where deficits
in provision may exist. The study was conducted in three distinct phases: (1) a literature review, (2) a
regional audit of patient information and (3) a critique of patient information. The literature review was
conducted as part of a scoping exercise to focus the direction of future research projects. The review
highlighted particular issues of interest around patient information that were investigated further in
the audit. The literature review identified patient-related barriers to earlier integration of palliative
care, misconceptions of what palliative care is and a lack of understanding of the role and breadth of
services available.34 The lack of information available to patients about palliative care and their unmet
information needs was evident in the literature, which led us to conduct an audit of patient palliative
care information in our geographical area. Our regional audit of patient information resources found
that patient information relating to palliative care is not widely available to cancer patients. Our audit
showed that < 13% of all inpatient units, 7% of outpatient departments and 25% of chemotherapy
day units had written information available for patients regarding palliative care. Despite this, > 90%
of palliative care teams that were surveyed said that information leaflets had been produced but
were not in routine circulation. Our audit shows that, although information resources exist within the
trusts, these are often distributed to patients only after they have received a palliative care referral.
Our review of the content of patient information resources, where these exist, shows considerable
variation. The majority of the resources fail to describe the referral process and what patients can
expect once they have been referred. None of the information leaflets explain that palliative care can
be integrated alongside oncology care. Patient and health professionals’ understanding of this concept
is key to achieving an integrated service in which patients can receive appropriate palliative care input
alongside cancer treatment.35 More research is required to explore ways to disseminate information
about palliative care effectively and sensitively. This research has been published.26
Work package 1.3: promoting self-management
Developing educational approaches in the self-management of cancer pain for patients
with advanced cancer
A simultaneous component of the WP was focused on developing education materials to support
patient self-management of pain. Supporting self-management has become a standard approach for
health professionals working with people who experience chronic non-cancer pain,21,22 and many
studies and reviews have reported that patient-focused educational interventions, including self-
management, can also improve pain control in patients with advanced cancer.23–30 We sought to
determine the optimal content, format and timing of an educational intervention for patients and
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carers to support the self-management of cancer pain. This is consistent with National Institute for
Health and Care Excellence (NICE) guidance on prescribing strong opioids for pain in adult palliative
care, which describes the importance of providing written and verbal information to support patients.36
Systematic review of evidence for self-management education interventions for patients
with cancer
Flemming et al.37
A review of evidence drawn from systematic reviews of complex interventions was combined with a
synthesis of qualitative research to identify the key components of a self-management intervention
for advanced cancer pain. We identified four systematic reviews examining interventions for the
self-management of advanced cancer pain. Although attributes of a pain management intervention
were recommended in each of the reviews, the essential key components could not be determined.
As part of subsequent qualitative evidence syntheses, a further three systematic reviews were identified
and integrated with the effectiveness reviews. The key components of a self-management intervention
following the integration included the importance of addressing patients’ knowledge, skills, individualised
approaches to care and attitudes towards pain management, alongside the significance of the role of team
approaches and interdisciplinary working in the management of pain. Mapping the findings of each paper
onto a behaviour change framework led us to identify the contextual and intervention components that
are essential for the development of successful educational programmes.We concluded that educational
interventions to promote the self-management of advanced cancer pain by patients and that their carers
should seek to include content that addresses how individuals manage their pain in the context of their
situation and that of their health professionals, while also focusing on those intervention functions that are
known to influence behaviour. This research has been published.37
Understanding patient, carer and health professionals’ perspectives on the role of
educational interventions for self-management of cancer pain
Hughes et al.38
This study was undertaken to ascertain the views of specialist palliative care health professionals on
patient self-management of cancer pain to inform the development of a new educational intervention.
Focus group interviews were conducted with 17 health professionals [community CNSs, n = 6;
complementary therapists, n = 3; hospice nurses, n = 5; hospice social worker, n = 1; hospice spiritual
care co-ordinator, n = 1; and palliative care consultant physician, n = 1). The aim of the focus groups was
to elicit experiential perspectives that would help us to extend and refine an educational intervention
that focused on the use of strong opioids for control of cancer pain, which was produced and tested
during earlier work by the team.39 Participants viewed self-management of cancer pain as desirable
and achievable, but also as something that could be problematic. Challenges to self-management were
perceived in patient attitudes and behaviours, health professionals’ own beliefs and actions and the
wider social system. Practitioners showed awareness of potential tension between their espoused views
(the desirability that patients manage pain autonomously) and their tacit views (the undesirability
of patients managing pain in ways that conflict with health professionals’ knowledge and identity).
This research has been published.38
Developing an educational self-management resource for patients with advanced cancer
Following on from the systematic review and health professional engagement, outlined above, two
stages of patient engagement occurred: (1) focus group interviews with patients and family caregivers
to understand perceptions of ‘self-management’ for cancer pain and methods for delivery, and (2) a
feasibility study with community-dwelling adults with pain from advanced cancer that evaluated the
use of an educational self-management intervention for cancer pain. The first stage informed the
design of an educational self-management resource for patients with pain from advanced cancer
and their caregivers, and the second stage informed the feasibility of using this resource.
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Focus group interviews
We conducted a qualitative descriptive study by undertaking focus group interviews with patients and
family caregivers. We conducted four focus group interviews between August 2013 and January 2014:
three with patients and one with family caregivers. We recruited patients (n = 8) through day-care
services at two local hospices and through patient support groups at a cancer information centre. We
gained access to carers (n = 4) through a bereavement support group at one of the hospices. Patients
were aged 40–67 years (average age 58 years; five male, three female) with cancers of brain (n = 1),
breast (n = 2), bowel (n = 2), and prostate and throat (n = 2), and metastatic disease reported in the
bones and liver (n = 1). Family caregivers were aged 63–68 years (average age 65 years; all female). All
had been bereaved, and their partners had died from cancers of the stomach (n = 1), prostate (n = 1),
lung (n = 1) and skin (n = 1).
Patients and family caregivers reported varied perspectives on pain management, many of which were
incorporated directly into the educational materials that we created to support self-management.
For example, patients described their own self-management practices, including relaxation, distraction,
comfort measures and medication scheduling. The family caregivers we interviewed spoke about their
own activities to try to help relieve their partners’ pain, typically by administering pain medication, rather
than their partners’ self-management behaviours. One defining characteristic of the experience that they
reported was their partners’ unwillingness to talk about their pain. We concluded that education to
support self-management of cancer pain in advanced disease should incorporate practitioner, patient and
family caregiver perspectives.
Educational self-management resource
Tackling Cancer Pain: A Toolkit for Patients and Families is informed by a wider body of international
research that has investigated patient education for managing cancer pain, and by our own research
with patients, carers and health professionals. The programme outlined in the resource is based on
principles of adult learning and is available in a multimedia format. The intervention is targeted at
patients who have cancer pain that is not relieved by their current medication regime or by other
pain control measures. It is also available for family members of people with cancer who are closely
involved with the patient’s pain experience. The toolkit provides an information resource that may be
used independently by patients and families, or with the guidance of a health professional. Tackling
Cancer Pain consists of five sections: understanding cancer pain, talking about pain, using drugs to
manage pain, additional approaches to managing pain and getting more help. Each section contains
information and self-directed learning activities along with sources of further information. The toolkit
has been formatted at the suggestion of patients and their families in a loose-leaf ring binder with an
accompanying digital versatile disc (DVD); they considered that this gave them the time to explore the
resource and to reflect on and revisit it as required, using it very much as a reference. It can be readily
transferred into a web resource in the future but that format was not preferred at the time of undertaking
the work. Importantly, it is written in easily understandable lay persons’ language.
Feasibility study
We recruited community-dwelling adults with pain from advanced cancer, taking baseline measures of
pain intensity and frequency [using the Brief Pain Inventory (BPI)]40 along with assessing participants’
knowledge and experience of cancer pain [using the Patient Pain Questionnaire (PPQ)].41 We explained
the content, format and purpose of the Tackling Cancer Pain: A Toolkit for Patients and Families resource
and gave a copy to each participant. We asked them to watch or read (or both) self-selected parts
of Tackling Cancer Pain and to carry out associated learning activities from the resource that were
related to pain management for a period of 4 weeks. At 4 weeks, we conducted face-to-face interviews
with participants to understand the feasibility of the intervention in terms of the acceptability of both
its content and the mode of delivery. After a further 4 weeks we interviewed the participants again
and repeated the baseline measures.
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Twenty-two patients consented and completed baseline measures. Seven patients were lost to follow-up
before the first interview (died, n = 2; too unwell, n = 2; admitted to hospice, n = 1; unable to contact,
n = 2). Fifteen patients completed a first follow-up interview (4 weeks after baseline). A further five
patients were lost to follow-up before the second interview (died, n = 1; too unwell, n = 1; unable to
contact, n = 3). Ten patients completed a second interview (baseline+ 8 weeks), although only nine
of these patients provided complete data. Of the 15 participating patients, four nominated a family
caregiver who was willing to take part. Three family caregivers took part in a joint interview with the
patient and one caregiver was interviewed separately. Two family caregivers completed both interviews;
all were female. Three caregivers were spouses and one was a close friend of the patient. The average
age of the patients interviewed was 66.9 years (range 45–89 years). Six patients were female and nine
were male. The primary cancer diagnoses included stomach (n = 1), myeloma (n = 1), prostate (n = 5),
breast (n = 3), throat (n = 1), ovary (n = 1), endometrium (n = 1) and colon (n = 1) (and one undisclosed).
The time since diagnosis ranged from 13 years to < 1 year. The average age of the 22 participants
(female, n= 12; male, n= 10) who consented and completed the baseline measures (missing data for
one participant) was 71 years. The average age of the seven participants (female, n= 6; male, n= 1) who
completed the baseline measures but were not interviewed was 83 years (missing data for one participant).
Of the nine patients who provided complete data, four patients reported (using the BPI) having less
pain, on average, at the end of the study period and three patients reported having more pain. For
two patients, the average pain score (using the BPI) was unchanged. On the PPQ Experience subscale,
three patients reported less pain, three patients reported more pain and three reported no change.
Five patients indicated, according to the PPQ Knowledge subscale scores, that their knowledge of
cancer pain had increased. There was no change for two patients and the remaining two patients
reported having less knowledge at 8 weeks than at baseline (this may have been an artefact of
variation in the interpretation of the questions). Average scores for the overall utility of Tackling Cancer
Pain changed from 7.5 out of 10.00 at baseline to 7.2 out of 10.00 at 8 weeks.
We recognise the small number of patients who were able to contribute data to this stage of
development of the educational resource. However, we intended to understand only feasibility
of delivery and acceptability at this stage, as we considered our randomised clinical trial a more
definitive evaluation of this component of our complex intervention.
Commendation
In September 2016, Tackling Cancer Pain, our educational self-management resource, was highly
commended at the British Medical Association (BMA) Patient Information Awards. The BMA reviewers
described it as an excellent resource.
Work package 2: can systems for capturing and communicating clinical and
patient-reported outcomes on pain assessment be integrated into routine
practice by community-based health professionals?
In the UK, the application of information and communication technology (ICT) in health-care settings
has been highlighted as a means of improving patient outcomes42 and ensuring that patients receive
high-quality care.43 ICT can include all digital technologies that facilitate the electronic capture,
processing, storage and exchange of information.44 Electronic systems have been developed that use
ICT to facilitate the capture of clinical data directly from patients; these approaches are deemed
acceptable by patients.45 This workstream carried out user engagement with patients, caregivers and
health professionals to inform the development of an ICT system (Figure 3). The ICT system, which was
developed with a technology partner, aimed to facilitate routine reporting and management of pain for
patients with advanced cancer.
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Implementation feasibility study with clinical and
economic evaluation
Development and piloting of interventions to 
support self-management of pain by patients with
advanced cancer
Overall aim: to improve the management of cancer pain for palliative care patients and their carers who are living at home
Principal objectives: to enable patients and their carers to more easily access support and advice, communicate their pain and 
obtain timely and effective medication, and to evaluate the impact of our interventions in routine care





































































































































































































































































































The ICT systems have been developed to support different stages of the illness trajectory in cancer,
although their use to capture clinical data specifically in palliative care is at an early stage.46 Patients
in palliative care experience multiple physical symptoms47 that affect their quality of life (QoL) and
psychological well-being.48 Pain is reported by 66.4% of patients with advanced cancer,4,47 but this is
commonly undertreated.36 Frequently cited barriers to adequate pain management include knowledge
deficits, inadequate pain assessment and misconceptions regarding pain.49 The use of ICT is one
approach to addressing pain management barriers by facilitating greater communication between
patients and their palliative care health professionals.50 There is opportunity to develop and implement
online palliative care symptom reporting systems, with the aim of supporting timely communication.51
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Work package 2: data – routine
assessment and monitoring of pain
This WP addressed the following research questions:
1. What are the requirements of patients and health professionals in the design of ICT systems for
pain management in advanced cancer?
2. How should a system to support cancer pain self-management be designed and evaluated prior
to implementation?
3. Can ICT systems to support routine pain monitoring and assessment be implemented as part of
palliative care for patients with advanced cancer?
Three key areas of research activity were undertaken to address these questions:
1. user engagement with patients, caregivers and health professionals to understand their
requirements for the development of an ICT system for pain reporting
2. a complementary WP that involved the design and usability testing of an ICT platform developed in
response to identified user needs
3. a third strand of work evaluating the completed ICT system in the context of a trial.
Work package 2.1: developing an information management system
Developing an information and communication technology platform to support pain reporting and
assessment by community-based palliative care patients and their health professionals
To develop an ICT platform to facilitate pain reporting and assessment, we worked alongside a software
development company. We began by identifying the existing approaches to ICT use in pain management
in palliative care services through a systematic review.52 The team shared the requirements that were
identified from user engagement activities with developers to inform the architecture of an ICT system.
We tested the underlying infrastructure of the system to ensure its integrity for data collection. This
work was conducted with participants with chronic pain.53 We then completed usability testing of a
prototype system with patients with advanced cancer and health professionals prior to the inclusion of
the ICT system in the feasibility study.54 This work is described across three publications, as follows.52–54
Allsop et al.52
Our aim in this systematic review was to review existing ICT systems developed for pain management in
palliative care. The majority of the literature identified in our systematic review was of a non-experimental
research design. ICT systems included in the review were at various stages of development (planning,
analysis, design and evaluation), with no systems implemented into routine care. Most ICT systems
measured pain as part of a quality-of-life measurement and there was wide variation in the approaches
used to assess pain. We concluded that future development of ICT systems needs to increase the quality
and scale of development work, consider how recommendations for pain measurement can be integrated,
and explore how to effectively use system feedback with patients. This research has been published.52
Taylor et al.53
We recruited 34 participants with chronic pain who were asked to complete twice-daily pain assessments
over two consecutive days. Participants alternated their mode (personal computer/laptop, smartphone,
short messaging service or tablet computer) of accessing the ICT platform. Most participants completed
DOI: 10.3310/pgfar09150 Programme Grants for Applied Research 2021 Vol. 9 No. 15
Copyright © 2021 Bennett et al. This work was produced by Bennett et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
15
all four assessments. The system was reported to be useful for reporting pain. Participants suggested that
the platform could be useful to improve recall and monitoring of pain, promote self-management and
improve links with health professionals. Perceived benefits for health professionals included increased
understanding of pain experiences, improvements in pain monitoring and management, and enhanced
communication. This research has been published.53
Taylor et al.54
We undertook usability testing of the ICT system with 29 participants (advanced cancer patients,
n = 13; GPs, n = 4; CNSs, n = 4; district nurses, n = 3; palliative care doctors, n = 5). Patients and health
professionals were quickly able to understand and use the ICT system with very limited information
about what the system was designed to do or how it worked. Both patients and health professionals
were generally positive about PainCheck and found it easy to understand. Participants did have some
concerns about how PainCheck might work in clinical practice. Their concerns were largely related to
process issues, such as whether or not health professionals would have time to use the ICT system and
how a lack of response may have an impact on patient care. Patients’ and health professionals’ ability
to engage and use the technology was also mentioned as a potential barrier to ICT system integration.
This research has been published.54
Work package 2.2: ensuring engagement of patients and health professionals
Understanding user needs and perspectives to inform the development of an information
and communication technology system for pain reporting and assessment
Our goal was to adopt a patient-centred approach throughout all stages of the research programme,
working with a strong group of patient and public involvement contributors to bring their lived
experiences and perspectives of managing cancer pain central to the programme. We sought to
engage with end-user populations to determine the initial requirements of an ICT system for pain
management. Our earlier programme development work highlighted the complexities of and barriers to
the routine capture of data on pain and related distress focused on locations of care, circles of support
and management and sharing of data.50
Allsop et al.55
Face-to-face interviews were conducted with 13 patients with advanced cancer who were receiving
palliative care. Patients described technology as peripheral to existing processes of care. Simple
approaches that employ well-established technologies may be a preferred starting point. For system
content to have relevance for a patient with advanced cancer, it needs to take account of the complexity
of pain experiences and existing relationships with health professionals. Future research is required to
understand how ICT systems can be positioned flexibly within existing delivery models of palliative care.
This research has been published.55
Taylor et al.56
We carried out face-to-face interviews with 15 health professionals managing the palliative care of
patients living in the community. Participants included GPs, CNSs, district/community nurses and
palliative care doctors. Within our work, even the most sceptical of health professionals acknowledged
the potential benefits of implementing an electronic patient-reported pain monitoring system. Health
professionals had reservations about how PainCheck would work in practice. For optimal use, an ICT
system would need to be embedded within existing electronic health records. Electronic pain monitoring
systems were reported to have the potential to enable health professionals to support patients’ pain
management more effectively but only when barriers to implementation are appropriately identified
and addressed. This research has been published.56
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An eHealth intervention for routine assessment of pain: PainCheck
Allsop et al.57
We adopted a research-led development process that sought to develop an ICT system that met the
needs of patients and health professionals in real clinical settings and that was fit for clinical trial. Agile
software development methods were combined with health science research methods and ‘participatory
design,’ including diary studies, face-to-face interviews, questionnaires, observations of clinical settings,
prototyping, think-aloud, agile sprints, process reviews, requirements clustering and pilots. Three
iterations of ICT system development were necessary to prepare the tool for the feasibility study.
PainCheck, our information and communication intervention for the management of pain, was built
by a private company, X-Lab (Leeds, UK). X-Lab used a University of Leeds platform called QTool.
QTool is an electronic online questionnaire management software suite. QTool is used by health-care
practitioners and researchers to build and schedule complex questionnaires that can be completed by
patients and clinical staff. QTool has been used for patient-reported outcomes in cancer survivors and
self-report and management of adverse events during cancer treatment. QTool was selected as a
starting point for the development of PainCheck. This research has been published.57
PainCheck was accessed by patients and health professionals through a website hosted by the University
of Leeds. PainCheck allows patients to record their pain and gives them access to personalised pain
management advice. Patients are asked to respond to various questions, including providing a description
of their pain (Figure 4a); providing a rating of the intensity of current pain and the intensity of pain in the
last 12 hours (see Figure 4b); and giving the perception of control of their pain and how pain has interfered
with daily activities and their sleep. The majority of items seeking this information were taken from the BPI.
Patients are asked about pain management techniques, which of these techniques were helpful and
how likely they are to try them in the future (see Figure 4c). Various question response options are used,
including multiple choice, numerical slider scales (0–10 or 0–6) and free text. After completion, patients
are provided with a summary of their results and suggestions of pain management techniques that
they may want to try in the future (see Figure 4d). Health professionals can log in to PainCheck and
view all patients registered on PainCheck and see who has completed reports (Figure 5a). They are
then able to select a patient and view their responses to individual questions (see Figure 5b). Health
professionals are presented with a graph that tracks patients’ current pain and their pain in the last
(a)
FIGURE 4 Examples of PainCheck user interface. (a) Qualitative description of pain; (b) numerical sliding scales rating pain and
interference; (c) questions exploring what patients have undertaken to control their pain and if they were helpful (the second
page included self-help measure such as use of hot/cold, having a bath, exercise); and (d) patient feedback. (continued )
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FIGURE 4 Examples of PainCheck user interface. (a) Qualitative description of pain; (b) numerical sliding scales rating pain and
interference; (c) questions exploring what patients have undertaken to control their pain and if they were helpful (the second
page included self-help measure such as use of hot/cold, having a bath, exercise); and (d) patient feedback.
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FIGURE 5 Screenshots of health professional dashboard. (a) Health professional dashboard; (b) individual patient report;
(c) patient scores over time; and (d) record of health professional action.
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12 hours over time (see Figure 5c). Patients are given a ‘red flag’ in the health professional system if
they reach certain thresholds for current pain and pain control. After reading the patient report, health
professionals can decide what action, if any, they would like to take (see Figure 5d). Health professionals
have the option of contacting patients through PainCheck to provide information and advice. All data
entered into PainCheck can be exported into Microsoft Excel® (Microsoft Corporation, Redmond,
WA, USA) in comma-separated value format.
Testing of PainCheck for pain self-management as part of a feasibility study
The ICT system was included as part of the supported self-management (SSM) intervention in the
feasibility study. Two pieces of related work were subsequently undertaken to support this work: a
process evaluation of the ICT system as part of the multicentre RCT and a commentary on the current
state of ICT systems for pain management in palliative care. The commentary is outlined below, with
details of the process evaluation outlined alongside the multicentre RCT findings in the summary
of WP 4.
International workshop
In February 2017, an international workshop was organised by the IMPACCT team. Invited speakers
from the UK, the Netherlands, Germany and Ireland attended, alongside delegates from research
teams in Leeds, palliative care health professionals and software developers. An open discussion
following presentations focused on current issues in ICT development in palliative care and approaches
that could support the advancement of the research field. Key priorities for future development of ICT
systems were identified, including the need to better understand and define how user engagement
with ICT systems is understood and measured. In addition, the need for flexible approaches to the
evaluation of ICT systems was highlighted. Ideally, this would enable ICT systems to continue to
undergo iterative development in response to user feedback throughout periods of evaluation.
Work package 3: can the most important aspects of medicines management,
such as prescribing practice and access to analgesia, potentially be modified to
ensure that patients with cancer pain benefit from timely intervention?
Strong opioids, especially morphine, are the principal treatment for pain related to advanced and
progressive disease, and their use has increased significantly in the primary care setting. However,
many patients with advanced cancer experience pain that is poorly controlled. Although effective
and safe titration of opioids can have a major impact on patient comfort, advice to prescribers has
been varied and sometimes conflicting, and the wide range of formulations and preparations can
be confusing. Together with the complex web of attitudes, knowledge and communication skills of
prescribers, patients and the public, these factors have resulted in underdosing and avoidable pain,
or overdosing and distressing adverse effects. Furthermore, both prescribers and patients may be
concerned that opioids may reduce survival time, another barrier to optimising pain management.
A network of health professionals may be involved in the prescribing of strong opioids to manage
cancer pain, and we were keen to understand the components of current provision and to identify
opportunities for improving practice.
The overarching aim of this work package (Figure 6) was to explore ways of ensuring that patients
benefit from improved pain control through better management of medicines, including timely access
to both a prescriber and analgesia, and a greater opportunity for patients to discuss their medicines
with a health professional.
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support self-management of pain by patients with
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Overall aim: to improve the management of cancer pain for palliative care patients and their carers who are living at home
Principal objectives: to enable patients and their carers to more easily access support and advice, communicate their pain, 
obtain timely and effective medication; and to evaluate the impact of our interventions in routine care






































































































































































































































































































Work package 3: medicines – good
management of analgesic drugs
This WP planned to address the following research questions:
1. What is the pharmacoepidemiology of prescribed medicines and prescription pathways among
cancer patients during their last year of life?
2. What are the effects of non-medical prescribing (NMP) by nurses and pharmacists on timely access
to prescriptions for analgesics and what opportunities for intervention can be modelled?
3. What is the potential for intervention at community pharmacy level to improve cancer
pain management?
These three questions, covering the prescribing and subsequent access to analgesia and information/
advice for cancer pain management, were explored under three strands of activity: (1) mapping
pathways of prescriptions among cancer patients during their last year of life; (2) evaluating the
impact of NMP by nurses and pharmacists; and (3) conducting exploratory research to understand
the feasibility of community-based pharmacy medicine consultation interventions.
Work package 3.1: primary care-based interventions
Primary care-based interventions
Mapping pathways of prescriptions among cancer patients during their last year of life
We began by seeking to understand existing patterns of prescriptions for strong opioid treatment in
patients with cancer and to identify current practice. We investigated this through a regional analysis
of prescribing data on patients who had died from cancer.
In parallel, we undertook a systematic review to synthesise the research evidence on the relationship
between strong opioid analgesia and survival in patients with advanced cancer. We hypothesised
that one of the reasons that patients with advanced cancer pain are often undertreated may be that
the patient or their clinician perceive that strong opioids used in the terminally ill population can
hasten death. By undertaking this systematic review, we hoped that it would be possible to
substantiate or refute this perception.
Opioid prescribing for patients with cancer in their last year of life
Ziegler et al.58
We originally set out to understand the prescription pathways in a population of 400 deceased cancer
patients during their last year of life, including the analgesics prescribed (e.g. paracetamol, codeine,
strong opioids) and the adjuvant analgesics, such as antidepressants and antiepileptics, often used for
cancer neuropathic pain. We were able to substantially expand the original scope and increased the
study population to 6800 patients, accordingly increasing the power of our study to detect and test
associations. We used an innovative data linkage system (i.e. Openpseudonymiser) to link data derived
from the primary care electronic patient record system (SystmOne) within the electronic system within
a large acute NHS trust (Patient Pathway Manager) and data from the Northern and Yorkshire Cancer
Registry. Comprehensive linked data on 6080 patients who died from cancer over the 7-year period
(2005–12) were retrieved and analysed. To the best of our knowledge, this is the most comprehensive
data set of its type and is of international significance to the field.
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For all patients included in the linked cohort, all prescriptions for analgesics were identified for
the period 12 months prior to their death. These prescriptions were analysed to determine to what
extent and for what duration strong opioids were provided, exploring any differences that arose when
analysing prescriptions by clinical and patient characteristics. Strong opioids were prescribed for 48%
of patients in the last year of life (Figure 7). The median interval between the first prescription of a
strong opioid and death was 9 weeks (interquartile range 3–23 weeks). Prescribing was not influenced
by cancer type, duration of illness or sex, but we found a strong association with patients’ age, with
older patients much less likely to be prescribed a strong opioid. Patients who died in a hospital were
60% less likely to have received a strong opioid in primary care before admission than patients who
died in a hospice [relative risk ratio 0.4, 95% confidence interval (CI) 0.3 to 0.5; p < 0.01].
The study provides the first detailed analysis of the relatively late onset and short duration of strong
opioid treatment in patients with cancer before death in a representative UK cohort. This pattern of
prescribing does not match epidemiological data, which point to the earlier onset of pain.5 Although
the persistent under-treatment of cancer pain is well documented, this study suggests that strategies
for earlier pain assessment and the initiation of strong opioid treatment in community-based patients
with cancer could help to improve pain outcomes. In addition, our finding of unexplained variation in
the prescribing of opioids for younger and older patients indicates a previously unknown inequity in
access to pain relief. This research has been published.58
Association between regular systemic opioid analgesia and survival in adult patients
with cancer
Boland et al.59
The effects of opioids can be concerning for some clinicians and patients, with specific concerns
relating to the impact of opioids on length of survival. These concerns can lead to reductions in opioid
prescribing and issues with patient compliance, culminating in a detrimental impact on symptom
control.60 This study was conducted to determine whether or not there is an association between
opioid analgesia and shorter survival, specifically for adult patients with cancer. We systematically
searched for studies that assessed the effect of regular systemic opioid analgesia on survival. We
identified 526 unique records, with 20 articles meeting the inclusion criteria. Thirteen end-of-life
studies (11 of which were very low-quality retrospective studies) did not find a consistent association
between opioid analgesic treatment and survival. The findings from this review should be interpreted
with caution owing to the low quality of most of the studies that were included. In total, the included
studies comprised three RCTs and two prospective studies. Six of these studies indicated that opioids
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FIGURE 7 Cumulative proportion of patients (%) prescribed analgesics week by week for the last year of life.
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opioids on survival as a primary end point. In view of this, no definitive conclusions can be made as
to whether or not opioids affect survival in patients with cancer. These data suggest that, although
opioid analgesia does not affect survival at the end of life, in the context of longer-term treatment
higher-quality studies, with survival as a primary end point, are required to confirm any independent
association between opioid analgesia and shorter survival. An important limitation of research in this
field is that the relationship between greater analgesic requirements and shorter survival may be
mediated by painful progressive cancer; this mediation is not examined in research. This research has
been published.59
Non-medical prescribing by nurses and pharmacists to support timely access to
prescriptions for analgesics
Our second set of studies investigated the impact of a policy change in NMP that has the potential to
improve timely access to analgesia for cancer patients through community palliative care nurse and
pharmacist prescribers. During our programme development grant (PDG) (RP-DG-1108-10010), we
identified that the role of non-medical prescribers working in palliative care was due to expand, and in 2012,
the year that this programme grant began, the UK Department of Health and Social Care issued legislation
that enabled nurses and pharmacists with appropriate NMP qualifications to prescribe controlled drugs to
patients within their field of professional expertise. Prescribers anecdotally reported improvements in
patient care and patient safety, better use of health professionals’ skills and an increase in the amount of
flexible team working. However, there was a lack of empirical evidence of the clinical and economic impacts,
limiting the understanding of the future role of non-medical prescribers in a health-care system serving an
increasing number of people with palliative care needs.We sought to measure the impact of this legislation
and concurrent nurse prescribing in the UK through regional and national surveys of nurse and pharmacist
prescribers and to assess the extent of NMP within overall palliative care prescribing.
Surveys of non-medical prescribing in palliative care
Ziegler et al.61
We undertook what is, to our knowledge, the first study of NMP in palliative care in almost one decade to
explore the current position in the UK and the impact of the 2012 legislative changes on practice. An online
survey of nurses in a regional cancer network was conducted in mid-2013, to which 37 nurses responded.
We also undertook a national survey of pharmacist prescribers in the palliative care pharmacist network
(n= 71). Although these surveys found that non-medical prescribers embraced the 2012 legislative changes
and prescribed a wide range of drugs for cancer pain, we also identified scope to maximise the economic
and clinical benefits by improving the transition from qualified to active non-medical prescriber by reducing
the time interval between the two. Our findings indicate that nurses who are considering undertaking
training to be a non-medical prescriber may be encouraged by the provision of adequate study leave and
support to cover clinical work.We did not identify any substantial barriers to NMP in either survey. In our
original grant application, we planned to conduct case studies to understand the health system-wide factors
facilitating or inhibiting NMP. However, the lack of a national NMP sampling frame precluded a robust
sampling strategy and, therefore, we decided not to proceed. Participants in our multistakeholder event,
at which the findings of the NMP surveys were discussed, recommended amending our research plan
with an additional study to chart any changes in NMP activity in palliative care nationally, and establish a
better understanding of the proportion of NMP activity in relation to medical prescribing undertaken in
community palliative care. This research has been published.61
Analysis of growth and impact of non-medical prescribing
Zielger et al.62
We developed a novel methodology to establish the level of non-medical prescribers’ activity in
palliative care across England and to consider the likely overall contribution of non-medical prescribers
at a national level in this context in relation to medical prescribing. A ‘basket’ of 10 palliative care
drugs was co-developed with experts in prescribing research and a range of clinicians. All prescriptions
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for these ‘core’ palliative care drugs prescribed by GPs, nurses and pharmacists in England and
dispensed in the community between April 2011 and April 2015 were extracted by NHS Digital from
the electronic Prescribing Analysis Cost Tool (ePACT) system. The data were broken down by type
of prescriber and a basic descriptive analysis of prescription frequencies by opioid, non-opioids and
total prescriptions by year was undertaken. To evaluate the yearly growth of NMP, the total number
of prescriptions was compared by year for each of nurses, pharmacists and GPs.
We found that, overall, the total number of total prescriptions issued by NMPs rose by 28% per year
compared with 9% of those issued by medical prescribers, demonstrating some impact of the 2012
legislative change. In addition, there was an increase in the total number of opioid prescriptions that
had been issued by NMPs, which had risen by around 30% year on year. This rose by 31% in 2012–13,
by 28% in 2013–14 and by 33% in 2014–15. Similar to the increase in NMP for opioids, non-opioid
prescriptions also showed an increasing trend, with a 32% increase during 2012–13. During ensuing
comparative years, there was a slowing rate of increase, with a 12% increase during 2013–14 and
a 10% increase during 2014–15. This suggests that, during 2011–15, increases in the total number
of prescriptions from non-medical prescribers can be largely attributed to increases in prescriptions
for opioids.
However, the annual growth in non-medical prescribers’ prescriptions represented < 1% per year of
total community palliative care prescribing activity in England. We identified unexplained geographical
variation with a small number of ‘hot spots’ of palliative care prescribing by non-medical prescribers.
At the current rate of growth, it would be 20 years before non-medical prescribers were prescribing
25% of all drugs issued in community palliative care. Although our findings confirm that more patients
are receiving prescriptions in palliative care from non-medical prescribers, the findings indicate a
significant gap between policy and implementation. Prior to our study, to our knowledge, the only
evidence on patterns and trends in non-medical prescribing was from local service-level audits. This study
demonstrates, for the first time, that, although a growth in NMP is evident, the number of prescriptions
issued in palliative care remains small in relation to medical prescribing and there is potential for further
change. Non-medical prescribers manage a full range of drugs and their handling of opioids is proportionally
greater than that of doctors. Furthermore, although their total number of prescriptions may be small
relative to all prescriptions, a large proportion of this activity relates to end-of-life care and pain
management. This research has been published.62
Work package 3.2: pharmacy-based interventions
Pharmacy-based interventions
Although community pharmacists are well placed to provide advice and support in pain management,
our PDG work demonstrated that, in practice, they are not currently part of the palliative care team,
they lack access to even the most basic NHS information (so do not know if a patient has cancer),
and there is little communication between professions about patients with cancer pain.1 Furthermore,
although community pharmacists can provide a NHS medicines consultation [Medicines Use Review
(MUR)], this was rarely carried out for patients with cancer pain. To explore the potential for intervention
at the community pharmacy level, we sought to model methods of enhanced communication between
pharmacies and members of primary care and palliative care teams, examine continuity of pharmacy use
and model a MUR for patients with cancer pain and their carers.
Modelling methods of enhanced communication between pharmacies and members of
primary care and palliative care teams
We originally planned to explore the effects of both ‘soft’ (health professional personal referrals to and
from community pharmacies) and ‘hard’ (ICT integration) networking on patient-centred communication
between health professionals. We recruited five GP practices and nine community pharmacies that the
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practices knew dispensed many of their prescriptions. At the time that we submitted our PGfAR report
results, the NHS had introduced a demonstrator site in a single area in which community pharmacies
and general practice clinical systems were linked, and Bradford was set to be the second site. In the
event this did not proceed because of a NHS ICT policy change, so we focused on the development of
personal referrals and of a patient-held cancer pain medicines record.
Survey of health professionals’ views on community pharmacy services for patients
with cancer pain
Edwards et al.63
We explored the knowledge, experience and opinions of health professionals regarding community
pharmacist input for patients with cancer pain through a structured online survey in two clinical
commissioning groups (CCGs). GPs and nurses from those practices, a local practice pharmacist group
and community and outpatient-based palliative care nurses from the city hospital and hospice were
invited to take part. The 40 respondents, who represented all health professional groups, were divided
in their opinion of whether or not medicinal support needs were already being adequately met by the
palliative care team. Although a large majority of respondents agreed that community pharmacists
should become part of the palliative care team, additional training for cancer pain management and
consultation skills was thought to be needed. Lack of access to patient records was viewed by most as
a barrier to community pharmacist involvement. There was strong support for read access and slightly
less so for write access to the GPs’ clinical system. Remote provision of medicine consultations by
telephone was strongly supported, but Skype™ (Microsoft Corporation, Redmond, WA, USA)
consultations less so. Concerns raised by some respondents in additional comments were potential
duplication of services and the perception that if the patient was already under specialist palliative
care services then community pharmacists would provide little benefit.
The results showed a mixed picture, with some appetite for closer working with community pharmacists,
acknowledgement of the need for shared access to patient records and questions about community
pharmacists’ consultation skills and knowledge of cancer pain management. This research has
been published.63
Evaluating recruitment methods used in a pharmacist-led cancer pain medicines
consultation study
Edwards et al.64
In this part of the work package we also attempted to establish pathways to identify and refer patients
to a community pharmacy for a MUR in our planned feasibility study. Recruitment of patients with
advanced cancer into health services research studies is known to be challenging. Our aim was to
assess the effectiveness and efficiency of different recruitment methods, and the study also enabled
us to observe the extent to which health professionals engaged in referral of patients for a medicines
consultation. The methods of recruitment were community based (general practice computer search and
letter of invitation, health professional identification and referral of patients, and hospital oncology
outpatient clinic list search followed by postal invitation) and hospice based (hospice staff introducing
the study to inpatients and day-care patients). Recruitment via general practice computer searches and
letter of invitation was potentially efficient but with a low rate of recruitment, compounded by restrictions
of NHS regulations for the MUR service.We found a lack of engagement by health professionals, with only
two GPs and no community specialist nurses referring patients. In the hospice setting, the personal
involvement of hospice staff and the presence of the researcher to answer any questions facilitated
recruitment. The overall recruitment rate was in line with that of other studies in this patient group.
Our methods were less successful at recruiting patients who were not already engaged with hospice
services and this remains a challenge for future research. This study has been published.64
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Patient views of pharmacist medicines consultation
Edwards et al.65
We conducted a qualitative study to explore how patients with pain from advanced cancer currently use
community pharmacies and their attitudes towards medicines consultations from pharmacists delivered
in a pharmacy or remotely by telephone or Skype. Purposive sampling of GP clinical information systems
was used to recruit patients with advanced cancer; 13 patients took part in a semistructured interview
that was audio-recorded and transcribed verbatim. Around half of the patients were receiving palliative
care services. All patients reported using a single regular community pharmacy; several had changed
their pharmacy during the course of their cancer treatment, mainly to improve timely supply of their
medicines. Patients’ expectations of what community pharmacists and their teams might provide were
low, with convenience, service and staff friendliness as influential factors. Despite MURs having been
available for over 10 years, only one patient reported that they had received a MUR, and awareness
of MURs was generally low. Nevertheless, the idea of a community pharmacy medicines consultation
was acceptable to most patients, with telephone consultations positively received but Skype or other
electronic media not being feasible or acceptable for most. Patients perceived a hierarchy of health
professionals from whom they might actively seek advice about pain management, with those patients
in contact with specialist palliative care nurses placing those nurses at the top (owing to their combined
knowledge of their condition and medicines), followed by GPs and then community pharmacists.
Patients who were receiving specialist palliative care described pain that was better controlled and
thought that medicines consultations with a pharmacist would have been useful prior to their referral
for palliative care. Nevertheless, the interviews indicated that both patients who were not receiving
palliative care services and patients who were receiving palliative care services had unresolved
medicines-related problems (MRPs). The study findings showed a need for pain medicines support
for patients with advanced cancer, and unmet need appears greater for those not under the care of
specialist services. Medicines consultations, in principle, are acceptable to patients both in person and
over the telephone, particularly for patients less able to leave the house. This research has been published.65
Modelling a Medicines Use Review for patients with cancer pain and their carers
Systematic review of pharmacist educational interventions for cancer pain management
Edwards et al.66
We conducted a systematic review and meta-analysis; of the 989 studies identified, four were included
(three from China and one from the UK) and comprised 944 patients. Study interventions ranged from
5 to 12 pharmacist consultations, with a follow-up period of between 8 days and 6 months. Studies
were of varying quality and bias was detected in all. All studies included pain assessment as an outcome.
Meta-analysis found a reduction in pain intensity following the intervention of 0.76 (on a 0–10 pain
scale) in the intervention arm compared with the control arm, with a 95% CI. Improvements in patient
knowledge, reductions in side effects and increased patient satisfaction were also found. The results
indicate that pharmacist educational interventions are effective in reducing pain from cancer, but this
finding should be treated with caution because of the low study quality. The review demonstrated that
more studies of better quality and with homogeneous outcome measures are needed. This research has
been published.66
Feasibility and acceptability of pharmacist medicines consultation
Edwards et al.67
We held a multistakeholder workshop to explore whether or not existing community pharmacy
medicines consultations might be used for patients with pain from advanced cancer. Participants
included community and general practice pharmacists, palliative care health professionals, patients,
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commissioners, researchers and educators. We found that many of the health professionals who
attended knew little about MURs but were positive about them, and they identified methods of
integrating MURs into patient pathways in advanced cancer and of identifying signposting and referral
routes to and from pharmacies.
We recruited patients with advanced cancer living in the community using the methods described
in Patient views of pharmacist medicines consultation, Edwards et al., on page 28.67 Of a total of
128 patients identified, 47 met the inclusion criteria and 23 agreed to take part. Most (n = 17) of the
19 patients who completed the study were from a hospice setting. In the course of the study, very few
patients met the NHS criteria for eligibility for MUR in our nine pharmacies (because they had their
prescriptions dispensed at other pharmacies), so we decided to introduce research pharmacist-provided
telephone medicines consultations. In addition to increasing the number of patients who could take
part, this meant that we could test a medicines consultation with follow-up, a model analogous to the
New Medicines Service.
Consultations involved either one face-to-face consultation with a community pharmacist or two
telephone consultations with a research pharmacist. Community pharmacists are already trained and
accredited to provide MURs. We asked them to attend an interactive learning session designed to
address barriers identified in our earlier research: fears about talking to patients with advanced cancer
and being disconnected from the local palliative care team. Pharmacists spent time at workstations
where a pre-briefed palliative care nurse, a patient and a representative from a local cancer charity
drop-in centre raised these issues, encouraged participants to voice concerns and offered suggestions
and tips. Five patients subsequently had a community pharmacist-delivered consultation and 14 had
consultations conducted by the research pharmacist. Patients completed questionnaires about pain
levels, self-perceived knowledge and the acceptability of the pharmacist consultation before and after
the consultations. Pharmacists documented details of MRPs identified and these were categorised and
analysed using a validated typology.
In total, the 19 patients had 33 consultations in which 47 MRPs were identified (range 0–7;
median × per patient). Pharmacists resolved most (n= 38) MRPs with the patient by providing advice.
There were 10 referrals to other health professionals. The most common MRPs identified were pain
and constipation of varying severity. Tiredness, other side effects and concerns about concomitant
medicines were also identified. Most referrals to other health professionals were to initiate treatment
with laxatives or to change pain medicines. Eleven patients, most of whom said that they would
recommend the consultation to others, completed both the pre- and the post-consultation questionnaires.
A small number of patients reported that their knowledge about pain medicines had increased.
These findings suggest that many patients with advanced cancer have unresolved MRPs, even when they
are receiving specialist palliative care. Medicines consultations with a pharmacist resolved many of the
problems through advice and education, and enabled referral to prescribers to optimise treatment and
manage side effects. The vast majority of MRPs required ‘generalist’ rather than ‘specialist’ knowledge;
therefore, they fell within the current expected knowledge and scope of practice of community
pharmacists, confirming the finding from our PDG study that there is not a knowledge deficit.68
Some aspects of acceptability and feasibility of delivering medicines consultations were demonstrated.
We were able to recruit patients to the study and to retain four in five of them. However, only one in
two patients completed both pre- and post-consultation questionnaires, limiting the conclusions that
we could draw about patients’ experiences. Other limitations of the study include the small number
of patients who were not receiving palliative care services; the difficulty of establishing a workable
referral pathway from GP practices to community pharmacies; and that most consultations were
conducted by the research pharmacist, hence limiting generalisability. Further research is needed to
refine the intervention and delivery pathway prior to a future trial.
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Work package 4: can a cancer pain pathway (based on work packages 1–3)
be clinically effective and cost-effective in reducing pain and related
distress, and on reducing pain-related hospital admissions?
Work package 4 (Figure 8) sought to determine whether or not a cancer pain pathway (comprising pain
self-management interventions developed across prior work packages) could be clinically effective and
cost-effective in reducing pain and related distress, and reduce pain-related hospital admissions. The
overarching research question for this work package was ‘Can a cancer pain pathway (based on work
packages 1–3) be clinically effective and cost-effective in reducing pain and related distress, and on
reducing pain-related hospital admissions?’
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obtain timely and effective medication; and to evaluate the impact of our interventions in routine care






































































































































































































































































































Work package 4: evaluation –
cost-effectiveness and feasibility
Research activities were broken down into two strands of activity, with the following underpinningresearch questions:
1. What is the most appropriate measure of utility and the relative importance of different aspects of
cancer pain management to service users?
2. Can the implementation of evidence-based interventions into routine clinical practice be evaluated
in terms of fidelity and impact on pain and health-care resource use?
This first half of this chapter relates to the first of these subquestions, outlining the development of
the most appropriate measure of utility and the relative importance of different aspects of cancer pain
management to service users. This work was carried out to inform the development of an economic
model for use in an implementation feasibility trial, detailing the incremental cost-effectiveness ratio
(ICER) for a pain self-management intervention compared with standard care for pain management
in the treatment of people with advanced cancer. The second half of the chapter focuses on the
findings from a multicentre RCT, assessing the clinical effectiveness and cost-effectiveness of a pain
self-management multicomponent intervention developed through the research activities outlined in
earlier chapters.
Work package 4.1: developing a model for economic evaluation
Prior to the start of the clinical trial evaluating SSM, we conducted work to inform how QoL (utility)
and resource use might best be captured to enable a full economic evaluation of trial data. We
approached this by asking patients and carers to complete a survey that included a resource use
questionnaire, pain assessments and several ways of capturing health state utility. We also included in
this a stated preference survey [discrete choice experiment (DCE)] to understand which aspects of pain
management services were most important to them.
These survey data in turn were used to inform the development of a decision model to estimate the
cost-effectiveness of SSM. The purpose of the model was not only to enable an economic evaluation of
the interventions prior to the completion of the trial, but also to enable any costs and benefits observed
in the trial, to be extrapolated forward for a longer time horizon. A separate trial-based economic
evaluation was undertaken following completion of the multicentre RCT.
Costs and quality of life associated with pain in patients with advanced cancer
We conducted a cross-sectional survey with patients with cancer pain and their carers to establish the
feasibility of utility and health-care resource use data collection in this group; to explore the validity
of alternative measures of utility [including the EuroQol-5 Dimensions (EQ-5D), ICECAP-A (ICEpop
CAPability measure for Adults) and EORTC-8D (European Organisation for Research and Treatment
of Cancer – 8 Domains)]; to generate utility and cost parameter values for a decision model; and to
determine whether or not proxies could report on behalf of patients. Two-hundred and forty-eight patients
completed the survey. There were minimal missing data and no ceiling/floor effects on the utility measures.
There were more missing data on the resource use measure. All utility measures correlated well and all
discriminated between pain severity groups (no/mild, moderate, severe) but the EQ-5D appeared better
able to do this than the ICECAP-A and EORTC-8D. Although formal and informal carer reports of utility
correlated with those of the patient, there were non-trivial differences between these reports and the
informal carers represented a better proxy than formal carers. Results suggest that patients are able to
complete measures at the end of life and that proxy reports may not be necessary or desirable.
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We were able to use the survey data to generate cost and utility parameter values for a decision
model and inform the data collection of the IMPACCT trial to enable an economic evaluation. Given
the degree of missing data in patient-reported resource use we experienced here, we made use of
administrative data to a larger degree in the trial.
Understanding patient preferences
We conducted a DCE with patients to understand their preferences for various aspects of pain
management services. This also provided information on patient preferences for alternative pain
management service types.
Meads et al.69
A DCE and focus groups with patients were undertaken to understand their preferences for pain
management services and to inform service development. Focus groups were used to develop the
attributes and levels of the DCE. The attributes were waiting time, type of health professional,
out-of-pocket costs, side effect control, quality of communication, quality of information and pain
control. Patients completed the DCE along with clinical and health-related quality-of-life (HRQoL)
questions. Conditional and mixed logit models were used to analyse the data. Patients with cancer
pain (n = 221) and within palliative care services completed the survey (45% female; mean age 64.6 years;
age range 21–92 years). The most important aspects of pain management were good pain control, zero
out-of-pocket costs and good side-effect control. Poor or moderate pain control and £30 out-of-pocket
costs were the least preferred aspects. Respondents preferred control of side-effects and provision of
better information and communication over access to certain health professionals. Those with a lower
HRQoL were less willing to wait for treatment and more willing to incur higher costs than those with a
higher HRQoL. The presence of a carer influenced preferences. Outcome attributes were more important
than process attributes but the latter were still valued. Thus, supporting self-management, for example
by providing better information on pain, may be a worthwhile endeavour. However, service provision may
need to account for individual characteristics, given the heterogeneity in preferences. This research has
been published.69
Health economic model development
Meads et al.70,71
We constructed a decision-analytic model to estimate the cost-effectiveness of supported self-management
(SSM) interventions compared with UC. The model would enable an estimate of cost-effectiveness prior
to the completion of the trial and would allow the possibility of evaluating the cost-effectiveness of other
interventions and of testing scenarios. However, the main motivation for the model development was to
facilitate the extrapolation of costs and benefits from the trial over a longer time horizon (should that
be warranted). The model was a Markov model structured around pain severity health states (no/mild,
moderate, severe pain), each of which had associated costs and QoL/utility estimates (which were informed
by the patient survey). It estimated costs and quality-adjusted life-years (QALYs) for a cohort of individuals
with cancer pain over 1 year.We evaluated PainCheck (online pain reporting system) and the Tackling
Cancer Pain toolkit (an education self-management resource) separately against UC and took the effectiveness
of these (measured in terms of change in pain rating scores) from published meta-analyses of similar
interventions.37 This research has been published.70,71
The results indicated that both PainCheck and the Tackling Cancer Pain toolkit would be cost saving
and cost-effective but, owing to the higher implementation costs and lower assumed effectiveness of
the former, the latter intervention offered the greater value for money. These results were relatively
robust to a series of sensitivity analyses. However, it should be noted that the conclusions from the
modelling may have been different had the meta-analysis results it incorporated been updated with
the WP 4.2 trial results.
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Work package 4.2: pragmatic multicentre randomised controlled trial
Aims and research questions
Having developed two evidence-based interventions, an educational resource (Tackling Cancer Pain) and
a pain monitoring system (PainCheck) in earlier work streams, we sought to assess the feasibility of
implementation, effects and cost-effectiveness in a RCT. A protocol for the implementation feasibility
RCT has been published previously.70
The trial is registered with the ISRCTN registry, with reference 18281271. Details of the registration
can be found at the following link: https://doi.org/10.1186/ISRCTN18281271.
The combined intervention (UC plus SSM), delivered by community palliative care, aimed to:
l improve the management of cancer pain for palliative care patients who are living at home
l enable patients to more easily access support and advice, communicate their pain and obtain timely
and effective medication
l educate patients on Tackling Cancer Pain through an educational intervention.
Trial methods
Summary of trial design
IMPACCT is a pragmatic multicentre RCT in patients with active and incurable cancer that aimed to
evaluate the delivery and implementation of evidence-based interventions into routine clinical practice,
developed and piloted as part of the IMPACCT programme grant.
We aimed to recruit 160 participants at the point of identification for referral into palliative care.
Participants were randomised on a 1 : 1 basis to receive either the intervention [UC plus SSM
delivered within the oncology clinic and palliative care services by locally assigned community palliative
care nurses (health professional), consisting of self-management/educational support and pain monitoring],
or UC. Participants were identified and recruited in the oncology (or related) clinic by the research nurse
in consultation with the patients’ clinician/treating team. All participants were referred to their local
palliative care team for pain management. The recruiting team were not involved in subsequent
intervention delivery.
The follow-up period of the trial was 12 weeks, with patient-reported outcome measures collected by
post at 6 and 12 weeks following randomisation. When required, the blinded IMPACCT trial researcher
collected these data by telephone. Medical data were obtained directly from patient hospital and
palliative care records by the research nurse and palliative care team, respectively. All participants
were followed up for overall survival until the final participants’ 12-week follow-up.
A subsample of consenting participants and health professionals were invited to take part in an
interview at approximately 6 or 12 weeks post randomisation (see Process evaluation).
Protocol amendment
A substantial amendment to the protocol and trial design was implemented early on in the trial,
6 months after opening to recruitment and after 13 participants had been recruited (Table 1). The
original protocol (v3.0) had an additional aim to evaluate early screening and referral. However, early
screening and recruitment methods were scrutinised and it was not feasible to implement an early
referral pathway into the existing cancer pain pathways in the RCT. Once our screening procedures
had identified cancer patients with significant pain (≥ 4 on a rating scale of 0–10), oncology staff were
reluctant to allow patients to be randomised, potentially to UC, and felt obliged to make a clinical
referral to palliative care. With the support of the TSC, we agreed an amendment to recruit at the
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point of referral so that all patients eligible for community-based palliative care could be recruited and
randomised, with community palliative care referral in both trial arms, essentially removing the early
referral pathway of the intervention.
Recruitment, setting and participants
For full details of recruitment procedures, see Allsop et al.70 The inclusion criteria for patients were
that they (1) were male or female aged ≥ 16 years; (2) had a diagnosis of advanced incurable cancer
(locally advanced or metastatic) and were experiencing cancer-related pain (tumour or treatment
related), with a pain score of ≥ 4 on the ‘average pain’ item of the BPI; (3) had the potential to benefit
from pain management; (4) had an expected prognosis of ≥ 12 weeks; (5) were living at home; (6) lived
in the local catchment area of a participating hospice; and (7) were able and willing to provide written
informed consent. The exclusion criteria were patients who (1) were currently receiving or had previously
received community palliative care support; (2) had insufficient literacy or proficiency in English to
contribute to the data collection required for the research; (3) lacked capacity to provide informed
consent to this trial; or (4) had dominant chronic pain that was not cancer related (tumour or treatment).
Randomisation and blinding
A computer-generated minimisation programme incorporating a random element was used to
randomise participants to either the UC plus SSM arm or the UC arm. Randomisation was completed
on a 1 : 1 basis. The randomisation process ensured that trial arms were well balanced for both the
recruiting site and the participants’ average pain scores at baseline using the BPI score ranges
(4–6, 7–10).
TABLE 1 Details of substantial protocol amendment
Pre-amendment (protocol v3.0, n= 13) Post-amendment (protocol v4.0, n= 148)
Eligibility criteria
Inclusion criteria Has the patient been diagnosed with advanced
incurable cancer in one of the following disease areas:
l Breast




Has the patient been diagnosed with
advanced incurable cancer?
Exclusion criteria Has the patient previously been referred to the
palliative care team?
Has the patient previously received or
is currently receiving community
palliative care?
Trial arms
Intervention arm Pain management support
l Community palliative care referral (early referral)
l Educational support (Tackling Cancer Pain)
l Routine pain assessment and monitoring (PainCheck)
UC plus SSM
l Community palliative care referral
l Community palliative care referral
l Educational support (Tackling
Cancer Pain)
l Routine pain assessment and
monitoring (PainCheck)
Control arm Standard care
l Standard oncology outpatient care (community
palliative care referral not prohibited but not part of
the UC; participant is ineligible if already identified
for referral)
UC
l Community palliative care referral
GI, gastrointestinal.
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Participants, clinicians, research nurses in the recruiting clinics and palliative care nurses were, of
necessity, aware of treatment allocation, but the collection of patient outcomes via the IMPACCT trial
researcher was blinded.
Intervention
The intervention components are outlined in Table 2, reporting according to the Template for
Intervention Description and Replication (TIDieR) checklist.79
TABLE 2 The TIDieR checklist
Intervention components Description
UC (received by both arms) Referral to community palliative care: screening of patients with pain from
advanced cancer will be implemented by optimising entry points to the care
pathway via oncology (or related) outpatient services and will facilitate the flow
of patients to appropriate pain support as and when required. Oncology research
nurses will refer trial participants to the local community palliative care team, at
which point the locally assigned palliative care nurse will endeavour to arrange an
initial visit/appointment with the participant within 1 week of randomisation
Appointment into palliative care: this will take place with a locally assigned
community palliative care nurse. Routine practice will be followed, including an
assessment of the participants’ other palliative care needs. For those participants
allocated to receive UC and SSM, the nurse will be trained in the trial interventions




Name: Tackling Cancer Pain: A Toolkit for Patients and Families
Why: Tackling Cancer Pain: A Toolkit for Patients and Families is based on a review of
current evidence and on focus group interviews with patients, family caregivers and
health professionals working in specialist palliative care.37,38 Providing information
to patients with cancer pain and addressing concerns regarding pain and analgesia
are effective interventions that support self-management and lead to improvements
in pain outcomes72–76
What: Tackling Cancer Pain: A Toolkit for Patients and Families is formatted as a
loose-leaf ring binder with an accompanying DVD. It consists of five sections:
understanding cancer pain, using drugs to manage pain, additional approaches to
managing pain, talking about pain and getting more help. Each section contains
information and self-directed learning activities along with sources of further
information. It is written in easily understandable lay persons’ language. The
booklet and DVD contain essentially the same information but in different formats
and are structured so that they can be used independently by patients or family
members. Guidance is given in each chapter about how to use the information
presented. Step-by-step tuition is provided on non-pharmacological pain relief
measures such as relaxation and visualisation, and on how to initiate and conduct
conversations about pain with health professionals
Who provides: Tackling Cancer Pain: A Toolkit for Patients and Families will be
introduced to participants by their trained locally assigned community palliative
care nurse within 1 week of randomisation, and subsequent participant questions
on the booklet and DVD can be addressed to this palliative care nurse. Training on
the content and use of Tackling Cancer Pain: A Toolkit for Patients and Families will be
provided by the trial researchers. The training will include written instructions on
how to train participants in the interventions and a contact for any future queries
How: Tackling Cancer Pain: A Toolkit for Patients and Families is accessed by the
patient or their family by reviewing the information contained in the loose-leaf ring
binder and on the accompanying DVD
continued
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TABLE 2 The TIDieR checklist (continued )
Intervention components Description
Where: the expectation is that Tackling Cancer Pain: A Toolkit for Patients and
Families will be accessed by patients and their families while in the community
setting (i.e. in their usual place of residence)
When and how much: participants are not provided with details of schedule,
duration, intensity or dose for using Tackling Cancer Pain: A Toolkit for Patients and
Families. Instead participants are free to use the resource as they would like
Modifications: no modifications to the intervention were made during the study
How well (planned): intervention data collection (baseline) will identify that the
patient received the intervention. Semistructured end-of-trial interviews with
patients and health professionals will also inform how the intervention is used
How well (actual): overall, baseline data determined that 72 patients were
introduced to the intervention
eHealth intervention for routine
pain assessment and monitoring
in patients with advanced cancer
Name: ‘PainCheck’
Why: the process of assessing pain and presenting data to physicians prior to
consultation, who then use those within discussions, significantly improves pain
outcomes and QoL for patients.77 PainCheck was developed to facilitate this
communication by enabling patients to routinely report and share pain data for
health professionals to access. Its development was informed by patient, caregiver
and health professional involvement52–55
What: PainCheck allows patients to record their pain and gives them access to
personalised pain management advice. Patients are asked to answer questions
about their pain, including providing a description of their pain, rating current pain
intensity and intensity in the last 12 hours, pain control, interference and sleep.
Items were taken from the BPI40 and the Coping Strategies Questionnaire.78
Patients are asked about pain management techniques, which of these are helpful
and how likely they are to try them in the future. A variety of question response
options are used, including multiple choice, numerical (0–10 or 0–6) slider scales
and free text. After completion, patients are provided with a summary of their
results and suggestions of pain management techniques that they may want to try
in the future. Health professionals can log in to PainCheck and view all patients
registered on PainCheck and see who have completed reports. They are then able
to select a patient and view responses to individual questions. Health professionals
are presented with a graph that tracks patients’ current pain and pain in the last
12 hours over time. Patients are given a ‘red flag’ in the health professional system
if they reach thresholds for current pain and pain control. After reading the patient
report, health professionals can decide what action, if any, they would like to take
as a result. Health professionals have the option to contact patients through
PainCheck to provide information and advice PainCheck was developed using
QTool. QTool is a secure online system, which can be integrated in real time
with the electronic patient records, enabling the collection of patient-reported
information (such as symptoms, treatment side effects, pre-clinic questions,
satisfaction surveys). QTool was developed by the collaborative efforts of multiple
research groups based at the University of Leeds, pooling approximately £400,000
of research funding. The version of PainCheck used in the trial did not utilise
linkage with existing electronic clinical record systems; instead PainCheck was
run as a standalone intervention
Who provides: PainCheck is introduced to participants by their locally assigned
community palliative care nurse within 1 week of randomisation. Training on using
PainCheck with patients is provided by trial researchers to community palliative
care nurses. Training includes instructions for training the participants in the
interventions, which include a demonstration for the participant on how to log
on and use the routine pain assessment and monitoring system at the initial visit
How: PainCheck is introduced to patients by their locally assigned community
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TABLE 2 The TIDieR checklist (continued )
Intervention components Description
palliative care nurse. The introduction involves participants logging in to the
system (using unique login details that will be provided by the community palliative
care nurse) and working through an assessment using the instruction leaflet as a
guide. The palliative care nurse oversees the participant’s first access and use of
PainCheck and provides additional support/guidance if necessary. At induction into
the system, participants are made aware that PainCheck should not be used to
request urgent or emergency help; when urgent or emergency help is required
participants are told to contact the emergency services. On visiting PainCheck
participants are reminded, by use of an on-screen message, that should they need
immediate medical attention they should call the emergency services. If they
require urgent medical advice they are advised to contact their doctor, nurse or
pharmacist. This reminder is provided near the beginning and at the end of each
PainCheck session. Following an introduction to PainCheck, participants (or a
person submitting responses on a participant’s behalf) are expected to complete
pain assessments without the community palliative care nurse present. Each pain
assessment asks for clarification on who is entering data (i.e. a patient or someone
on their behalf) which is reflected in reports when viewed by health professionals.
Based on reports submitted by participants, the PainCheck system provides two
types of e-mail alert to health professionals: high priority (generated immediately
when a patient submits a report indicating high pain and/or low levels of control)
and low priority (a weekly e-mail sent when participants are interacting with
PainCheck but reporting very low levels of pain or no pain). After reviewing
reports submitted to PainCheck, a health professional is asked to record in the
system what action they took: (1) no further action, (2) contact another health
professional, (3) contact the patient or (4) other. PainCheck can be accessed by
patients and health professionals using any device that enables access to the
internet (e.g. using laptop, smartphone or tablet computer)
Where: the expectation is that PainCheck would be accessed by patients or their
families while in the community setting, which could include usual place of
residence or alternative chosen location
When and how much: following the introduction of routine completion of PainCheck
in the community, participants are encouraged to use the system at least once per
day, with additional entries being encouraged when/if pain events occur. PainCheck
is available to participants until 14 days after their 12-week follow-up assessment.
Participants are notified in writing that access to PainCheck is ending
Modifications: no modifications to the intervention were made during the study
How well (planned): intervention data collection (at baseline) is used to confirm
that a patient received details to access PainCheck. Data captured by PainCheck
can provide insight into the frequency of use by patients, alongside identifying
interaction between health professionals and patients that occurs through
PainCheck (i.e. messages sent to patients by health professionals). Semistructured
end-of-trial interviews with patients and health professionals are used to inform
how the intervention is used
How well (actual): baseline data showed that, of the 78 participants recruited and
willing to participate in the trial, 47 (58.8%) are introduced to PainCheck. Of those
introduced to PainCheck, 32 participants (51.6%) logged in. In total, 23 participants
(40%) are deemed engaged with the intervention, logging in and submitting a pain
report three or more times
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Trial data collection
For a full description of trial data collection, see Allsop et al.70
Objectives
Objectives relate to both the feasibility of delivery and the implementation of interventions into
routine practice and an assessment of the effectiveness of the intervention.
Primary objectives
l Delivery and implementation of the intervention: the primary implementation objective is to
evaluate adherence in terms of the uptake and retention rate of each intervention.
l Potential effectiveness of the intervention: the primary effectiveness objective is to assess the
effectiveness of the intervention compared with UC, as measured by pain severity on the BPI
(the mean and the proportion of responders with a ≥ 30% reduction in the BPI pain score) 6 and
12 weeks after randomisation.
Secondary objectives
l To assess differences in patient-rated pain, as measured using the BPI pain interference and the
7-point global rating of change in pain at 6 and 12 weeks.
l To assess health-care use in each arm, in particular hospital admissions within 12 weeks
of randomisation.
l To assess patients’ pain knowledge and experience, as measured using the PPQ at 6 and 12 weeks.
l To assess the differences in patients’ general and cancer-specific QoL as measured using the EQ-5D
and EORTC QLQ-C30 at 6 and 12 weeks.
l To document the cost-effectiveness of the interventions.
Furthermore, we aimed to report on the delivery and implementation of the intervention through a
process evaluation using qualitative data to explore participant and palliative care nurse views.
Statistical methods
Sample size
To assess the effectiveness of the intervention, the power calculation was based on the difference in
mean pain severity on the BPI at 12 weeks. With 80% power and a two-sided type I error rate of 0.05,
we estimated that 128 patients (64 per arm) were required to detect a moderate intervention effect
size of 0.580 between the intervention and the control arms.
In addition, a relative reduction of ≥ 30% in pain severity (BPI) is an accepted threshold for clinically
significant improvement in pain trials.81 Results from a previous study involving automated symptom
modelling found a 27% difference in such improvement rates at 12 weeks.82 Our estimated sample size
also provided 80% power to detect a similar difference in rate.
As our patient sample was drawn from a generally frail population, we allowed for an attrition rate of
20% and, therefore, aimed to recruit 160 participants (80 per arm).
Data analyses
No interim analyses were conducted and all analyses were planned prior to the final analysis. Analyses
were conducted on the intention-to-treat population, with all participants included in the analysis
according to allocation regardless of non-compliance with the intervention. An overall two-sided 5%
significance level was used for all statistical analyses.
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The completion and scoring of patient-reported questionnaires were analysed in line with scoring
manuals including guidance on how to handle missing items. If no direction was given, then scores
were prorated if ≥ 50% of the items were completed, and the ‘worst’ response was taken when
multiple consecutive responses were recorded.
We used descripitive statistics and CI estimations to evaluate the primary implementation outcome.
We compared the primary and secondary effectiveness patient-reported questionnaire outcomes using
linear (and logistic regression, where appropriate) mixed-effects regression models with repeated
measures (6 and 12 weeks) using an unstructured covariance pattern correlation structure. Analyses
were adjusted for randomisation stratification factors and average pain (4–6/7–10), and baseline response.
We undertook appropriate regression diagnostics to check the validity of the statistical modelling.
Primary analysis handled missing outcome data using multiple imputation.83 The characteristics of
participants with and participants without the primary outcome were summarised to explore the
missing data mechanism. Logistic regression was used to determine whether or not missing data
differed by participants’ baseline characteristics, and forward selection (with 10% significance level)
was used to identify key participant characteristics predictive of missing data at 6 or 12 weeks for
inclusion in a multiple imputation model. Sensitivity analysis were conducted to the availability of data.
For further details of the statistical methods, see Allsop et al.70
Key findings
Study summary
Figure 9 presents the overall trial Consolidated Standard of Reporting Trials (CONSORT) flow diagram
depicting the flow of participants through the study from screening to analysis, summarising screening,
accrual, intervention receipt and participant follow-up at 6 and 12 weeks (see Report Supplementary
Material 1, Table 14, for further details).
Screening and recruitment
Screening and recruitment took place between October 2015 and January 2018 across eight hospital
sites (Figure 10; see Report Supplementary Material 1, Table 15). A total of 2395 patients were screened:
274 (11.4%) were eligible and 161 (58.8% of those eligible; 6.7% of those screened) were randomised
into the trial (see Figure 9; see Report Supplementary Material 1, Figure 16); 81 participants were
allocated to the UC arm and 80 were allocated to the SSM arm.
A total 2121 patients (88.6% of screened) were not eligible. The most common reasons for ineligibility
were having an average pain score of < 4 (41.2% of those ineligible), having a previous palliative care
referral (39.2%), living outside the local hospice/community palliative care team catchment area (9.1%)
and their dominant chronic pain not being cancer related (6.7%) (see Figure 9).
Of the 274 eligible patients, 260 (94.9%) were introduced to the trial, 172 (62.8%) were able and
willing to consent, and 161 (58.8%) were randomised. A total of 113 (41.2%) eligible patients were,
therefore, not recruited to the trial, largely because the patient did not want to be involved in research
or palliative care; the patient declined or was not interested in taking part; the patient was too unwell;
the patient or clinician felt that the patient’s pain was already well controlled; the clinician deemed it
not appropriate for the patient to take part; the patient became ineligible during screening; or the
patient changed their mind (see Figure 9).
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There was variation across hospitals in the number and proportion of patients screened, eligible and
recruited (Table 3). The largest recruiting site screened 58.7% of patients and recruited 70.8% of all
participants. The eligibility rate was, however, the lowest in this site (9.6%), whereas the proportion
of eligible patients who went on to be randomised was the highest (84.4%). This highlights the
differences in screening procedures, investment and resources across the sites; the highest recruiting
sites had dedicated research nurses focusing almost exclusively on the screening and identification of
potential subjects.
Excluded
(n = 2121, 88.6%)
• Average pain score of < 4, n = 873
• Previously referred to palliative care, n = 832
• Not living in local hospice catchment area, n = 194
• Dominant chronic pain, not cancer related, n = 142
• Insuff icient literacy or English, n = 26
• Expected prognosis of < 12 weeks, n = 26
• Not able/willing to consent, n = 16
• Lacks capacity, n = 14
• No potential to benef it from pain management, n = 15
• Not living at home, n = 13
• Not aged ≥ 16 years, n = 3
• Not diagnosed with advanced incurable disease, n = 3
• Missing (n = 3, 0.2%)
Excluded
(n = 113, 41.2%)
• Trial not introduced (n = 14, 5.1%)
• Patient not able/willing (n = 88, 32.1%)
• Initially willing, not randomised (n = 11, 4%)
• Did not want to be involved in research, n = 30
• Patient declined/not interested, n = 19
• Patient too unwell, n = 19
• Pain well controlled, n = 14
• Not interested in palliative care, n = 13
• Clinician/nurse decision: not appropriate, n = 9
• No longer/not eligible, n = 6
• Patient changed their mind, n = 3
• Another trial prohibits co-enrolment, n = 1
Randomised
(n = 161, 58.8%)
SSM
(n = 80)
• Initial palliative care visit, n = 78
• Received booklet, n = 72
• Introduced to PainCheck, n = 47
• Not introduced, n = 31
• No computer, n = 19
• Patient choice, n = 3
• CNS deemed inappropriate, n = 5
• Error, n = 1
• Seen in work, n = 1
• Unknown, n = 2
UC
(n = 81)
• Initial palliative care visit, n = 71
• Contamination: received booklet, n = 1
Lost to follow-up
6 weeks (n = 29, 36.3%)/12 weeks (n = 39, 48.8%)
Reason
• Died, n = 7/17
• Too unwell, n = 3/2
• Withdrawal, n = 2/3
• Unable to contact, n = 10/8
• Contacted not returned, n = 5/8
• Administrative error, n = 2/1
Lost to follow-up
6 weeks (n = 25, 30.9%)/12 weeks (n = 35, 43.2%)
Reason
• Died, n = 6/12
• Too unwell, n = 5/9
• Withdrawal, n = 2/3
• Unable to contact, n = 9/7
• Contacted not returned, n = 3/3
• Administrative error, n = 0/1
Follow-up 








• Ineligible (n = 2072, 86.5%)
• Unable to approach to verify eligibility, n = 46, 1.9%
FIGURE 9 Trial CONSORT flow diagram.
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Recruitment to the trial was originally planned to be for 1 year; however, the staggered start of
recruitment across sites and the lower than expected monthly recruitment led to a substantial
amendment to the protocol (see Table 1). The substantial amendment was implemented in April 2016
following retraining and the launch of the revised protocol (see Figure 2); a total of 13 participants
were recruited pre amendment (protocol v3.0) and 148 were recruited post amendment (protocol v4.0)
(see Report Supplementary Material 1, Table 16). A funded recruitment extension was also obtained with
a projected recruitment rate of six participants per month, allowing recruitment to complete to target
after a total of 2 years and ≈ 3 months.
Eligibility violators
One participant allocated to the intervention arm was identified as not fulfilling the eligibility criteria
owing to the ongoing receipt of community palliative care prior to trial entry. One participant allocated
to the UC arm (pre amendment, protocol v3.0) was identified as not fulfilling the eligibility criteria
owing to a previous un-actioned referral to community palliative care prior to trial entry (note that this
participant would have been eligible post amendment, protocol v4.0).
Screening characteristics
Patient characteristics were broadly similar across the patients screened, eligible and randomised in
terms of age, ethnicity, other types of cancer, stage of disease and time since diagnosis; therefore, the
recruited participants can be considered a representative sample (see Report Supplementary Material 1,
Table 17). There was, however, a slightly higher proportion of male patients in randomised patients
(55.3% vs. 47.2%) and patients with haematological cancer (9.3% vs. 2.1%) than in all those screened.
Participant characteristics
Randomisation resulted in balanced trial arms for the randomisation strata, centre and average
pain item on the BPI (see Report Supplementary Material 1, Table 18). Three-quarters of participants
were randomised with an average pain score on the BPI of 4–6 (representing mild/moderate pain),
whereas one-quarter were randomised with a higher pain score of 7–10 (representing severe pain).

















Leeds 1407 (58.7) 135 49.3 9.6 114 70.8 84.4
Scarborough 37 (1.5) 12 4.4 32.4 4 2.5 33.3
Huddersfield 38 (1.6) 22 8.0 57.9 9 5.6 40.9
Bradford 74 (3.1) 7 2.6 9.5 2 1.2 28.6
York 444 (18.5) 45 16.4 10.1 15 9.3 33.3
Nottingham 358 (14.9) 37 13.5 10.3 8 5.0 21.6
Grimsby 31 (1.3) 11 4.0 35.5 6 3.7 54.5
Oxford 6 (0.3) 5 1.8 83.3 3 1.9 60.0
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Participant demographics and disease characteristics were generally well balanced across the trial arms
(Tables 4 and 5). Across all participants, 55.3% were male, the mean age was 64.1 years [standard
deviation (SD) 11.59 years], 93.2% were white British and 76.4% had access to a computer.
TABLE 4 Participant demographics
Demographic
Trial arm
Total (N= 161)SSM (N= 80) UC (N= 81)
Local hospice,a n (%)
St Gemma’s Hospice, Leeds 18 (22.5) 25 (30.9) 43 (26.7)
Wheatfields Hospice, Leeds 31 (38.8) 28 (34.6) 59 (36.6)
Mid Yorkshire Hospitals NHS Trust 2 (2.5) 3 (3.7) 5 (3.1)
Kirkwood Hospice, Huddersfield 6 (7.5) 7 (8.6) 13 (8.1)
Marie Curie, Bradford 4 (5.0) 1 (1.2) 5 (3.1)
St Leonard’s Hospice, York 8 (10.0) 7 (8.6) 15 (9.3)
Nottingham CityCare Partnership 4 (5.0) 4 (4.9) 8 (5.0)
Care Plus Group, Grimsby 3 (3.8) 3 (3.7) 6 (3.7)
St Catherine’s Hospice, Scarborough 2 (2.5) 2 (2.5) 4 (2.5)
Sobell House Hospice, Oxford 2 (2.5) 1 (1.2) 3 (1.9)
Gender, n (%)
Male 42 (52.5) 47 (58.0) 89 (55.3)
Female 38 (47.5) 34 (42.0) 72 (44.7)
Age at randomisation (years)
Missing 0 0 0
Mean (SD) 62.5 (11.73) 65.7 (11.29) 64.1 (11.59)
Median (range) 64.5 (19–84) 68 (33–85) 66 (19–85)
Ethnicity, n (%)
White British 73 (91.3) 77 (95.1) 150 (93.2)
Non-white British 4 (5.0) 2 (2.5) 6 (3.7)
Missing 3 (3.8) 2 (2.5) 5 (3.1)
Does patient have access to a computer,b n (%)
Yes 61 (76.3) 62 (76.5) 123 (76.4)
Willing to use PainCheck 59 (73.8) 61 (75.3) 120 (74.5)
Not willing to use PainCheck 1 (1.3) 0 (0.0) 1 (0.6)
Missing 1 (1.3) 1 (1.2) 2 (1.2)
No 19 (23.8) 19 (23.5) 38 (23.6)
a Marie Curie Bradford and Kirkwood Huddersfield Hospices were local to patients recruited from Leeds as well as
their main recruiting site.
b Patients’ computer access and willingness to use PainCheck was discussed further with participants allocated to the
intervention once referred into palliative care.
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TABLE 5 Disease characteristics
Demographic
Trial arm
Total (N= 161)SSM (N= 80) UC (N= 81)
ECOG performance status,a n (%)
0 3 (3.8) 0 (0.0) 3 (1.9)
1 48 (60.0) 45 (55.6) 93 (57.8)
2 23 (28.8) 29 (35.8) 52 (32.3)
3 6 (7.5) 7 (8.6) 13 (8.1)
Type of advanced cancer, n (%)
Breast 20 (25.0) 16 (19.8) 36 (22.4)
Prostate 11 (13.8) 16 (19.8) 27 (16.8)
Colon or rectal 11 (13.8) 10 (12.3) 21 (13.0)
Upper GI 10 (12.5) 9 (11.1) 19 (11.8)
Haematological 6 (7.5) 9 (11.1) 15 (9.3)
Non-small-cell lung 7 (8.8) 6 (7.4) 13 (8.1)
Lung (other/not specified) 4 (5.0) 5 (6.2) 9 (5.6)
Urological (other/not prostate) 6 (7.5) 4 (4.9) 10 (6.2)
Gynaecological 2 (2.5) 0 (0.0) 2 (1.2)
Soft and connective tissue 1 (1.3) 1 (1.2) 2 (1.2)
Unknown 2 (2.5) 5 (6.2) 7 (4.3)
Years since original diagnosis (to randomisation)
Mean (SD) 4.0 (5.09) 3.7 (4.77) 3.8 (4.92)
Median (range) 2.1 (0–21.3) 1.5 (0–20.2) 1.9 (0–21.3)
Patient currently (or within the past month) receiving active cancer treatment, n (%)
Yes 54 (67.5) 56 (69.1) 110 (68.3)
Chemotherapy 32 (40.0) 35 (43.2) 67 (41.6)
Radiotherapy 7 (8.8) 8 (9.9) 15 (9.3)
Hormone therapy 14 (17.5) 19 (23.5) 33 (20.5)
Surgery 1 (1.3) 0 (0.0) 1 (0.6)
Immunotherapyb 2 (2.5) 2 (2.5) 4 (2.5)
Inhibitors of bone painb 4 (5.0) 3 (3.7) 7 (4.3)
No 26 (32.5) 25 (30.9) 51 (31.7)
Strongest pain medication, n (%)
Strong opioid 48 (60.0) 47 (58.0) 95 (59.0)
Weak opioid 23 (28.8) 24 (29.6) 47 (29.2)
Non-opioid 9 (11.3) 9 (11.1) 18 (11.2)
No medication 0 (0.0) 1 (1.2) 1 (0.6)
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Over half of all participants (57.8%) were reported to have a European Cooperative Oncology Group
(ECOG) performance status of 1, whereas 32.3% were status 2 and 8.1% were status 3 (see Table 5).
Breast cancer was the most common type of advanced disease (22.4% of participants), followed by
prostate (16.8%), lung (non-small-cell, small-cell or unspecified; 13.7%), colon or rectal (13%), upper
GI (11.8%) and haematological (9.3%) cancer. The median time from the participant’s original diagnosis
to their randomisation was 1.9 years; however, this was highly variable, ranging from 2 weeks to
21.3 years. Over two-thirds of participants were receiving (or had recently received) active cancer
treatment (68.3%), comprising mainly chemotherapy or hormone therapy. All participants but one were
receiving pain medication; participants were taking a mean of 2.4 different pain medications (SD 0.9)
and 59% of participants were taking a strong opioid. See Report Supplementary Material 1, Table 19 for
further disease characteristics,
The mean worst pain, as reported on a 0–10 numerical rating scale on the BPI, was 7.7 (SD 1.76), and
three-quarters of participants reported a severe level of worst pain (7–10) (Table 6). Mean scores
for composite outcomes of overall pain severity and pain interference, also reported on the BPI,
were 5.0 (SD 1.47) and 5.5 (SD 2.37), respectively. On the patient pain knowledge and experience
questionnaire, participants reported a mean score of 38.2 (SD 15.3) out of a possible 90 on the
knowledge subscale, and 41.5 (SD 9.3) out of a possible 70 on the experience subscale, with higher
scores indicating poorer experience of pain, knowledge and attitudes. On the cancer-specific QoL
questionnaire, the EORTC QLQ-C30, the mean summary score was 55.7 (SD 16.9) out of a possible
100, with higher scores indicating high QoL.
Participant follow-up
Withdrawals
Nine (5.6%) participants withdrew from trial processes: four (5%) who were allocated to the SSM
arm and five who were (6.2%) allocated to the UC arm (see Report Supplementary Material 1, Table 20).
All withdrew from questionnaire completion via researcher contact and all but one withdrew from
postal questionnaire completion. All remained willing for further data to be collected from their
medical records. The majority of withdrawals were because the participant was too unwell and were
clustered around the 6- and 12-week follow-ups.
Participant questionnaires
A total of 115 (71.4%) participants had at least one successful follow-up, with questionnaires
completed at 6 or 12 weeks post randomisation: 56 (70.0%) in the SSM arm and 59 (72.8%) in the
UC arm (see Report Supplementary Material 1, Table 21).
TABLE 5 Disease characteristics (continued )
Demographic
Trial arm
Total (N= 161)SSM (N= 80) UC (N= 81)
Number of pain medications
Mean (SD) 2.4 (0.82) 2.4 (0.98) 2.4 (0.90)
Median (range) 2 (1–4) 2 (0–5) 2 (0–5)
ECOG, Eastern Cooperative Oncology Group.
a The 6-point scale includes 0 (fully active, able to carry on all pre-disease performance without restriction), 1
(restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature),
2 (ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50%
of waking hours), 3 (capable of only limited self-care; confined to bed or chair for more than 50 of waking hours),
4 (completely disabled, cannot carry on any self-care, totally confined to bed or chair) and 5 (dead).
b There were three participants allocated to the SSM arm whose current treatment did not include chemotherapy,
radiotherapy, hormone therapy or surgery, only inhibitors of bone pain (one patient) or immunotherapy (two patients).
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TABLE 6 Baseline participant questionnaire responses
Questionnaire
Trial arm
Total (N= 161)aSSM (N= 80)a UC (N= 81)a
BPI (scores 0–10; higher score = increased pain)
Worst pain
Mean (SD) 7.7 (1.84) 7.6 (1.70) 7.7 (1.76)
Median (range) 8 (0–10) 8 (4–10) 8 (0–10)
Worst pain category, n (%)
No pain 1 (1.3) 0 (0.0) 1 (0.6)
Mild pain (1–4) 1 (1.3) 1 (1.2) 2 (1.2)
Moderate pain (5–6) 15 (18.8) 22 (27.2) 37 (23.0)
Severe pain (7–10) 62 (77.5) 58 (71.6) 120 (74.5)
Least pain
Mean (SD) 2.5 (1.97) 2.8 (1.94) 2.6 (1.95)
Median (range) 2 (0–9) 2.0 (0–10) 2.0 (0–10)
Average pain
Mean (SD) 5.6 (1.36) 5.4 (1.47) 5.5 (1.42)
Median (range) 5 (2–10) 5 (2–10) 5 (2–10)
Pain right now
Mean (SD) 4.0 (2.33) 4.2 (2.41) 4.1 (2.37)
Median (range) 4 (0–10) 4 (0–10) 4 (0–10)
Overall pain severity score
Mean (SD) 4.9 (1.39) 5.0 (1.56) 5.0 (1.47)
Median (range) 4.8 (2–8.8) 4.5 (2–10) 4.8 (2–10)
Pain interference score
Mean (SD) 5.2 (2.48) 5.7 (2.25) 5.5 (2.37)
Median (range) 5.3 (0–10) 5.9 (1.4–10) 5.6 (0–10)
PPQ (higher score = poorer experience of pain)
Knowledge subscale (scores 0–90)
Mean (SD) 38.2 (13.52) 38.1 (16.94) 38.2 (15.30)
Median (range) 35 (10–80) 38 (5–70) 37 (5–80)
Experience subscale (scores 0–70)
Mean (SD) 41.3 (9.70) 41.7 (8.96) 41.5 (9.30)
Median (range) 40 (18–61) 42 (27–61) 40.5 (18–61)
Total score (scores 0–160)
Mean (SD) 79.4 (16.50) 79.9 (20.22) 79.7 (18.42)
Median (range) 79 (43–124) 81 (34–123) 80 (34–124)
EORTC QLQ-C30 summary score (scores 0–100; higher score= high QoL and functioning)
Mean (SD) 57.4 (17.20) 54.1 (16.53) 55.7 (16.89)
Median (range) 58.9 (20–91.6) 53.7 (13.6–91.3) 56.2 (13.6–91.6)
a Baseline scores available for 79 SSM and 81 UC participants with the exception of the EORTC QLQ-C30 summary
score, available for 77 and 79 participants, respectively, owing to missing item-level data.
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Baseline questionnaires were completed face to face with the recruiting researcher and were returned
for all but one participant (see Report Supplementary Material 1, Table 21, and Table 6). The majority of
participants completed follow-up questionnaires via the post; over one-quarter had help completing
the questionnaires at 6 weeks and just under 20% had help at 12 weeks, with help provided primarily
by the participants’ partner or child (see Report Supplementary Material 1, Table 22). Questionnaire
packs were completed for 107 (66.5%) participants at the 6-week follow-up and 87 (54.4%) participants
at the 12-week follow-up (Table 7). Questionnaires were not returned at 12 weeks owing to participant
death (n= 29, 39.2%), illness (n= 11, 14.9%), and withdrawal (n= 6, 8.1%). Questionnaires were also not
returned when these had been sent by post and the participant was contacted by telephone to offer
telephone completion (n= 11, 14.9%), when there was difficulty contacting the participant by telephone
(n= 15, 20.3%) or when the participant was not contacted by telephone (n= 2, 2.7%).
The majority of questionnaires were completed within a 2-week time window: 94.4% at 6 weeks and
93.1% at 12 weeks (see Table 6; and Report Supplementary Material 1, Figure 17).
Comparison of baseline characteristics between participants with and participants without follow-up
(primary outcome completion; see Report Supplementary Material 1, Table 23) indicated that those not
completing follow-up at 6 or 12 weeks were more likely to be male, younger and taking a strong opioid
and to have a higher ECOG performance status; had more recently received their original diagnosis;
had lower baseline QoL scores (EORTC-8D, EQ-5D-3L); and had worse baseline measures on the BPI
(worst pain, pain severity and interference), PPQ (Patient Pain Questionnaire) (experience scale) and
QLQc30 (Quality of Life Questionnaire c30) (global health status, physical, social and role functioning).
The completeness of questionnaire data, including missing item level data, outcome scores and multiple
item responses, is summarised in Report Supplementary Material 1, Tables 24 and 25.
Researcher unblinding
Researcher unblinding occurred for three participants by their 6-week follow-up; all of the participants
were allocated to the SSM arm and were recruited under the original v3 protocol. Two instances
occurred as the participant discussed the intervention during the telephone follow-up (follow-up
completed) and one occurred as the researcher became aware of palliative care contact following nurse
contact (follow-up not completed).
Safety
No related and unexpected serious adverse events (RUSAEs) were reported during the trial.
Deaths were recorded throughout the trial up to the last participant’s 12-week follow-up. A total
of 92 (57.1%) participants were reported to have died (see Table 26, Figure 11), with an overall
median survival of 53.3 weeks (95% CI 40.9 to 59.6 weeks) and similar estimates across trial arms.
A total of eight (5%, 95% CI 1.6% to 21.1%) participants had died by 6 weeks post randomisation,
and 25 (15.5%, 95% CI 9.9% to 21.1%) participants had died by 12 weeks post randomisation. Almost




In accordance with the original protocol (v3.0), six participants allocated to the UC arm were not
referred to community palliative care, whereas the 75 (92.6%) participants allocated to UC in
accordance with the amended protocol (v4.0) were referred to community palliative care as part of
UC (see Report Supplementary Material 1, Table 16).
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TABLE 7 Questionnaire completion by time point
Baselinea 6-week follow-up 12-week follow-up
SSM UC Total SSM UC Total SSM UC Total
Questionnaire pack completed, n (%)
Yes 79 (98.8) 81 (100.0) 160 (99.4) 51 (63.8) 56 (69.1) 107 (66.5) 41 (51.3) 46 (56.8) 87 (54.0)
No 1 (1.3) 0 (0.0) 1 (0.6)b 29 (36.3) 25 (30.9) 54 (33.5) 39 (48.8) 35 (43.2) 74 (46.0)
Reason not completed, n (%)
Participant
withdrawal
NA NA NA 2 (6.9) 2 (8.0) 4c (7.4) 3 (7.7) 3 (8.6) 6c (8.1)
Participant died NA NA NA 7 (24.1) 6 (24.0) 13 (24.1) 17 (43.6) 12 (34.3) 29 (39.2)
Participant too
unwell
NA NA NA 3 (10.3) 5 (20.0) 8 (14.8) 2 (5.1) 9 (25.7) 11 (14.9)
Contacted not
returned
NA NA NA 5 (17.2) 3 (12.0) 8 (14.8) 8 (20.5) 3 (8.6) 11 (14.9)
Unable to contact NA NA NA 10 (34.5) 9 (36.0) 19 (35.2) 8 (20.5) 7 (20.0) 15 (20.3)
Administrative error 1 (100.0) NA 1 (100.0) 2 (6.9) 0 (0.0) 2 (3.7) 1 (2.6) 1 (2.9) 2 (2.7)
Method of completion, n (%)
Face to face 79 (100.0) 81 (100.0) 160 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.4) 1 (2.2) 2 (2.3)
Telephone NA NA NA 1 (2.0) 1 (1.8) 2 (1.9) 0 (0.0) 0 (0.0) 0 (0.0)
Post NA NA NA 50 (98.0) 55 (98.2) 105 (98.1) 40 (97.6) 45 (97.8) 85 (97.7)
All questionnaires completed? n (%)d
Yes 79 (100.0) 81 (100.0) 160 (100.0) 48 (94.1) 55 (98.2) 103 (96.3) 37 (90.2) 45 (97.8) 82 (94.3)



































































Baselinea 6-week follow-up 12-week follow-up
SSM UC Total SSM UC Total SSM UC Total
Timing of completion (weeks)
Mean (SD) –0.0 (0.33) –0.0 (0.21) –0.0 (0.28) 6.2 (0.88) 6.3 (1.05) 6.3 (0.97) 12.1 (1.28) 12.0 (0.97) 12.1 (1.12)
Median (range) 0.0 (–1.4–2.4) 0.0 (–1.9–0.0) 0.0 (–1.9–2.4) 6.0 (4.9–9.4) 6.0 (4.7–9.4) 6.0 (4.7–9.4) 11.9 (10.7–18.1) 11.6 (11.0–15.3) 11.7 (10.7–18.1)
Completed within 2 weeks, n (%)
Yes 78 (98.7) 81 (100.0) 159 (99.4) 50 (98.0) 51 (91.1) 101 (94.4) 38 (92.7) 43 (93.5) 81 (93.1)
No 1 (1.3) 0 (0.0) 1 (0.6) 1 (2.0) 5 (8.9) 6 (5.6) 3 (7.3) 3 (6.5) 6 (6.9)
NA, not applicable.
a SSM, n = 80; UC, n= 81; total, n = 161.
b One baseline questionnaire was lost and not returned to CTRU.
c Withdrawals as patients too unwell, with the exception of two participants at each time point: ‘Does not want to focus on pain’ (SSM) and ‘Not in pain does not want to
continue’ (UC).
d Completed questionnaire packs contained missing questionnaires or pages of questionnaires for 4 out of 107 (3.7%) participants at 6 weeks, and 5 out of 87 (5.7%) participants at
12 weeks. At 6 weeks two participants did not complete the global change in pain score, and two only partially completed the health economic questionnaire. At 12 weeks two






































































































































































































































































































Intervention training in each hospice took place face to face prior to the hospital site opening to
recruitment, and ranged in duration from 20 minutes to 2 hours 20 minutes (median 1 hour
15 minutes) (see Report Supplementary Material 1, Table 27). Refresher training was offered to all sites
during the trial; 5 out of 11 hospice sites received further face-to-face training, with a maximum of
four face-to-face refresher training sessions taking place for a site. The number of health professionals
(palliative care nurses, health professionals) trained across the hospices (with recruited participants)
ranged from 5 to 16.
Usual care
An initial palliative care visit took place for 78 (97.5%) participants in the SSM arm and 71 (87.7%)
participants in the UC arm (see Report Supplementary Material 1, Table 28). The visits mainly took place
in participants’ own homes (95.3%) a median of 1 week following randomisation, and lasted a median
of 75 minutes in both arms.
During the initial visit, the following palliative care needs were addressed with similar rates across trial
arms (see Report Supplementary Material 1, Table 29): pain in 94.6% of participants, additional symptoms
in 57.5%, psychological needs in 47.7%, carer concerns in 20.1% and other care needs in 14.1%.
A recommended change to pain medication was made for 67.1% of participants: 65.4% in the SSM arm
and 69.0% in the UC arm.
A total of 58 health professionals were involved in the 149 participants’ initial palliative care visits
(Figure 12); 46 health professionals for 78 participants in the SSM arm and 38 health professionals for
71 participants in the UC arm. Of these, 26 health professionals saw participants across trial arms for
44 SSM and 56 UC participants.
For further details of palliative care receipt during the trial, see Health-care use (see Table 13;
see Report Supplementary Material 1, Tables 40 and 41).
Supported self-management
Primary intervention implementation outcome
Of the 80 participants allocated to the SSM arm, the Tackling Cancer Pain booklet and DVD were
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FIGURE 11 Kaplan–Meier survival estimates.
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The PainCheck online monitoring system was introduced to 47 (58.8%, 95% CI 47.2% to 69.7%)
participants (see Figure 8). The main reasons that PainCheck was not introduced were that the
participant did not have a computer (n = 19), the health professional felt that it was not appropriate
(n = 5) and the participant chose not to use the computer (n = 3). A total of 32 (40%, 95% CI 29.2% to
51.6%) participants logged on to PainCheck and 23 (28.8%, 95% CI 19.2% to 40%) were found to have
engaged with the intervention, having used PainCheck on three or more occasions.
Of the 32 participants using PainCheck, the median total time spent on PainCheck over the 12-week
trial period was just under 1 hour, with times ranging from 6.5 minutes to > 10 hours. Participants
logged on a median of five times, ranging from one time to 82 times when the participant used
PainCheck daily (see Figures 8 and 9). A health professional also used PainCheck for 21 (65.6%) of the
32 participants using PainCheck (see Report Supplementary Material 1, Table 30). The median number
of times that a health professional logged on was one time, ranging from one time to 55 times
(see Figures 8 and 9). Of the health professionals using PainCheck, the median total time spent on
PainCheck per participant (n = 21) was 25.7 minutes, ranging from 3.1 minutes to > 7 hours.
Contamination
Contamination was reported for one participant allocated to UC for whom the Tackling Cancer Pain
booklet and DVD were provided to the participant in error.
Qualitative process evaluation
Process evaluation during implementation of multicomponent intervention for
pain management
To understand the process of implementation surrounding the pain self-management intervention,
we conducted semistructured interviews with 12 patients and 12 hospice-based palliative care
nurses. Participants were interviewed at their home and at their place of work. Interviews were guided
conversations to elicit accounts of participants’ experiences in their own words of taking part in the
trial using a topic guide. Key themes that emerged from the process evaluation are outlined below.
SSM (n = 80)
No initial palliative care visit (n = 2; 2.5%)
Initial palliative care visit (n = 78; 97.5%)
UC (n = 81)
Initial palliative care visit (n = 71; 87.7%)
No initial palliative care visit (n = 10; 12.3%)
Participants seen by
20 HCPs (n = 34)
Participants seen by
26 HCPs (SSM, n = 44;
UC, n = 56)
Participants seen by 
12 HCPs (n = 15)
46 HCPs conducted the initial
palliative care visit for 78 SSM
participants overall
38 HCPs conducted the initial
palliative care visit for 71 UC
participants overall
58 HCPs conducted the initial palliative care visit for 149 participants overall
FIGURE 12 Health professional delivery of the initial palliative care visit.
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Emotional barriers to referral to palliative care
There were emotional barriers associated with referral to palliative care that influenced the perceived
acceptability of the trial. About two-thirds of health professionals believed palliative care to be appropriate,
particularly for those patients who were in severe pain, for whom pain was not their only issue and for
whom there was clear specialist need. However, one-third of health professionals described palliative care
as symbolising something that they thought patients were not psychologically ready for and said that
it was inappropriate for the patients’ stage in the disease process. Health professionals believed that
patients’ symptoms should be managed by the hospital-based palliative care nurse because the patients
were still embedded within the hospital system and receiving active treatment. For half of patients, the
association of palliative care with closeness to death was a barrier to accessing supportive care for pain.
They believed that they were not yet at that stage and ‘felt a fraud’. Despite this, being engaged with
palliative care reassured these patients that help would be easily accessible when their disease progressed.
Although they were reluctant to acknowledge the appropriateness of their referral to palliative care, they
were engaged with participating in the trial.
Impact of interventions on delivery of care
Half of health professionals did not think that being involved with the trial had added to their workload
and discussed how they could use the eHealth component of the intervention (PainCheck) to proactively
manage their workload to save time in the future. However, all health professionals felt that this could
become burdensome if a larger number of patients on their caseload were using the eHealth tool. Patients
felt that taking part in the trial had increased their care and provided them with a support system. They no
longer felt isolated but were connected to and embedded within services. CNSs were fulfilling a role that
previously did not exist, and patients felt reassured that help was there if they needed it. Both health
professionals and patients asserted that both interventions improved patients’ self-management of pain.
They described how the education resource (Tackling Cancer Pain) was a good resource for patients to use
at their own pace and refer to, and resulted in positive changes to self-management. PainCheck then
provided a good baseline for patients and acted as a reminder to engage in self-management strategies.
For some, it provided the opportunity to reflect on previous pain scores, both providing context for their
present pain and enabling them to re-evaluate past pain as less intense than they had remembered.
Acceptability, engagement and feasibility of eHealth intervention
Health professionals were the gatekeepers to patient acceptability of and access to PainCheck.
However, many health professionals also reported a lack of knowledge about, understanding of and
familiarity with PainCheck. This affected the degree to which health professionals encouraged and
facilitated patient usage. Patient acceptability of the interventions was largely determined by their
health professionals, with CNSs facilitating the introduction to and monitoring of PainCheck. Some
patients were not introduced to the PainCheck because CNSs wanted to avoid what they perceived
as an unnecessary additional burden for them. For patients, a lack of familiarity with ICT or having
no internet connection at home influenced the perceived value to them of using PainCheck.
Engagement with interventions
Participants who used the eHealth tool and the educational resources described the interventions as
straightforward, easy to use, quick, user-friendly and unobtrusive. The eHealth tool was considered by
participants as a simple tool to aid with monitoring their symptoms and communicating with professionals.
Those who had limited engagement with PainCheck were not regular users of technology and computers,
and often did not have or were unable to use internet connections. They found engaging with PainCheck
to be stressful and subsequently were not interested in integrating it into their daily lives.
Feasibility of eHealth intervention
Health professionals felt that there was a place for PainCheck in current practice if its use was
streamlined (Figures 13 and 14). Some felt that it easily supported their current way of working by adding
in another layer of detail, which they could use to monitor patients’ pain. Others felt that it enhanced
the care that they provided because it enabled them to think about other aspects of pain management.
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• Delay in patient contact and then CNS felt not appropriate
• Patient declined home visits as pain was well controlled
Happy to receive care in the community
(n = 78; 97.5%, 95% CI 91.3% to 99.7%)
Introduced
(n = 72; 90.0%, 95% CI 81.2% to 95.6%)
Participant accepted copy of the Tackling
Cancer Pain booklet and DVD
Introduced
(n = 47; 58.8%,
95% CI 47.2% to 69.7%)
Logged in
(n = 32; 40.0%, 95% CI 29.2% to 51.6%)
Engaged
(n = 23; 28.8%, 95% CI 19.2% to 40.0%)
Accepted Tackling Cancer Pain booklet/DVD and engaged with PainCheck
(n = 22; 27.5%, 95% CI 18.1% to 38.6%)
Regular user





• Too unwell, n = 2
• Overwhelmed, n = 1
• Reason missing, n = 2
• CNS error, n = 1
Not used at all
(n = 15)
• HCP non-user, n = 6
• HCP 1–2 uses, n = 3
Participant PainCheck use:
3–4 uses (n = 6)
5–9 uses (n = 7)
10–19 uses (n = 5)
≥ 20 uses (maximum 82) (n = 5)
HCP PainCheck use:
Non-user (n = 5)
1–2 uses (n = 9)
3–4 uses (n = 4)
5–9 uses (n = 1)
10–19 uses (n = 2)
≥ 20 uses (maximum 55) (n = 2)
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• No computer, n = 19
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    • Patient too ill, n = 1
• Patient choice/did not want to use
    computer, n = 3
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    • Patient too unwell, n = 3
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FIGURE 13 Intervention uptake.
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Although digital technologies were viewed as becoming more pervasive within health care, health
professionals believed that these would not replace their current way of working. This research is now
published and available at http://eprints.whiterose.ac.uk/155107/.
Effectiveness analysis
Missing data
The primary outcome was available for all time points for 78 (48.4%) participants, for at least one
follow-up time point for 37 (23.0%) participants and for baseline only for 45 (28.0%) participants, and
was not available at any time point for one (0.6%) participant (Table 8). Forward selection identified
BPI worst pain, sex, age, centre, opioid use, health today and QoL from the EuroQol-5 Dimensions,
three-level version (EQ-5D-3L), as key participant characteristics predictive of missing data at 6 or 12 weeks
in multivariable models (see Report Supplementary Material 1, Tables 31 and 32). Multiple imputation for
primary analysis, therefore, used the above predictive variables (worst pain on the BPI replaced by the
relevant baseline value for secondary outcomes) in addition to randomisation strata (dichotomised average
pain response and centre) and allocation. A total of 52 imputations were made for all models, corresponding
to the overall percentage of missing data (i.e. 52% missing at least one time point).
Primary outcome
Pain severity: worst pain (Brief Pain Inventory)
The mean worst pain was 7.7 points (SD 1.76 points, n = 160) at baseline, representing a severe level
of pain. This was 5.8 points (SD 2.35 points, n = 107) at the 6-week follow-up and 4.7 points (SD 3.09
points, n = 86) at the 12-week follow-up, each representing a reduced moderate level of pain and an
increase in variability given the high level of loss to follow-up (see Report Supplementary Material 1,
Table 33 and Figure 18). Three-quarters of participants reported a severe level of worst pain at baseline
(7–10 points), reducing to 43% of participants at 6 weeks and 34% of participants at 12 weeks. Mean
scores were slightly higher in the SSM arm than in the UC arm and an increased proportion of participants
reported severe pain at 6 and 12 weeks.
Based on participants’ change in worst pain compared with baseline, there was a mean reduction of
1.5 points (SD 2.62 points, n = 107) at 6 weeks and 2.7 points (SD 3.54 points, n = 86) at 12 weeks (see
Report Supplementary Material 1, Table 34). A total of 41.1% of participants were classed as a responder
at 6 weeks and 57% at 12 weeks, having had a reduction in worst pain score of ≥ 2 points or ≥ 30%,
with similar rates across trial arms.
The primary and sensitivity analyses found no significant treatment differences for the primary
outcome or for other secondary outcomes of pain severity items on the BPI (Table 9, and see Figure 10
and Report Supplementary Material 1, Tables 35 and 36). The mean adjusted difference between the trial
arms (SSM –UC) at 12 weeks was 0.5 (95% CI –0.7 to 1.8; p = 0.4102), representing no significant
difference between the trial arms. There was similarly no significant difference in the odds of a
response, with an odds ratio of 0.84 (95% CI 0.39 to 1.82; p = 0.6558) (Table 10).
Exploratory subgroup analysis
Based on summary statistics, participants in the intervention arm who engaged in the use of PainCheck
(n = 23) had slightly increased worse pain scores at baseline, 6 weeks and 12 weeks compared with
those who did not engage (n = 57); there was no evidence of a significant difference (Figure 15;
see Report Supplementary Material 1, Figure 19).
Secondary outcomes
Mean scores improved in both arms across all secondary outcomes of pain severity (BPI), pain
interference (BPI), patient pain knowledge and experience (PPQ), and cancer-specific QoL (QLQc-30)
(see Report Supplementary Material 1, Figures 20–22 and Table 37). Unadjusted mean scores suggested
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TABLE 8 Missing data pattern
Baseline 6 weeks 12 weeks
BPI, n (%) PPQ, n (%)
QLQc30 summary score 7-point change in painaWorst pain Pain severity Pain interference Knowledge Experience Total
O O O 78 (48.4) 76 (47.2) 78 (48.4) 75 (46.6) 78 (48.4) 75 (46.6) 74 (46.0) 76 (47.2)
O O Missing 29 (18.0) 31 (19.3) 28 (17.4) 31 (19.3) 29 (18.0) 31 (19.3) 28 (17.4) 29 (18.0)
O Missing O 8 (5.0) 8 (5.0) 9 (5.6) 9 (5.6) 8 (5.0) 9 (5.6) 9 (5.6) 9 (5.6)
O Missing Missing 45 (28.0) 45 (28.0) 45 (28.0) 45 (28.0) 45 (28.0) 45 (28.0) 45 (28.0) 47 (29.2)
Missing O O 1 (0.6) NA
Missing O Missing 1 (0.6) NA
Missing Missing Missing 1 (0.6) 1 (0.6) 1 (0.6) 1 (0.6) 1 (0.6) 1 (0.6) 3 (1.9) NA
a Note that global change in pain is not collected at baseline.
‘O’ indicates that no data were missing at this time point.
TABLE 9 Adjusted mean scores with 95% CIs for the primary outcome and secondary pain severity outcomes on the BPI (primary analysis adjusted for baseline score and covariates,
with multiple imputation)
BPI pain severity outcomea
6 weeks, mean (95% CI), SE; p-value 12 weeks, mean (95% CI), SE; p-value
SSM UC Differenceb SSM UC Differenceb
Primary outcome: worst pain 6.7 (5.9 to 7.6), 0.44 6.3 (5.4 to 7.3), 0.47 0.4 (–0.4 to 1.2), 0.42; 0.3304 5.8 (4.6 to 6.9), 0.57 5.2 (4.2 to 6.3), 0.54 0.5 (–0.7 to 1.8), 0.65; 0.4102
Secondary pain severity outcomes
Least pain 3.5 (2.6 to 4.4), 0.47 3.2 (2.2 to 4.1), 0.47 0.3 (–0.4 to 1.1), 0.39; 0.3830 3.3 (2.3 to 4.3), 0.51 2.9 (1.9 to 3.8), 0.50 0.5 (–0.4 to 1.4), 0.47; 0.3122
Average pain 4.7 (3.7 to 5.6), 0.48 4.4 (3.6 to 5.3), 0.44 0.3 (–0.4 to 1.0), 0.35; 0.4650 4.0 (3.0 to 5.1), 0.52 4.0 (3.1 to 4.9), 0.46 –0.0 (–1.0 to 1.0), 0.50; 0.9925
Pain right now 4.0 (3.0 to 5.0), 0.52 4.1 (3.1 to 5.1), 0.53 –0.1 (–1.0 to 0.8), 0.45; 0.8587 3.7 (2.7 to 4.8), 0.54 3.6 (2.6 to 4.7), 0.53 0.1 (–1.0 to 1.2), 0.55; 0.8856
Overall pain severity score 4.7 (3.8 to 5.6), 0.45 4.4 (3.6 to 5.2), 0.42 0.3 (–0.4 to 1.0), 0.36; 0.4510 4.1 (3.2 to 5.1), 0.49 3.9 (3.0 to 4.8), 0.48 0.2 (–0.8 to 1.2), 0.50; 0.6515
SE, standard error.
a Score of 0–10; higher score= increased pain.



































































slightly worse pain severity in the SSM arm than in the UC arm at 6 and 12 weeks, slightly better pain
knowledge and experience in the SSM arm than in the UC arm at 6 and 12 weeks, and slightly better pain
interference and QoL in the SSM arm than in the UC arm from baseline to the 6- and 12-week follow-ups.
There was, however, no evidence of a significant difference in trial arms in primary or sensitivity analysis for
the secondary outcomes (Table 11; see Report Supplementary Material 1, Table 38) at 6- or 12-week follow-up.
Global rating of change
An increase in pain on the 7-point global rating of change in pain was reported for 31 (29.5%) participants
at 6 weeks and 27 (31.8%) participants at 12 weeks, and a reduction in pain was reported for 59 (56.2%)
participants at 6 weeks and 43 (50.6%) participants at 12 weeks (see Report Supplementary Material 1,
Table 39). A higher rate of increase in pain and a lower rate of reduction in pain was observed in the SSM
arm than in the UC arm at 6 weeks. However, this difference was not observed at 12 weeks; instead, a
higher rate of reduction in pain was observed in the SSM arm than in the UC arm.
Health-care use
Hospital attendances
Hospital outpatient appointments were reported during the 12-week trial period for the majority of
participants (95%), with a similar rate across trial arms (Table 12). The number of visits per participant
TABLE 10 Mean proportions, odds and odds ratios with 95% CIs for response (≥ 30% or ≥ 2-point reduction) on the
primary outcome adjusted for baseline score and covariates, with multiple imputation
Time point
(weeks)
Mean proportion (95% CI), SE Odds (95% CI)
Odds ratio (95% CI);
p-value
SSM UC SSM UC SSM vs. UC
6 0.40 (0.25 to 0.56),
0.08
0.45 (0.31 to 0.58),
0.07
0.68 (0.36 to 1.29) 0.81 (0.47 to 1.40) 0.84 (0.39 to 1.82);
0.6558
12 0.55 (0.38 to 0.72),
0.08
0.57 (0.42 to 0.72),
0.08






















































FIGURE 15 Estimated mean worst pain scores with 95% CIs for unadjusted, adjusted primary and adjusted sensitivity
analyses. Primary analysis – multiple imputation; sensitivity analysis – to availability of data.
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TABLE 11 Mean scores with 95% CIs for secondary outcomes adjusted for baseline score and covariates, by multiple imputation
Secondary
outcome
6 weeks, mean (95% CI), SE; p-value 12 weeks, mean (95% CI), SE; p-value
SSM UC Differencea SSM UC Differencea
BPI pain
interferenceb








39.6 (34.9 to 44.3), 2.40 38.2 (33.5 to 43.0), 2.42 1.4 (–2.7 to 5.4), 2.06; 0.5027 35.5 (29.7 to 41.4), 2.95 34.8 (29.6 to 40.0), 2.63 0.7 (–4.9 to 6.4), 2.87; 0.8033
PPQ total scoree 77.3 (69.2 to 85.5), 4.15 74.7 (66.6 to 82.7), 4.09 2.7 (–5.0 to 10.4), 3.91; 0.4946 74.4 (65.6 to 83.2), 4.48 70.6 (62.1 to 79.1), 4.33 3.8 (–4.6 to 12.3), 4.31; 0.3751
EORTCQLQc-30
summary scoref
54.6 (48.7 to 60.5), 2.99 54.0 (48.5 to 59.5), 2.81 0.6 (–4.3 to 5.6), 2.52; 0.8067 60.0 (53.7 to 66.3), 3.20 59.5 (53.3 to 65.7), 3.15 0.5 (–5.4 to 6.4), 3.01; 0.8739
a Difference: SSM –UC.
b Scores 0–10; higher score = increased pain.
c Scores 0–90; higher score = poorer experience of pain.
d Scores 0–70; higher score = poorer experience of pain.
e Scores 0–160; higher scores= poorer experience of pain.



































































TABLE 12 Accident and emergency attendances and hospital admissions
Hospital use SSM (N= 80) UC (N= 81) Total (N= 161)
Outpatient visit
Yes, n (%) 75 (93.8) 78 (96.3) 153 (95.0)
Outpatient visits per participant
Visits (n) 449 615 1064
Mean (SD) 5.6 (4.56) 7.6 (5.42) 6.6 (5.09)
Median (range) 4 (0–20) 6 (0–27) 6 (0–27)
Reason for outpatient visit (not mutually exclusive), n (%)
Cancer-related pain 30 (6.7) 37 (6.0) 67 (6.3)
Cancer treatment and routine follow-up 324 (72.2) 482 (78.4) 806 (75.8)
Assessment/scan/review 83 (18.5) 100 (16.3) 183 (17.2)
Intervention/treatment 24 (5.3) 23 (3.7) 47 (4.4)
Disease complications 10 (2.2) 11 (1.8) 21 (2.0)
A&E attendance, n (%)
Yesa 11 (13.8) 13 (16.0) 24 (14.9)
A&E attendances per participant
Visitsb (n) 12 15 27
Mean (SD) 0.2 (0.39) 0.2 (0.45) 0.2 (0.42)
Median (range) 0 (0–2) 0 (0–2) 0 (0–2)
Reason for A&E attendance (not mutually exclusive), n (%)
Cancer-related pain 2 (16.7) 4 (26.7) 6 (22.2)
Intervention/treatment 0 (0.0) 4 (26.7) 4 (14.8)
Disease complications 10 (83.3) 8 (53.3) 18 (66.7)
Admission/inpatient stay
Yes,c n (%) 31 (38.8) 39 (48.1) 70 (43.5)
Admission/inpatient stays per participant
Visitsb, n 45 63 108
Mean (SD) 0.6 (0.81) 0.8 (1.00) 0.7 (0.91)
Median (range) 0 (0–3) 0 (0–4) 0 (0–4)
Reason for inpatient stay (not mutually exclusive), n (%)
Cancer-related pain 17 (37.8) 21 (33.3) 38 (35.2)
Cancer treatment and routine follow-up 3 (6.7) 11 (17.5) 14 (13.0)
Assessment/scan/review 1 (2.2) 6 (9.5) 7 (6.5)
Intervention/treatment 7 (15.6) 8 (12.7) 15 (13.9)
Disease complications 25 (55.6) 25 (39.7) 50 (46.3)
A&E, accident and emergency.
a Three participants attended A&E twice.
b 15 A&E attendances resulted in an admission and are included in both summaries. This comprised seven attendances
in the SSM arm and eight attendances in the UC arm.
c 41 (25.5%) were admitted once, 13.7% twice, 3.1% three times and 1.2% four times.
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was larger in the UC arm, with a mean of 7.6 visits (SD 5.42 visits) compared with 5.6 visits (SD 4.56 visits)
in the SSM arm. Over three-quarters of appointments were for cancer treatment and routine follow-up.
Accident and emergency (A&E) attendances were reported for 14.9% of participants overall, with similar
rates across the trial arms. A&E attendances were most frequently for disease complications (66.7%),
and a higher proportion were owing to cancer-related pain (22.2%) than outpatient appointments (6.3%).
Hospital admissions were reported for almost half of participants: 38.8% in the SSM arm and 48.1% in the
UC arm. A maximum of four admissions were reported per participant. The most frequent reasons for
admission were disease complications (46.3%) and cancer-related pain (35.2%).
Palliative care contacts
All participants in the SSM arm and the majority (92.6%) in the UC arm received some palliative care
contact, including telephone contact, home visits, day or outpatient hospice attendances and inpatient
stays, during the 12-week trial period (see Report Supplementary Material 1, Table 40; Table 13).
Over half of participants continued within palliative care at the end of the trial, with a slightly larger
number of SSM participants (62.5%) than UC participants (53.1%). One-fifth were discharged from
palliative care at the end of the trial: 17.5% in the SSM arm and 22.2% in the UC arm. The remaining
participants were discharged before 12 weeks, largely owing to the participants’ death (see Report
Supplementary Material 1, Table 40).
Almost all participants (93.2%) received telephone palliative care contact, with a median of four contacts
(see Table 34). A median of two home visits took place in both arms, ranging up to 10 in the SSM arm
and eight in the UC arm. The reason for home visits were mainly because of the initial palliative care
visit, cancer-related pain or cancer-related pain with other reasons.
The number of participants with a day/outpatient visit and an inpatient stay and the number of
visits/stays was similar between arms. Just under one-fifth of participants had a day/outpatient visit:
17.5% in the SSM arm attended up to four times and 21% in the UC arm attended up to nine times.
A total of 10.6% of participants had an inpatient stay: 12.5% of participants in the SSM arm attended
on up to two occasions and 8.6% of participants in the UC arm attended once. Inpatient stays were on
average a median of 11.5 days, ranging up to 50 days.
Pain medications
All participants but one were receiving pain medication at baseline and all but four participants (alive, with
available data) were receiving pain medication at 6 and 12 weeks (see Report Supplementary Material 1,
Table 41). Participants were taking a mean of 2.4 different medications (ranging from 0 to 5 medications)
at baseline, increasing to a mean of 2.8 and 2.9 medications (ranging from 0 to 7 medications) at 6 and
12 weeks, respectively. The proportion of participants on a strong opioid increased from a baseline rate
of 59% to 72.4% at 6 weeks and 71.8% at 12 weeks. Medication use was similar across trial arms, albeit
with a slightly higher rate for all classes of medication in the SSM arm than in the UC arm.
Cost-effectiveness analysis of the IMPACCT trial
The cost-effectiveness analysis of the IMPACCT trial was based on within-trial outcomes, with
costs and HRQoL data collected at baseline, 6 weeks and 12 weeks. The decision model presented
in WP 4.1 was not used here to extrapolate the outcomes of the trial over a longer time horizon,
principally because the statistical analysis of the trial data found no difference between the trial arms
in terms of the primary outcome measure (pain). Without a differential in pain outcome, there could
be no differential in the costs and effects in the model. Thus, the time horizon for the evaluation
was 12 weeks. Where possible, we followed the National Institute for Health and Care Excellence’s
reference case, reporting cost per incremental QALY [based on EuroQol-5 Dimensions, 5-level version
(EQ-5D-5L), and EORTC-8D].
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TABLE 13 Type, number and reason for palliative care contact during the 12-week trial period
Type and number of contacts
Trial arm
Total (N= 161)SSM (N= 80) UC (N= 81)
Telephone calls
Yes, n (%) 78 (97.5) 72 (88.9) 150 (93.2)
Mean (SD) 5.0 (3.91) 5.5 (4.27) 5.3 (4.09)
Median (range) 4 (0–21) 5 (0–16) 4 (0–21)
Home visits
Yes, n (%) 76 (95.0) 71 (87.7) 147 (91.3)
Mean (SD) 2.8 (2.30) 2.7 (2.13) 2.8 (2.21)
Median (range) 2 (0–10) 2 (0–8) 2 (0–10)
Reason for home visit, n (%)
Cancer-related pain 71 (31.7) 69 (31.1) 140 (31.4)
Initial visit 74 (33.0) 68 (30.6) 142 (31.8)
Cancer-related pain and other reason 59 (26.3) 65 (29.3) 124 (27.8)
Other 20 (8.9) 20 (9.0) 40 (9.0)
Day/outpatient visit
Yes, n (%) 14 (17.5) 17 (21.0) 31 (19.3)
Mean (SD) 0.3 (0.87) 0.6 (1.59) 0.5 (1.28)
Median (range) 0 (0–4) 0 (0–9) 0 (0–9)
Reason for day/outpatient visit, n (%)
Cancer-related pain 9 (33.3) 11 (22.4) 20 (26.3)
Initial visit 1 (3.7) 3 (6.1) 4 (5.3)
Cancer-related pain and other reason 8 (29.6) 19 (38.8) 27 (35.5)
Other 9 (33.3) 16 (32.7) 25 (32.9)
Inpatient stays
Yes,a n (%) 10 (12.5) 7 (8.6) 17 (10.6)
Mean (SD) 0.2 (0.46) 0.1 (0.28) 0.1 (0.38)
Median (range) 0 (0–2) 0 (0–1) 0 (0–2)
Reason for inpatient stay, n (%)
Cancer-related pain 2 (15.4) 1 (14.3) 3 (15.0)
Cancer-related pain and other reason 6 (46.2) 1 (14.3) 7 (35.0)
Deteriorating condition 4 (30.8) 4 (57.1) 8 (40.0)
Other 1 (7.7) 1 (14.3) 2 (10.0)
Days per palliative care inpatient stay
n 13 7 20
Mean (SD) 14.9 (13.79) 10.9 (9.34) 13.5 (12.31)
Median (range) 11 (2–50) 12 (0–27) 11.5 (0–50)
a All had one inpatient stay except three participants in the SSM arm with two inpatient stays.
DOI: 10.3310/pgfar09150 Programme Grants for Applied Research 2021 Vol. 9 No. 15
Copyright © 2021 Bennett et al. This work was produced by Bennett et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
63
Our primary analysis was based on the EQ-5D-5L direct valuation84 with supplementary analyses
presented based on the EQ–5D-5L crosswalk to the EQ-5D-3L85 and the EORTC-8D, derived from
the QLQ-C30.86
The QALY calculation combined HRQoL and survival information and, thus, was based on a linear
interpolation, area-under-curve approach. Given that some patients were observed to die between
follow-up waves, some further assumptions were required for such cases. For patients who died with
their last HRQoL observation as positive, we calculated the aggregate HRQoL measure on the basis that
such patients had a linear fall in this measure from this point to death, imposing the assumption that
HRQoL deteriorates in a linear fashion until the value zero is reached at death. For patients who died
with their last EQ-5D observation as negative, we calculated the aggregate HRQoL observation measure
on the basis that such patients had this constant level of HRQoL according to this measure from this
point until death, imposing the assumption that HRQoL does not improve from this level until death.
Costs
We used a combination of the IMPACCT patient-completed questionnaires and administratively collected
records to estimate the health resource use of each patient within the trial. We prioritised data from the
latter source because patient-completed questionnaires rely on both accurate recall and the individual
being willing and able to provide information at the time of the 6- and 12-week follow-ups.
Our cost estimates were formed of four components: primary care costs, hospital and hospice
secondary care costs, prescribed medication costs and programme costs. For all but primary care
costs and programme costs, we derived activity estimates for each of these from administratively
completed records. The administratively completed records specified whether or not hospital visits
and admissions were pain related. Although the a priori assumption would be that data on the former
would be more specific and reduce noise in the results, discussions with nurses collating administrative
data, and examination of the text responses made alongside these records, indicated that these data
were potentially confounded. For example, frequently, although resource use was indicated to have
been pain related, text responses indicated that there were multiple, including non-pain-related,
reasons for admission. That being the case, we elected to use all reported resource use and not
just those indicated to be pain related. Prescribed medication details (both specific type/brand of
medication and dosage) were also derived from administrative records.
Health-care resource use (primary and secondary care) was costed using the most recently available
data from national resource reports. The unit costs employed, sources and the year from which these
costs were taken are documented in Table 14. We inflated all such costs to 2018/19 prices using the
NHS Pay & Prices index for years up to 2015/1691 and Monitor’s published Economic Assumptions92 for
2016/17 onwards, with the inflator used for data from each calendar year documented in Table 15.
Prescribed medication costs were assigned from the August 2018 NHS Electronic Drugs Tariff,93 with
adjustments made for dosage as applicable, with the modal dosage assumed in cases for which this
was missing. Programme costs, arising from staff costs and the production of digital and physical
information materials to support pain self-management, amounted to a one-off per-patient cost of
£63.35 and a weekly per-patient cost of £15.17.
Missing data
Given the substantial number of cases for which we did not have observations for all dependent and
independent variables (a ‘complete case’), we carried out multiple imputation on missing outcomes.
Given that our cost data were predominantly based on administrative records, we encountered missing
data with patient recall of primary care usage only: this occurred in 32% of cases. In such cases,
we imputed costs related to primary care usage only and added this to other costs derived from
administrative data. This category amounted to under 6% of all costs included in our analysis and,
thus, should not unduly influence results.
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Contact with health services, section 1
GP
Surgery visit (face to face) 37.74 Unit Costs of Health and Social Care 201787 2017
Telephone/e-mail (assumed to be
the same for any values entered
for telephone contacts in the final
column for all of ‘GP surgery
visit,’ ‘GP home visit,’ ‘GP out of
hours home visit’)
28.97 Unit Costs of Health and Social Care 2017,87
Unit Costs of Health and Social Care 201588
2017
Home visit (face to face) 95.47 Unit Costs of Health and Social Care 201787 2017
Out-of-hours home visit
(face to face)





Face to face 6.74 Unit Costs of Health and Social Care 201787 2017
Telephone/e-mail 5.19 Unit Costs of Health and Social Care 201787 2017
District nurse
Face to face 38.61 ‘District Nurse, Adult, Face to face’89 2016
Telephone/e-mail 17.74 ‘District Nurse, Adult, Non face to face’89 2016
Health visitor
Face to face 57.39 ‘Health Visitor, Other Clinical Intervention’89 2016
Telephone/e-mail 24.12 ‘Health Visitor, Other Clinical Intervention,’89




Home visit (face to face) 84.84 ‘Hourly cost of Community Palliative Nursing
Visit (e.g. as provided by Marie Curie)’90
2012
Telephone/e-mail 8.48 ‘Hourly cost of Community Palliative Nursing
Visit (e.g. as provided by Marie Curie)’90
2012
Counsellor (face to face)a 63.78 Unit Costs of Health and Social Care 201588 2013
Psychologist
Face to face 175.98 ‘Clinical Psychology outpatient’89 2016
Telephone/e-mail 83.54 ‘Clinical Psychology, Non-Admitted Non-Face-to-
Face Attendance, Follow-up,89 using volume-




Face to face 55.81 ‘Physiotherapist, Adult, One to One’89 2016
Telephone/e-mail 32.41 ‘Physiotherapy, Non-Admitted Non-Face-to-Face
Attendance, Follow-up,’89 using volume-weighted
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We determined relevant variables to be used in imputation by whether they were predictive of either
or both outcomes or missingness, and also included baseline values of costs and HRQoL. In addition to
these baseline values and in line with methods used in the main statistical analysis, we included sex,
age, a grouped variable of the site at which the patient was recruited, the patient’s self-reported health
out of 100 according to the EQ-5D visual analogue scale measure and the individual’s baseline pain
stratum as measured by the BPI score, as well as whether or not and what type of opioid pain relief
the patient received.
Analysis
We primarily estimated costs and HRQoL outcomes using seemingly unrelated regression (SUR),
accounting for correlation between observed costs and utilities, as well as a three-stage least squares
complier average causal effect (CACE) analysis, as proposed by DiazOrdaz et al.94 This treated
compliers as being those who engaged with the PainCheck software three or more times, effectively
using treatment allocation as our identifying restriction for compliance. We have presented results
from a generalised linear model regression using a log-link function and gamma distribution.







Face to face 80.06 ‘Occupational Therapist, Adult, One to One’89 2016
Telephone/e-mail 42.78 ‘Occupational therapy, Non-Admitted Non-Face-
to-Face Attendance, Follow-up,’89 (consultant-led
and non-consultant led reference costs identical)
2016
Contact with health services, section 2
Hospital inpatient stay, per day 415.30 ‘Inpatient Specialist Palliative Care, 19 years
and over’89
2016
Hospice stay, per day 468.26 ‘Inpatient Day in Hospice Care’90 2012
Hospital day centre, per visit 206.61 ‘Inpatient Specialist Palliative Care, Same Day,
19 years and over’89
2016
Hospital outpatient clinic, per visit 199.25 ‘Palliative Medicine, Total Outpatient
attendances’89
2016
Hospital accident and emergency,
per visit
154.43 ‘Unit costs, by point of delivery: A&E’89 2016
a Note that counsellor telephone/e-mail consultation costs were not recorded as no instances of this were documented.
TABLE 15 Inflation indices
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We subsequently used the results of these regressions to take 10,000 draws from implied parametric
distributions to graphically illustrate the uncertainty around this estimate using cost-effectiveness
planes and cost-effectiveness acceptability curves. We carried out this analysis for both complete cases
and our multiply imputed data set, using base-case control variables of the relevant baseline outcome
(costs or HRQoL), the site of patient recruitment, the patient’s baseline pain stratum and the patient’s
status as alive at each of 4, 8, 12, 16, 20, 24, 28 and 32 weeks from baseline. Although the inclusion
of these time-to-death indicator variables is unusual in such cost-effectiveness analyses, we included
them on the basis that the intervention employed in this case was not intended or expected to extend
life. Consequently, we considered these variables both exogenous in our analyses, and likely to be
relevant in explaining hospital costs given existing evidence on the relationship between time-to-death
and medical expenditures, and the degree to which time-to-death proxies for underlying morbidity in
such relationships.95–98
Results regarding the cost-effectiveness of an intervention are most commonly presented as ICERs,
representing the ratio of incremental costs and incremental effects, each of which were generally
positive for a given intervention. The interpretation of such a combination (positive costs, positive
effects) was to compare the derived ICER with a benchmark threshold, with a value below this
threshold deemed to represent a cost-effective intervention.99
This interpretation of the ICER was somewhat different in cases in which either or both incremental
costs and incremental benefits were negative. In cases in which negative ICERs resulted from a
combination of negative incremental costs and positive incremental QALYs, this implied a dominant
intervention, both cost saving and health improving. In cases in which negative ICERs resulted from
a combination of positive incremental costs and negative incremental QALYs, however, this implied
a dominated intervention, both more costly and health reducing. In cases in which both costs and
effects were negative, however, point estimates implied positive ICERs and a positive value above
the threshold is deemed to represent a cost-effective intervention, that is, although there may be a
negative impact on HRQoL from the intervention, the cost saving occasioned by it implied a net gain
in population health.
Given these well-established issues regarding the use of ICERs, which were particularly pertinent in
this case, we present our results primarily in terms of a point estimate of net monetary benefit (NMB)
per patient treated. This was calculated as:
NMB = ΔE.λ–ΔC,
where E is effects, C is costs and λ is the relevant threshold, with the intervention deemed to be
cost-effective if, and only if, the derived value of this is positive.100
All analyses were conducted using Stata® 15 (StataCorp LP, College Station, TX, USA).
Results
Characteristics (at baseline for all bar survival) of the UC and SSM arms are presented in Table 16.
The UC arm was on average slightly older and contained slightly more male participants than the SSM arm.
Base case
The mean costs in each trial arm of each of the cost components, including imputed costs (for primary
care resource use only), are presented in Table 17. The programme costs were estimated to be £232 per
person on average. Although the UC arm on average incurred lower hospice costs, it also incurred
significantly higher hospital costs than the SSM arm. Differences between arms in terms of primary care
and medication costs are relatively small.
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Table 18 presents the average EQ-5D-5L scores at baseline, 6 weeks and 12 weeks, broken down by trial
arm. The SSM arm exhibited on average higher HRQoL than the UC arm at each of baseline, 6 weeks and
12 weeks.
Table 19 presents the average total QALYs attained by those in each trial arm over the time period
observed. Minimal differences were observed, with the SSM arm again exhibiting marginally higher
values than the UC arm.
The results from the SUR base-case analysis implied, for the trial duration, a point estimate (SSM vs. UC)
of a reduction in costs of £587 (p = 0.54) and a point estimate QALY increase of 0.0018 (p = 0.67).
This implied an ICER with a point estimate of –£321,795, indicating that the IMPACCT programme
dominated standard care (having lower costs and higher QALYs). The NMB per patient was estimated
at £623 at a threshold of £20,000. The probability of SSM being cost-effective was estimated at 73.86%
at a threshold of £20,000. The probability of SSM being cost saving was estimated at 72.9%. Figures 16
and 17 show the level of uncertainty around the base-case results in the form of the cost-effectiveness
plane and the cost-effectiveness acceptability curve, respectively. Figure 18 illustrates the distribution of
the estimated difference in costs between SSM and UC.
TABLE 16 Characteristics of the UC and SSM arms
Characteristic
Trial arm, mean (SD)
UC SSM
Age (years) 65.68 (11.29) 62.29 (11.7)
Male 0.58 (0.497) 0.519 (0.503)
BPI score of > 6 0.222 (0.418) 0.203 (0.404)
Survival at (weeks)
4 0.975 (0.156) 0.975 (0.158)
8 0.938 (0.242) 0.911 (0.286)
12 0.877 (0.331) 0.823 (0.384)
16 0.741 (0.441) 0.759 (0.43)
20 0.667 (0.474) 0.658 (0.477)
24 0.58 (0.497) 0.633 (0.485)
28 0.58 (0.497) 0.595 (0.494)
32 0.556 (0.5) 0.57 (0.498)
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The majority of our results from alternative model specifications and measures of HRQoL suggested
a positive NMB from IMPACCT, implying that it was more likely than not to be cost-effective, with a
probability varying from 67.88% to 76.33% in our SUR analyses of multiply imputed data (Table 20) and
94.72% to 98.76% when using complete cases only (Table 21). These results were driven by the results of
the cost side of our regressions, which generally exhibited greater statistical significance than the QALY side.
Following multiple imputation for missing data, we estimated cost and effects using SUR. In a further
set of results, we presented the outcome of a CACE analysis. The economic evaluation demonstrated
that the most important driver of cost-effectiveness was the level of pain reduction, and our interventions
resulted in lower health-care costs. Using a cost-effectiveness threshold of £20,000 per QALY, there was a
67% chance that our interventions were optimal in our base-case analysis. Substantially higher estimates
of this probability – in excess of 93% – were derived when a CACE analysis was conducted. This result was
driven chiefly by differences in estimated costs per patient between arms of the trial, with our base case





6 weeks 0.655 0.667
12 weeks 0.697 0.719




EQ-5D-5L (direct) 0.135 0.137
EQ-5D-3L (crosswalk from EQ-5D-5L) 0.110 0.114


























FIGURE 16 Cost-effectiveness plane and ellipse: IMPACCT vs. no IMPACCT (SUR, base case).
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implying a saving of £586.76 with the IMPACCT intervention, and our CACE analysis implying a saving of
£4356.36. Although the SSM arm appeared to incur greater hospice use cost than the UC arm, this is
outweighed by lower hospital visit/stay costs in the SSM arm. Most analyses suggest that IMPACCTwas
dominant; however, there was minimal difference in QALYs between arms.
Limitations of the trial
Study design
We had originally intended to evaluate early screening and referral to palliative care as well the
effectiveness of our two interventions. However, after opening the trial with the original protocol, it












































–4000 –2000 0 2000
FIGURE 18 Distribution of estimated cost difference (negative represents SSM cost-saving). Mean = –£587. Probability
of cost-saving (shaded area)= 72.9%.
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pain pathways within the RCT. Once our screening procedures had identified cancer patients with
significant pain (≥ 4 on a 0–10 rating scale), oncology staff were reluctant to allow patients to be
randomised, potentially to UC, and felt obliged to make a clinical referral to palliative care. Instead, we
randomised all patients to early palliative care with or without SSM. In effect, the revised study design
forced the UC arm to have earlier access to palliative care services and this might explain the lack of
observed benefit. Greater differences between the arms in relation to pain management might have
been apparent had we been able to continue with the original protocol.








EQ-5D-5L Baseline values –716.12 –0.0023 671.10 73.75
Baseline values, pain stratum, site –747.92 –0.0018 711.30 75.99
Baseline values, pain stratum, site,
time to death
–586.76 0.0018 623.23 73.86
EQ-5D-3L crosswalk Baseline values –716.28 –0.0019 679.19 74.05
Baseline values, pain stratum, site –748.05 –0.0014 720.77 76.33
Baseline values, pain stratum, site,
time to death
–586.64 0.0016 617.77 73.71
EORTC-8D Baseline values –605.04 –0.0051 502.13 67.88
Baseline values, pain stratum, site –716.09 –0.0047 623.04 72.61
Baseline values, pain stratum, site,
time to death
–499.06 0.0004 507.04 69.30
a Assumes a threshold of £20,000.








EQ-5D-5L Baseline values –2341.95 0.0010 2361.29 98.07
Baseline values, pain stratum, site –2309.11 0.0020 2349.50 98.43
Baseline values, pain stratum, site,
time to death
–1797.59 0.0019 1834.86 95.56
EQ-5D-3L crosswalk Baseline values –2406.97 –0.0020 2367.70 98.17
Baseline values, pain stratum, site –2426.88 0.0001 2429.26 98.76
Baseline values, pain stratum, site,
time to death
–1895.49 –0.0006 1882.77 96.09
EORTC-8D Baseline values –2058.90 0.0001 2061.13 96.07
Baseline values, pain stratum, site –2246.90 0.0000 2246.90 97.57
Baseline values, pain stratum, site,
time to death
–1840.13 0.0003 1845.25 94.72
a Assumes a threshold of £20,000.
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Although cancer pain remains common, severe and undertreated, our trial showed that routine screening
for pain in oncology patients can prompt earlier referral to specialist palliative care support and in itself
be an important intervention in relation to improving outcomes for patients. The difficulty that faces
patients is that access to specialist palliative care support in routine care often occurs very late and
only weeks before death. Our trial patients were recruited and referred to palliative care a median of
53 weeks before their death compared with referral in routine care around a median of 7 weeks before
death.22 This resulted in significant improvements in pain for our trial participants in both trial arms
because they were able to access a widely acknowledged good standard of palliative care services in
the UK.101 Other research by our team using national data has also shown that for patients at home,
good pain relief is significantly associated with contact with community palliative care services.102
Fidelity of intervention
Despite recognising the potential role that our interventions might have in routine care, health
professionals acted as gatekeepers to patient acceptability of, and access to, PainCheck in particular.
We identified an ambivalence towards digital technologies in palliative care; some health professionals
felt that it easily supported their current way of working whereas others felt that PainCheck needed
to be streamlined, and they were concerned that it could become burdensome if they had a larger
number of patients on their caseload who were using it. Many believed that it would not replace their
current way of working.
Patients who used PainCheck and educational resources described the interventions as straightforward,
easy to use, quick, user-friendly and unobtrusive, with the eHealth tool considered a simple tool to aid
with monitoring their symptoms and communicating with professionals. By contrast, patients who had
limited engagement with PainCheck were not regular users of technology or computers, and often
did not have or were unable to use internet connections. They found engaging with it stressful and
subsequently were not interested in integrating it into their daily lives.
Overall, there was low engagement with PainCheck and possibly with Tacking Cancer Pain too, and
this low fidelity might also have contributed to a lack of difference in pain outcomes between the two
trial arms. We do not regard the low engagement as a failure of the research study, but as a finding:
engagement with digital technology in routine palliative care was low.
Policy context
During the course of our research programme, NHS England introduced a new initiative called
‘Enhanced Supportive Care’, which is designed to provide earlier integration of supportive care for
patients with cancer (at any stage of disease). A number of pilot sites have been set up in larger cancer
centres, although none of these was at the hospitals involved in our trial. This type of initiative may
in future help to encourage earlier referral of patients with pain from cancer to community palliative
care services, although the delivery and outcomes of this initiative have not been fully evaluated.
One challenge is that, although some cancer centres have in-hospital ‘supportive care’ teams, there is
no such community equivalent. Although palliative care services are well established, this is not the
case for supportive care services and so earlier referral to palliative care (as opposed to referral to
supportive care) is advocated. Currently, most of these initiatives are being delivered by existing
palliative care teams within hospitals and we have indicated that it is possible to provide early
palliative care in this context to community-based patients.
Economic analysis
The difference in QALYs between the two trial arms was negligible and this was not in line with our
expectations or the decision model that we had developed. Our a priori hypothesis was that SSM
would increase pain control. Given that this was not the case, we were unable to use the decision
model to extrapolate benefits forward because it was structured around mutually exclusive pain
severity health states. It may have been possible to adapt the model to capture cost savings associated
with the SSM intervention only but, given that this was already highly likely to be cost-effective in
12 weeks, the additional modelling was not considered informative.
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The decision modelling (WP 4.1) indicated that information and feedback interventions similar to the
SSM intervention developed in IMPACCT can be cost-effective. However, the trial-based economic
evaluation (WP 4.2, which did not include the model) found SSM to be cost-effective but for different
reasons: it did not improve pain relief but did reduce health-care resource use costs.
The intervention did not significantly affect survival or HRQoL. It is possible that the HRQoL
measurement schedule missed important pain experiences and events and future research should
consider more frequent pain assessments, especially when area under the curve analyses are being
estimated. Although evidence regarding the cost-effectiveness of palliative care from RCTs remains
scant, our results add to the growing body of evidence of the cost-saving nature of palliative care
interventions and point to the importance of carrying out robust studies of cost-effectiveness even
when there is little evidence of clinical effectiveness.
Supported self-management appears to lead to non-trivial cost savings per patient which, if factored up
across commissioning areas, could be substantial. One interpretation of our result is that patients felt
better able to manage pain at home and/or with the help of hospice staff and were therefore less likely
to visit, and be admitted to, hospital. Additional qualitative research and exploration of the process
evaluation may elucidate this point. Should this shift of resource use from secondary care to hospice
be a real effect, there may be resource allocation implications to be considered.
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Our research programme aimed to improve the management of cancer pain for palliative carepatients and their carers who are living at home. We were successful in developing interventions
that enabled patients and their carers to more easily access support and advice, communicate the patient’s
pain, and obtain timely and effective support for the patient’s medication. We evaluated the impact of our
interventions in routine care. The programme recruited over 1400 participants during the development
work and clinical trial. We also built on the research within IMPACCT to secure external project funding
from the National Institute for Health Research (NIHR) [Research for Patient Benefit (RfPB), Health
Technology Assessment (HTA) and Health Services and Delivery Research (HSDR) awards], as well as
securing four externally funded senior research fellowships. This has provided longer term sustainability
for the Academic Unit of Palliative Care at the University of Leeds and secured increased research
capacity within this field nationally.
Our interviews with patients, carers and health professionals revealed several new perspectives on
managing cancer pain. We identified that for patients, managing their pain is a constant daily challenge
involving trade-offs between pain, adverse effects of analgesia and sustaining what is valued in terms
of life quality. In primary and community care, we found that health professionals and the systems
in which they work vary considerably in the extent to which they identify patients with cancer pain
who need more help. The complexity of cancer as an advanced disease with features of chronic illness,
albeit life-threatening, meant that a simplistic linear cancer pain pathway could not be modelled easily.
A mixed picture emerged regarding oncologists’ perception of optimal timing of referral to palliative
care. From the qualitative studies, engagement of early supportive care alongside treatment for
managing symptoms was regarded as optimal by cancer specialists, although patients were often
reluctant to accept referral. This may reflect variable access to such support depending on which point
in the service system patients are located and the extent to which practices are in process of change.
Our data analyses from Leeds and from our national hospice survey revealed for the first time,
to our knowledge, the relatively short duration of palliative care that many patients with advanced
progressive diseases receive before they die. Importantly, we demonstrated that older patients and
those with non-cancer diseases receive even less palliative care than younger patients and those
with cancer, highlighting significant inequality in service access and provision. Our earlier qualitative
research helped us to understand these data in terms of the challenges in identifying patients who
need referral.
We analysed systematic reviews to determine the key components of an education intervention
underpinned by behaviour change theory that might support self-management. We also explored
health professionals’ views on this concept. We combined these insights, together with those from
our longitudinal patient and carer interviews, to develop and evaluate our own intervention, Tackling
Cancer Pain. This was regarded as an excellent resource by the BMA Patient Information Awards, and
was accepted and liked by patients. We recognise that we did not conduct a definitive evaluation of
this resource as a single intervention to establish its efficacy before combining this with PainCheck
for our complex intervention. We considered that this was not necessary (and would delay the RCT)
given the systematic review evidence showing broad effectiveness of this approach and our careful
development of Tacking Cancer Pain using patient, carer and health professional input. However, this
may be regarded as a limitation.
During the development of PainCheck, we learned that patients with advanced cancer and their health
professionals recognised the benefits of an electronic system to monitor pain but had reservations
about how such a system might work in practice. We developed and tested a prototype PainCheck
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system that users were generally positive about and found easy to understand, albeit with some concerns
about implementation. We recognised that any ICT system should be embedded within the electronic
record to maximise usefulness, although we were not able to achieve this within the life of the programme.
For those patients who used PainCheck within the clinical trial, it was found to be helpful and
supportive. However, our process evaluation showed that the perceptions of PainCheck by specialist
nurses, as either a useful adjunct to practice or an unnecessary burden, directly influenced patients’
attitudes. Although we trained the teams in the delivery of PainCheck, we may not understand its real
value unless we can embed electronic assessments into health-care records and in routine care, and
better engage health-care staff in the value of PainCheck. We recognise that not all patients want to
or can manage electronic reporting systems and so we need to determine how to engage patients who
are most likely to use it. Despite the assertions of patients and staff in the development phases, we
identified that in practice, engagement was much lower than expected.
Our medicines management research showed for the first time, to our knowledge, in a large sample of
patients with advanced cancer, that many will be prescribed a strong opioid only a few weeks before
death, that older patients are less likely than younger patients to receive opioids and that patients
admitted to hospital are less likely to have been prescribed an opioid in the community. These findings
bring new insights into the reasons underlying uncontrolled pain from advanced cancer in the last year
of life. The pattern of opioid prescribing does not match epidemiological data, which point to earlier
onset of pain. Although persistent undertreatment of cancer pain is well documented, this study
suggests that strategies for earlier pain assessment and the initiation of strong opioid treatment in
community-based patients with cancer could help to improve pain outcomes.
We had expected that more NMPs would prescribe for pain in palliative care after the enabling
legislation was implemented in 2012. Through our novel methodology we were able to confirm this
hypothesis but our analysis also showed that 5 years later NMP prescribing still made only a small
contribution to total palliative care prescribing in the community. Our findings suggest that there is
still much scope for NMPs to improve access to pain medicines; future research should identify and
evaluate good practice.
Our research on the potential for role of pharmacist interventions showed that other health
professionals’ concerns about duplication of work were not corroborated. Indeed, even patients
receiving palliative care services were found to have unresolved MRPs, many of which could be
resolved through discussion with a community pharmacist. Importantly, a medicines consultation with
a pharmacist enabled referral to the prescriber in which a change in pain medicines was needed to
improve pain control or treat side effects of strong opioids. Most patients who received a medicines
consultation said that it could have been more helpful earlier in their cancer pain journey at the time
when opioids were first prescribed. We were not able to find a reliable method of easily identifying
patients prior to their referral to palliative care but did find that many patients were not aware that
their community pharmacist could provide this service, indicating the need for awareness raising.
A limitation of this study was the small numbers of patients who were not receiving palliative care
services. Future research could explore how this intervention might be applied to patients when
they are first prescribed opioids and perhaps before they are referred to palliative care services.
Overall, our findings can inform prescribing practice and prompt better utilisation of existing medicines
optimisation services by pharmacists. Changes in NHS policy have altered the landscape of the use of
ICT and the deployment of pharmacists in different primary care settings. During the latter part of
our PGfAR study, access to patients’ medicines lists in their summary care record was piloted by NHS
Digital and then rolled out across England. This was a step forward in making it possible for community
pharmacists to see patients’ prescribed medicines during a MUR. Community pharmacists do not
currently have access permissions for information about diagnosis so are limited in their ability to
identify patients with cancer.
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During the final year of our PGfAR study, a national NHS England programme began to deploy 2000
clinical pharmacists into GP practices by 2020 in response to GP shortages. This new medicines
optimisation resource has untested potential to be utilised in cancer pain management and to
strengthen links with local community pharmacies. Future research should investigate the role
of interventions by general practice pharmacists. This increasing emphasis within UK health policy for
pharmacists to be more closely involved in supporting patients meant that our work with community
pharmacists was timely.
We were able to identify aspects of pain management that were of greatest value to patients and
used these data to develop a health economic model. Our economic modelling based on systematic
review data indicated that self-management interventions were likely to be cost-effective in this
setting. Our clinical trial showed that enhancing existing community palliative care support with our
Tackling Cancer Pain and PainCheck interventions did not result in additional clinical benefit. The
economic evaluation demonstrated that the most important driver of cost-effectiveness was level of
pain reduction, and our interventions resulted in lower health-care costs. Using a cost-effectiveness
threshold of £20,000 per QALY, there was a 67% chance that our interventions were optimal in our
base-case analysis.
Limitations
In the RCT, the low fidelity of the interventions and the challenge of the study design that forced the
UC arm to have earlier access to palliative care services might explain the lack of observed benefit.
We do not regard the low engagement as a failure of the research study, but as a finding: engagement
with digital technology in routine palliative care was low.
We noted that the initial trial protocol (which aimed to randomise patients to early palliative care
or UC) was not feasible because once our screening procedures had identified cancer patients with
significant pain (≥ 4 on a 0–10 rating scale), oncology staff were reluctant to allow patients to be
randomised, potentially to UC, and felt obliged to make a clinical referral to palliative care. Instead,
we randomised all patients to early palliative care with or without SSM. Greater differences between
the arms in relation to pain management might have been apparent had we been able to continue
with the original protocol. Our cost-effectiveness literature review did not include null results from
the trial within this programme and so we cannot be certain that our interventions were cost-effective.
We did not focus our research on patients with learning disabilities or cognitive impairment and so are
unable to comment on meeting the palliative care needs of these patients.
The trial demonstrated that patients were experiencing high levels of pain around 1 year before they
died. Earlier integration of palliative care (involvement in the trial a median of 53 weeks before death
compared with routine care a median of 7 weeks before death) resulted in significant improvements in
pain for participants in both trial arms. The recent NHS England initiative ‘Enhanced Supportive Care’
was designed to provide earlier integration of supportive care for patients with cancer (at any stage
of disease), and our trial findings demonstrate the need for this. However, the delivery and outcomes
of this initiative have not been fully evaluated and supportive care as a recognised service is not
widely available. We recognise that there is little consensus regarding the terminology that surrounds
supportive and palliative care; palliative care may be regarded as one aspect of supportive care, or
it may be regarded as a separate approach. What is clear, however, is that although palliative care
services are well established, this is not the case for supportive care services, and so earlier referral
to palliative care (as opposed to referral to supportive care) is advocated. Currently, most of these
initiatives are being delivered by existing palliative care teams and we have shown that it is possible
to provide early palliative care in this context.
DOI: 10.3310/pgfar09150 Programme Grants for Applied Research 2021 Vol. 9 No. 15
Copyright © 2021 Bennett et al. This work was produced by Bennett et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
77
Patient and public involvement in the programme
We established a PPI panel for the NIHR IMPACCT that consistently supported the research and
championed our work at external meetings and conferences, and has been a model for subsequent
projects. PPI members attended quarterly investigator meetings at which they freely commented and
advised on our work, and they have closely supported the development of specific WPs based on their
individual skills and interests. From individual experiences of our PPI members we have learnt that
enabling early access to the right care and a focus on supporting self-management of symptoms are
priorities for patients approaching the end of life and their carers.
Our PPI members were actively engaged in the workstreams as well as in the overall programme.
Some examples include the following:
l Provided advice in the development of protocols and patient recruitment strategies.
l Reviewed patient information sheets and consent forms to determine whether or not wording was
likely to be appropriate and adequately sensitive for the patient population.
l Reviewed ethics forms and documentation for NHS ethics applications.
l Helped the WP1 research team map a clinical pathway for a specific cancer type based on
personal experience.
l In WP2, provided personal perspectives as a carer to inform the early design of the IMPACCT
electronic system, and completed a ‘walkthrough’ of the electronic system to explore how well it
related to the reality of a patient’s pain experience from a carer’s perspective.
l Attended a WP3 multistakeholder meeting at which they provided valuable contributions to inform
the design of research methodology and patient materials for the pharmacy-delivered intervention.
l In WP4, helped to design the DCE vignettes and helped our discussions regarding protocol
amendments for the main trial.
l Informed NIHR fellowship proposals related to IMPACCT, and provided input into research project
grant applications aligned with IMPACCT [Marie Curie, Yorkshire Cancer Research (Harrogate, UK)
and the NIHR RfPB funding stream].
l Our academic unit hosted a European research seminar in October 2015 in which the focus
was on pain management. Over 70 international delegates attended and our IMPACCT work
was presented (judged independently in an open competition). We encouraged and funded
Christine Allmark and Diana Robinson to attend the 2-day meeting to see the broader international
context. They found the meeting very helpful for supporting dissemination throughout their own
PPI networks.
Our PPI panel feedback (included in our annual report to NIHR): ‘it has been really positive for me
to observe the widening inclusion of more lay colleagues in the trial management and development
processes,’ and ‘since my initial involvement at the grant application stage, I have been impressed by
the IMPACCT team’s commitment to getting input and perspectives from patients and carers who are
affected by cancer’ (PPI member, personal communication).
Developing and supporting PPI members has been crucial to securing new grant awards for the
research team. We have ensured that PPI members have been supported to attend related conferences
and workshops relevant to cancer pain management to help the design of future applications. Our
PPI panel (of which Jean Gallagher and Diana Robinson were subsequent PPI co-applicants) helped
secure the SMARTE (Self-Management and related Treatments at End of life) HTA award, the STEP
(Supporting Timely Engagement with Palliative care) RfPB award and most recently the RESOLVE
programme grant award from Yorkshire Cancer Research.
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Recommendations for future research
Our programme generated a number of research recommendations for future work that relate to some
of the priorities identified by the James Lind Alliance (Southampton, UK) for research in palliative and
end-of-life care, as well as for living with and beyond cancer:103,104
l How can access to palliative care services be improved for everyone regardless of where they are in
the UK?
l What are the best ways to make sure that palliative care patients receive adequate pain and
symptom relief?
l What are the benefits and best ways of providing care in the patient’s home and how can home
care be maintained as long as possible? Does good co-ordination of services affect this?
l Are outcomes (e.g. symptom control and incidental prolonging of life) better for terminally ill
patients the sooner palliative care is introduced and services are accessed?
l What are the best ways to manage persistent pain caused by cancer or cancer treatments?
¢ There is a need for further research to understand and improve triggers that prompt health
professionals to consider earlier integration of palliative care and pain management within
oncology services.
¢ There is a need to determine the optimal timing of technologies for self-management in
the context of pathways for progressive illness. Patients with advanced cancer were able
to participate throughout the development of PainCheck and used technology to communicate
with friends and family, but there remained uncertainty about its role in palliative care delivery.
¢ During the development and subsequent testing of PainCheck there was a lack of research
literature guiding how engagement with systems could be conceptualised. There is a need to
develop better approaches to measuring and understanding engagement with technologies and
how to use this information to inform their development.
¢ We cannot directly comment on whether or not self-management approaches that use
information and communication technologies lead to improvements in pain management for
patients with advanced cancer. PainCheck will require further research and evaluation as a
single intervention to better understand its role in supporting pain management for patients
with advanced cancer. Gaining a better understanding of the mechanisms of action underpinning
PainCheck could help to inform the potential of its role in supporting pain management in
advanced cancer.
¢ Studies to change prescriber and patient behaviour to achieve earlier pain assessment, initiation
and use of strong opioid treatment in community-based patients with cancer are recommended.
¢ The novel methodology developed in our study of community palliative care prescribing could be
researched further to examine GP and NMP since 2015. Future research could investigate how
the data could be used to provide audit/feedback reports at general practice level for CCGs and
to measure the effects on prescribing.
¢ We have established that patients with pain from advanced cancer have unresolved MRPs
amenable to community pharmacist intervention and we identified barriers to referral by
other health professionals. A challenge prior to a future pragmatic trial would be to establish
whether or not a workable referral pathway in primary care is feasible. Alternative models
should be explored including hospice-based pharmacist telephone outreach and general practice
pharmacist involvement.
¢ Our health economic evaluation demonstrated that the most important driver of cost-effectiveness
was level of pain reduction and further research to better understand this relationship in more
detail would inform future intervention delivery.
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¢ A key limitation of the clinical trial was the fidelity of the intervention delivered by community
palliative care nursing teams. Our development research in WPs 2–3 suggested that health
professionals recognised the value of the interventions but had reservations regarding their
implementation in routine care. Further research, particularly regarding attitudes towards digital
technology within palliative care, is needed.
¢ Our trial screening experience and our process evaluation revealed that there remains
significant reluctance to discuss palliative or supportive care approaches with cancer patients.
Research that explores ways to overcome these barriers is needed.
Implications for practice and lessons learnt
Research generated within the IMPACCT programme has several implications for practice:
l Outcomes for patients in relation to cancer pain management may need to reflect the trade-offs
that patients make between acceptable pain relief and acceptable cognitive side effects from
analgesia, rather than simple pain intensity scales.
l Access to palliative care occurs relatively late for many patients with cancer (and even later for
those with non-cancer diseases). Earlier access to palliative care for patients with pain who need
help is associated with better outcomes and is consistent with recently published guidance.105 Our
clinical trial demonstrated that screening for pain and integrating palliative care support a median
of 53 weeks before death (compared with only 7 weeks in clinical practice) led to important
improvements in patient outcomes.
l Digital technology will be an increasingly important aspect of palliative care provision if projected
increased demand is to be met with limited resources.
l Our finding that access to strong opioid analgesia occurs relatively late before death suggests the
importance of screening for pain within primary and secondary care.
l Our clinical trial failed to show an added benefit of our interventions to enhance existing
community palliative care support, although both the decision model and the economic evaluation
of the trial indicated that SSM could be cost-effective. Based on these, the correct implications
for practice remain as directed within the Care Quality Commission inspection framework for
end-of-life care: patients should be offered verbal or written support, particularly regarding their
medicines and patients should have their pain assessed when seen by a health professional and
have easy access to pain monitoring.
Perhaps the key lesson learnt was that it is possible to recruit patients with advanced cancer and
palliative care needs to a randomised clinical trial, and achieve an overall follow-up rate of 70% at
either 6 weeks or 12 weeks. To our knowledge, this is one of the largest and longest RCTs in palliative
care in the UK and demonstrates that it is feasible to engage this population in large-scale research.
CONCLUSIONS AND RECOMMENDATIONS




We gratefully acknowledge the NIHR PGfAR programme funding that enabled us to undertake this
programme of research. We thank all patients, caregivers, health professionals and clinical teams
that contributed to the development and implementation of the programme of research. We also
acknowledge the very valuable comments and guidance of our Project Steering Group and, in
particular, all of our PPI representatives.
Contributions of authors
Michael I Bennett (https://orcid.org/0000-0002-8369-8349) (St. Gemma’s Professor of Palliative
Medicine) was principal investigator for the programme.
S José Closs (https://orcid.org/0000-0002-3257-5277) (Professor of Nursing) led WP1 and worked
with Kate Flemming (https://orcid.org/0000-0002-0795-8516) (Professor of Hospice Practice and
Evidence Synthesis), Robbie Foy (https://orcid.org/0000-0003-0605-7713) (Professor of Primary
Care), Mary Godfrey (https://orcid.org/0000-0002-2408-534X) (Reader in Health and Social
Care), Julia Hackett (https://orcid.org/0000-0003-1720-6665) (Research Fellow), Nicholas Hughes
(https://orcid.org/0000-0003-0129-922X) (Senior Research Fellow) and Geoff Hall (https://orcid.org/
0000-0002-8864-5932) (Professor of Digital Health) to understand patient pathways and develop the
educational intervention.
Bridgette M Bewick (https://orcid.org/0000-0001-5752-5623) (Associate Professor in Psychological
Health and Wellbeing) led WP2 and worked with Matthew J Allsop (https://orcid.org/0000-0002-
7399-0194) (University Academic Fellow), Richard Jones (Professor of Chemical Pathology and Health
Informatics) and Sally Taylor (https://orcid.org/0000-0001-9026-1789) (Research Fellow in Applied
Health) to develop PainCheck.
Alison Blenkinsopp (https://orcid.org/0000-0001-8872-2769) (Professor of the Practice of Pharmacy)
led WP3 and worked with Zoe Edwards (https://orcid.org/0000-0001-6525-8190) (Research Fellow),
Matthew R Mulvey (https://orcid.org/0000-0002-6357-3848) (University Academic Fellow) and
Lucy Ziegler (https://orcid.org/0000-0001-9563-5014) (Associate Professor in Palliative Care) to
understand prescribing practices.
Julia Brown (https://orcid.org/0000-0002-2719-7064) (Professor of Clinical Trials Research) led WP4
and worked with Kath Black (NIHR Research Nurse), Marie Fletcher (https://orcid.org/0000-0001-
7545-1314) (Senior Trial Co-ordinator), Suzanne Hartley (https://orcid.org/0000-0003-2346-9461)
(Head of Trial Management – Complex Interventions), Angela Wray (https://orcid.org/0000-0002-
7075-9253) (Research Nurse), Alexandra Wright-Hughes (https://orcid.org/0000-0001-8839-6756)
(Senior Medical Statistician) to deliver the randomised trial.
The health economic analyses were conducted by Daniel Howdon (https://orcid.org/0000-0001-
8052-2893) (Research Fellow), Claire Hulme (https://orcid.org/0000-0003-2077-0419) (Chairperson
of Health Economics), David Meads (https://orcid.org/0000-0003-1369-2483) (Associate Professor in
Health Economics) and John O’Dwyer (https://orcid.org/0000-0002-7212-6089) (NIHR Research Fellow).
DOI: 10.3310/pgfar09150 Programme Grants for Applied Research 2021 Vol. 9 No. 15
Copyright © 2021 Bennett et al. This work was produced by Bennett et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
81
Sue H Pavitt (https://orcid.org/0000-0001-7447-440X) (Professor of Translational and Applied Health
Research) supported PPI engagement and worked with Peter Allen, Christine Allmark, Peter Rainey
and Diana Robinson (Lay Members).
All authors participated in programme management, WP management or dissemination meetings.
All authors provided a critical review and final approval of the report.
Publications
Ziegler L, Bennett MI, Blenkinsopp A, Coppock S. Non-medical prescribing in palliative care: a regional
survey to explore analgesic practice. Palliat Med 2015;29:177–81.
Boland JW, Ziegler L, Boland EG, McDermid K, Bennett MI. Is regular systemic opioid analgesia
associated with shorter survival in adult patients with cancer? A systematic literature review. Pain
2015;156:2152–63. https://doi.org/10.1097/j.pain.0000000000000306
Allsop MJ, Taylor S, Mulvey MR, Bennett MI, Bewick BM. Information and communication technology
for managing pain in palliative care: a review of the literature. BMJ Support Palliat Care 2015;5:481–9.
https://doi.org/10.1136/bmjspcare-2013-000625
Taylor S, Allsop MJ, Shaw J, Bennett MI, Jones R, Bewick BM. The feasibility of collecting patient reported
pain data using a system delivered across four modes of technology. Pain Med 2015;16:2212–13.
Ziegler L, Mulvey M, Blenkinsopp A, Petty D, Bennett MI. Opioid prescribing for patients with cancer
in the last year of life: a longitudinal population cohort study. Pain 2016;157:2445–51. https://doi.org/
10.1097/j.pain.0000000000000656
Flemming K, Closs SJ, Hughes ND, Bennett MI. Using qualitative research to overcome the shortcomings
of systematic reviews when designing of a self-management intervention for advanced cancer pain.
Int J Qual Meth 2016;15:1–11.
Hackett J, Godfrey M, Bennett MI. Patient and caregiver perspectives on managing pain in advanced
cancer: A qualitative longitudinal study. Palliat Med 2016;30:711–19. https://doi.org/10.1177/
0269216316628407
Hughes ND, Closs SJ, Flemming K, Bennett MI. Supporting self-management of pain by patients
with advanced cancer: views of palliative care professionals. Support Care Cancer 2016;24:5049–57.
https://doi.org/10.1007/s00520-016-3372-2
Bennett MI, Ziegler L, Allsop M, Daniel S, Hurlow A. What determines duration of palliative care
before death for patients with advanced disease? A retrospective cohort study of community and
hospital palliative care provision in a large UK city. BMJ Open 2016;6:e012576. https://doi.org/
10.1136/bmjopen-2016-012576
Taylor S, Allsop MJ, Bekker HL, Bennett MI, Bewick BM. Identifying professionals’ needs in integrating
electronic pain monitoring in community palliative care services: an interview study. Palliat Med
2017;31:661–70. https://doi.org/10.1177/0269216316677470
Meads DM, O’Dwyer JL, Hulme CT, Chintakayala P, Vinall-Collier K, Bennett MI. Patient preferences
for pain management in advanced cancer: results from a discrete choice experiment. Patient
2017;10:643–51. https://doi.org/10.1007/s40271-017-0236-x
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
Hackett J, Ziegler L, Godfrey M, Foy R, Bennett MI. Primary palliative care team perspectives on
coordinating and managing people with advanced cancer in the community: a qualitative study.
BMC Fam Pract 2018;19:177. https://doi.org/10.1186/s12875-018-0861-z
Allsop MJ, Ziegler LE, Mulvey MR, Russell S, Taylor R, Bennett MI. Duration and determinants of
hospice-based specialist palliative care for patients in the UK. A national retrospective cohort study.
Palliat Med 2018;32:1322–33.
Edwards Z, Blenkinsopp A, Ziegler L, Bennett MI. How do patients with cancer pain view community
pharmacy services? An interview study. Health Soc Care Community 2018;26:507–18. https://doi.org/
10.1111/hsc.12549
Ziegler L, Bennett MI, Mulvey M, Hamilton T, Blenkinsopp A. Characterising the growth in palliative
care prescribing 2011-2015: analysis of national medical and non-medical activity. Palliat Med
2018;32:767–74. https://doi.org/10.1177/0269216317739805
Allsop MJ, Wright-Hughes A, Black K, Hartley S, Fletcher M, Ziegler LE, et al. Improving the
management of pain from advanced cancer in the community: study protocol for a pragmatic
multi-centre randomised controlled trial. BMJ Open 2018;8:e021965.
Taylor SS, Wyld L, Ziegler L, Bennett MI. Is patient information on palliative care good enough?
A literature review and audit. Cancer Nursing Practice 2019;18:44–49.
Edwards Z, Bennett MI, Blenkinsopp A. A community pharmacist medicines optimisation service
for patients with advanced cancer pain: a proof of concept study. Int J Clin Pharm 2019;41:700–10.
https://doi.org/10.1007/s11096-019-00820-8
Allsop MJ, Johnson O, Taylor S, Hackett J, Allen P, Bennett MI, Bewick BM. Multidisciplinary software
design for the routine monitoring and assessment of pain in palliative care services: the development of
PainCheck. JCO Clin Cancer Inform 2019;3:1–17. https://doi.org/10.1200/CCI.18.00120
Meads DM, O’Dwyer JL, Hulme CT, Lopez RR, Bennett MI. Cost-effectiveness of pain management
strategies in advanced cancer. Int J Technol Assess Health Care 2019;35:141–9.
Edwards Z, Bennett MI, Petty D, Blenkinsopp A. Evaluating recruitment methods of patients
with advanced cancer: a pragmatic opportunistic comparison. Int J Pharm Pract 2019;27:536–44.
https://doi.org/10.1111/ijpp.12562
Edwards Z, Ziegler L, Craigs C, Blenkinsopp A, Bennett MI. Pharmacist educational interventions for
cancer pain management: a systematic review and meta-analysis. Int J Pharm Pract 2019;27:336–45.
https://doi.org/10.1111/ijpp.12516
Allsop MJ, Taylor S, Bennett MI, Bewick BM. Understanding patient requirements for technology
systems that support pain management in palliative care services: a qualitative study. Health Inform J
2019;25:1105–15. https://doi.org/10.1177/1460458217740724
Taylor S, Allsop MJ, Bennett MI, Bewick BM. Usability testing of an electronic pain monitoring
system for palliative cancer patients: a think-aloud study. Health Inform J 2019;25:1133–47.
https://doi.org/10.1177/1460458217741754
Hackett, Allsop MJ, Taylor S, Bennett MI, Bewick BM. Using information and communication technologies to
improve the management of pain from advanced cancer in the community: qualitative study of the experience
of implementation for patients and health professionals in a trial. Health Inform J 2020;26:2435–45.
DOI: 10.3310/pgfar09150 Programme Grants for Applied Research 2021 Vol. 9 No. 15
Copyright © 2021 Bennett et al. This work was produced by Bennett et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
83
Data-sharing statement
We shall make data available to the scientific community with as few restrictions as feasible, while
retaining exclusive use until the publication of major outputs. Requests for access to data can be made
through contacting the corresponding author.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and
support. Using patient data is vital to improve health and care for everyone. There is huge potential
to make better use of information from people’s patient records, to understand more about disease,
develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe
and secure, to protect everyone’s privacy, and it’s important that there are safeguards to make
sure that it is stored and used responsibly. Everyone should be able to find out about how patient
data are used. #datasaveslives You can find out more about the background to this citation here:
https://understandingpatientdata.org.uk/data-citation.
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